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INTRODUCTION
Hepatic cysts are benign fluid-filled cavities located in the liver that arise as congenital or 
acquired lesions.1, 2 Congenital hepatic cysts include two types of cysts: simple (or sporadic) 
cysts which arise solitary or with a few other cysts in the liver (Figure 1a), and cysts in 
the context of polycystic liver disease (PLD) where numerous cysts are diffusely spread in 
the liver (Figure 1b).3 Acquired cysts result from trauma, neoplastic disease, or parasitic 
infections.
In this thesis we focus on the minimally invasive treatment option aspiration sclerotherapy 
of large symptomatic congenital hepatic cysts.
Clinical course
Prevalence of simple hepatic cysts is estimated around 3-18% of the general population.4 
Cysts that arise in the context of PLD are infrequent. In most cases these lesions occur as 
extrarenal manifestation of the monogenetic renal disorder autosomal dominant polycystic 
kidney disease (ADPKD) with an estimated prevalence of 1 in 400-1000.5, 6 Around 83% of 
patients with ADPKD have multiple hepatic cysts.7
Over time, hepatic cysts gradually increase in volume.8 As a consequence, cyst volumes 
range between milliliters to several liters with extremes over ten liters described.9 In 
Figure 1. Congenital hepatic cysts that occur solitary (a) or in the context of PLD (b)
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most cases these lesions remain asymptomatic and are detected as coincidental findings 
on radiological imaging, since liver biochemistry is generally not affected by cysts. 
The prevalence of symptomatic cysts is estimated to be around 3.5%.4 Previous studies 
reported that symptoms occur more frequently with increasing age.4, 10, 11 Symptoms are 
thought to arise from mechanic pressure of the cyst on surrounding tissue. Frequently 
reported complaints are abdominal distension, pain, early satiety, nausea, and dyspnea 
which impair health-related quality of life.6, 12, 13 Typically, symptoms are initially mild but may 
progress into invalidating complaints due to ongoing growth. In addition, large cysts can 
cause a bulging abdominal mass causing cosmetic problems. Hence, treatment is indicated 
for symptomatic cysts. 
Several complications can occur in the setting of hepatic cysts. Most common are cyst 
hemorrhage and infection. A cyst hemorrhage typically presents as a sudden onset of severe 
abdominal pain which gradually decreases over days.1 Presentation of cyst infection can be 
variable but patients usually present with abdominal pain, fever, and increased serum CRP 
which usually requires hospitalization for antimicrobial treatment.14 
Pathophysiology
Congenital cysts are derived through defective growth and maturation of bile duct cells 
during the embryonic phase of life.1, 15, 16 Progressive dilation of these aberrant bile ducts 
leads to the formation of a hepatic cyst. This cavity in the liver is covered by a thin fibrous 
layer of cuboidal bile ducts cells: cholangiocytes. During maturation, the cyst becomes 
detached from the biliary tree.15 In PLD, cyst formation is caused by a somatic mutation upon 
a pre-existing germline mutation (two-hit model).17 In solitary cysts, this process has been 
less explored. Previous studies hypothesized that sporadic lesions may result from somatic 
defects in both alleles. Indeed, double-hit mutations have been found in some, but not all 
sporadic cysts suggesting other unknown mechanisms that lead to sporadic cyst formation.18
Expansion of cysts is driven by continuous fluid production and cholangiocyte 
proliferation.1, 8 One factor that maintains this process is the second messenger 3’,5’-cyclic 
adenosine monophosphate (cAMP) which stimulates expression of chloride channels and 
water pumps to the epithelium.19 In addition, cAMP stimulates the ERK1/2 pathway that 
promotes cholangiocyte hyperproliferation.20, 21 Finally, increased transepithelial pressure 
and stretch resulting from fluid secretion, can induce release of mitogenic cytokines leading 
to further cyst growth.22
Diagnosis
Hepatic cysts are distinctive lesions on ultrasound imaging as they present as circular or 
oval, anechoic lesions with sharp, imperceptible margins and posterior enhancement 
(Figure 2a).23 
By computed tomography (CT), cysts present as well-delineated lesions that contain 
homogenous fluid with a density of 0-10 Hounsfield Units, without contrast enhancement 
or septations (Figure 2b).24 On magnetic resonance imaging (MRI) cysts can be identified 
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as homogenous lesions, with a low intensity on T1- and high intensity on T2-weighted 
sequences (Figure 2c).24
Figure 2. Hepatic cysts visualized by ultrasonography (a), computed-tomography (b), and magnetic 
resonance imaging (c)
Due to its high accuracy, low costs and absence of radiation, ultrasonography is 
first choice for diagnosis of simple hepatic cysts.3 In contrast, complicated cysts are 
challenging. Especially cysts that underwent a previous bleeding can have highly diverse 
presentations. Ultrasonography may reveal thin floating intracystic hyperechogenic lines, 
cyst wall irregularities or rigid hyperechogenic layers that completely fill the cyst cavity 
(Figure 3).3, 25, 26 Occasionally, these hemorrhagic cysts can be hard to differentiate from pre-
malignant cystadenomas. MRI is indicated to aid differentiation between hemorrhagic cysts 
and cystadeno(carcino)mas.25 However, in some cases differentiation remains difficult and 
may necessitate surgical resection for confirmation.27
Laboratory findings in patients are generally limited to slightly elevated cholestatic 
enzymes including alkaline phosphatase and gamma-glutamyl transferase but they do not 
reflect presence of structural liver disease other than presence of cysts.1
Figure 3. Heterogeneous presentation of hemorrhagic cysts visualized by ultrasonography with (a) 
dense hyperechogenic layers and fluid or (b) floating intracystic constituents that may mimic cyst wall 
irregularities.
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Management
As cysts are benign, treatment is specifically indicated if symptoms or complications occur.28 
Traditionally, treatment is radiological or surgical. Radiological treatment encompasses 
percutaneous drainage with or without sclerotherapy. Surgical treatment of large 
symptomatic cysts mainly consists of laparoscopic fenestration which embodies aspiration 
and unroofing of the cyst.29, 30 In one surgical session, multiple large cysts can be treated. In 
case of large symptomatic cysts, both radiological and surgical interventions may serve as 
primary treatment options.1, 28
In addition, pharmacological agents have been investigated and shown to reduce volume 
of hepatic cysts.1 Somatostatin analogues inhibit formation of cAMP and therefore reduce 
cyst fluid production and cholangiocyte proliferation.31, 32 However, previous clinical studies 
only evaluated liver volume rather than actual cyst volume reduction. Overall, liver volume 
reduced with 3.6% in patients treated with either octreotide or lanreotide for 6-12 months 
compared to 1.8% increase in patients enrolled on placebo.33 
Complicated cysts are usually treated conservatively. Cyst hemorrhages are treated by 
analgesics which usually leads to resolution of pain in several weeks.1, 34 Primary treatment 
of cyst infection is by antibiotic treatment. In case of treatment failure of complicated cysts, 
invasive treatment is indicated.35
Aspiration sclerotherapy
Mere aspiration of cyst fluid is associated to complete cyst recurrence36, hence the need 
for sclerotherapy. In 1976, Goldstein and colleagues were inspired by previous results of 
sclerotherapy in renal cysts and applied this to hepatic cysts.37 They injected Pantopaque, 
an oily contrast medium, in the hepatic cyst cavity which resulted in reduction of the cyst.38 
Over the following decades numerous protocols have been published describing variations 
on this theme. All in all, aspiration sclerotherapy comes down to placement of a pigtail 
catheter in the cyst cavity to drain the hepatic cyst from its fluid (Figure 4a). After complete 
drainage, a sclerosing agent (e.g. ethanol, tetracycline, polidocanol) is injected in the cyst. 
This sclerosing agent causes lysis of the cyst epithelium with secondary sclerosis leading to 
regression of the cyst.39 As an option, contrast agent may be injected in the cyst to perform 
fluoroscopy in order to rule out peritoneal leakage or communication with blood vessels or 
the biliary tree (Figure 4b). Aspiration sclerotherapy can be performed with local anesthesia, 
conscious sedation or general anesthesia. In most centers, patients are treated in day care or 
admitted for one night observation.
Aspiration sclerotherapy is a minimally invasive procedure with a proposed high efficacy 
and low risk of adverse events. Indeed, treatment is applied in increasing numbers over 
the world. However, due to scattered evidence from multiple small studies, a clear consensus 
of its efficacy and safety is lacking. In addition, further ways to improve treatment outcomes 
are to be explored. Therefore, we introduce the following thesis aims.
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THESIS AIMS
The aims of this thesis are to determine efficacy and safety of aspiration sclerotherapy (I) and 
to explore possibilities to further improve outcomes of the intervention (II).
I. What is efficacy and safety of aspiration sclerotherapy of hepatic cysts?
Although aspiration sclerotherapy studies generally report favorable results, recent 
guidelines stated aspiration sclerotherapy as ineffective with considerable risks of adverse 
events.40-42 These contradicting statements emerge from the ambiguity around efficacy and 
safety of aspiration sclerotherapy in literature. Numerous protocols have been published 
over the last decades with different sclerotherapy approaches. These differences include 
type (e.g. ethanol, polidocanol, tetracycline, hypertonic saline), volume, and concentration 
of the sclerosing agent, single or multiple treatments per cyst, and sclerotherapy duration. 
In general, these studies reported favorable results of technical efficacy. However, due to 
the absence of unified outcome measures of technical response (i.e. diameter reduction, 
volume reduction, total or partial reduction, recurrence), a clear efficacy estimate remains 
absent.24, 43-45 Hence, an overview of literature reporting on efficacy of aspiration sclerotherapy 
is needed. In Chapter 2, we systematically review the literature in order to clarify efficacy and 
safety of aspiration sclerotherapy of symptomatic hepatic cysts. We hypothesized to find 
high levels of efficacy and safety in literature.
To further explore efficacy and safety rates of aspiration sclerotherapy, we evaluate 
the experience of two large cohorts with different treatment approaches in Chapter 3. 
We compared our rates of cyst diameter reduction, symptomatic relief and adverse with 
a second tertiary referral center (Medizische Hochschule Hannover, Germany) which applies 
polidocanol as sclerosing agent. Polidocanol was introduced as safe alternative sclerosing 
Figure 4. hepatic cyst puncture and placement of (a) pigtail catheter to perform aspiration followed by 
(b) injection of a contrast agent to rule out cyst leakage.
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agent with possibly lower rates of adverse events.47 By regression methods we corrected 
for possible confounding variables such as the amount of sclerosing agent, baseline cyst 
diameter, time between treatment and follow-up, and underlying diagnosis. We hypothesized 
to find similar rates of efficacy between centers.
Finally, although aspiration sclerotherapy is considered minimally invasive it may cause 
several complications which include postprocedural pain, cyst hemorrhage, cyst infection 
or intoxication due to systemic absorption of the sclerosing agent.47-49 The occurrence and 
course of these postprocedural complications has only been incidentally documented in 
literature.50, 51 Specifically, there is a paucity of data regarding hepatic cyst infections as 
a postprocedural complication of aspiration sclerotherapy. Chapter 4 presents the diagnosis 
and management of patients that developed a postprocedural hepatic cyst infection. As 
current literature on postprocedural hepatic cyst infection is limited, this case series aimed 
to provide new information regarding this complication.
II. How can we optimize efficacy and safety of aspiration sclerotherapy of hepatic 
cysts?
Patient and treatment variables alter outcomes of treatment. So far, it is unknown which 
factors predict treatment success or failure of aspiration sclerotherapy. Identifying these 
factors may provide new insight in mechanisms that improve treatment outcomes. In 
addition, identifying factors that predict clinical and technical response will support 
selection of patients that will benefit (or fail) from treatment. In Chapter 5, we aim to identify 
predictors of clinical and technical treatment response. We performed an international 
pooled analysis of individual patient data of two tertiary referral centers (Radboud university 
centers, Nijmegen, the Netherlands and Beaujon Hospital, Clichy, France) in order to identify 
predictors of treatment response using regression analysis. We hypothesized that strong 
cyst regression predicts clinical response. Moreover, we expected that increased levels of 
ethanol would improve technical response.
One factor that restricts cyst reduction after aspiration sclerotherapy is transitory cyst fluid 
re-accumulation. This well-described phenomenon of cyst relapse occurs directly following 
treatment.52, 53 We hypothesized that curtailing this postprocedural fluid production would 
lead to improved long-term reduction and stronger clinical response. One approach to do so 
is by targeting cAMP, the second messenger in the cholangiocyte which drives fluid secretion 
from the cell into the cyst cavity. Previous clinical trials demonstrated that somatostatin 
analogues lanreotide and octreotide reduce polycystic liver volume through inhibition of 
cAMP.33 Pasireotide, a new long-acting somatostatin analogue, has a broader binding profile 
to somatostatin receptors than its precedents.20, 54 We designed a randomized clinical trial 
to investigate the effect of adjuvant treatment of pasireotide to aspiration sclerotherapy. So 
far, a combination of pharmacological and invasive treatment of hepatic cysts has not been 
evaluated. In Chapter 6a we summarize the rationale and design of this trial. Subsequently, 
Chapter 6b describes the findings of this study.
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Finally, possibilities to improve safety of aspiration sclerotherapy have been explored. 
In a previous study, the interval and duration of sclerotherapy was minimized to prevent 
intoxications with ethanol.55 Moreover, other sclerosants were introduced to prevent 
ethanol intoxication and minimize pain following treatment.47, 56, 57 In order to prevent 
postprocedural cyst infections, our center administers prophylactic cefazolin prior to 
aspiration sclerotherapy. However, it remains unclear if this periprocedural prophylaxis is 
effective. Chapter 7 explores the ability of a prophylactic dose of cefazolin to reach adequate 
intracystic concentrations. Since we experienced postprocedural cyst infections despite this 
prophylaxis, we expected a limited penetration capacity of cefazolin.
Finally, Chapter 8 outlines the general discussion followed by future perspectives to 
further optimize aspiration sclerotherapy of patients with large hepatic cysts.
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ABSTRACT
Background
Aspiration sclerotherapy is a percutaneous procedure indicated for treatment of symptomatic 
simple hepatic cysts. The efficacy and safety of this procedure have been source of debate 
and disagreement for years. The purpose of this study was to assess the long-term efficacy 
and safety of aspiration sclerotherapy in a systematic review of the literature.
Methods
A systematic search was conducted of the electronic databases PubMed MEDLINE, Embase, 
Web of Science, and the Cochrane Library (until August 2015). Studies of proportional 
volume or diameter reduction after aspiration sclerotherapy of simple hepatic cysts were 
included for full-text evaluation. Case reports and case series were excluded. Risk of bias was 
assessed by use of the Newcastle-Ottawa scale.
Results 
From 9357 citations, 100 were selected for full-text assessment. We included 16 studies, 
which included 526 patients with a total of 588 treated cysts. Overall, risk of bias was high, 
with 12 of 16 studies having a score of poor. Proportional cyst volume reduction ranged 
between 76% and 100% after a median follow-up period of 1–54 months. Change in 
symptoms was evaluated in 10 studies: 72–100% of patients reported symptom reduction, 
and 56–100% reported disappearance. Postprocedural pain occurred most frequently, at 
a rate of 5–90% among studies. Ethanol intoxication occurred in up to 93% of cases and was 
reported more frequently in studies with either high ethanol volumes (133.7–138.3 mL) or 
long sclerotherapy duration (120–180 minutes).
Conclusions 
We found excellent results with respect to long-term efficacy and safety after aspiration 
sclerotherapy of hepatic cysts. Nevertheless, because of the high risk of bias in the included 
studies, definite conclusions regarding efficacy cannot be drawn.
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INTRODUCTION
Simple hepatic cysts are fluid-filled cavities that arise from malformations of the ductal plate 
during embryonic development.1 Solitary cysts are estimated to be present in 2.5-18% of 
the general population.2, 3 The presence of multiple hepatic cysts (arbitrarily > 20) is defined 
as polycystic liver disease(PLD). Both entities are thought to result in similar cystic hepatic 
lesions that tend to grow over time owing to fluid production by secretory epithelial 
cells.4 Cysts are asymptomatic in most cases, but because of continuous growth, they can 
become voluminous and cause symptomatic or complicated disease. Typical symptoms 
include abdominal pain and distension, dyspnea, early satiety, and nausea, leading to an 
impaired quality of life.5 Treatment of symptomatic cysts is indicated; the aim is to relieve 
the symptoms by reducing cystic volume. Mere aspiration of cystic fluid leads to complete 
recurrence of the cyst.6 which prompts the use of a sclerosing agent to destroy the secretory 
epithelium.7 Over time, different treatment protocols for aspiration sclerotherapy have 
been published. They differ mainly in terms of sclerosing agent (e.g. ethanol, tetracycline, 
polidocanol), volume instilled, and exposure time.8-12 Although heterogeneous, these 
studies generally reported good clinical and technical outcomes.13 Nonetheless, the efficacy 
and safety of aspiration sclerotherapy are under debate, and the technique has been labeled 
ineffective as a long-term treatment option 14-16 and as carrying considerable risk of adverse 
events.17, 18 A practical guideline for the management of focal liver lesions stated that 
aspiration sclerotherapy of simple hepatic cysts is associated low efficacy rates and is mainly 
indicated in patients not eligible for surgery.19 This discrepancy emphasizes the need for 
a systematic review to clarify the long-term efficacy and safety of aspiration sclerotherapy of 
symptomatic simple hepatic cysts. 
METHODS
We conducted a systematic review to identify and appraise studies that evaluated 
the efficacy of aspiration sclerotherapy of hepatic cysts. This study was reported according 
to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines.20 Because of known great clinical heterogeneity between studies, meta-analytical 
methods were not performed. The study protocol was registered in the Prospero database of 
systematic reviews (CRD42015016560) on February 9, 2015. 
Search strategy
We systematically searched the electronic databases of PubMed-MEDLINE (1946 - August 
2015), EMBASE (1974 - August 2015), Web of Science (1945 - August 2015) and the Cochrane 
Library (until August 2015), assisted by an experienced librarian from the Radboud University, 
Nijmegen, the Netherlands. We used the keywords “hepatic OR liver”, “cyst OR cysts OR 
polycystic liver disease”, “aspiration OR drainage” and “sclerotherapy OR sclerosis OR ablation 
OR injection”. To achieve the highest possible sensitivity with our search, we included 
synonyms for each search term (Supplementary File 1). English, French, German and Dutch 
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languages were search limits. Reference lists of included studies and review articles were 
manually searched for additional studies. We exported all identified studies to a citation 
management program (EndNote, version X5.0.1, Thomson Reuters). First, two investigators 
(TW and AG) independently screened title and abstract to determine the eligibility of each 
study. Second, full text studies were thoroughly assessed for eligibility.
Inclusion and exclusion criteria
Studies were eligible for inclusion if they met the following inclusion criteria: adult patient 
with one or more simple (nonparasitic, nonneoplastic) hepatic cysts either solitary or in 
context with other hepatic cysts; single or multiple percutaneous aspiration sclerotherapy 
procedures; and cyst volume or diameter reduction evaluated with ultrasound, CT, or MRI. 
Owing to the observational design of studies, the existence of a comparison group was 
not mandatory for inclusion. Moreover, unpublished data (e.g. conference abstracts) were 
included in order to reduce the risk of publication bias.21 If needed, additional information 
was requested from the original authors.
Studies were excluded for the following reasons: inclusion of hydatid cysts, primary 
outcome not reported, sample size fewer than 10 patients, or case report or case series. To 
differentiate between case series and cohort studies, we used predefined recommendations.22 
Finally, if more than one publication from the same study group was available with 
overlapping patient data, the most recent study was included. 
Critical appraisal
Because the included studies were mainly of observational design, we used the Newcastle-
Ottawa Scale (NOS) for cohort studies to assess the quality of individual studies.23 
Quality was evaluated over three categories: selection of participants (up to 4 stars), 
comparability of study groups (up to 2 stars), and outcome (up to 3 stars), leading to 
a collective overall quality assessment classified as good, fair, or poor per study.
Data extraction
Data on study level were collected and extracted into a standardized registry form. This 
included patient characteristics (age, sex, solitary or multiple cysts, and baseline cyst 
volume), treatment characteristics (type, amount, and exposure time of the sclerosing 
agent, preprocedural or postprocedural use of drains, and number of treatment sessions), 
cyst reduction (proportional change in cyst volume or diameter, interval follow-up, and 
imaging modality), symptomatic change (overall symptom reduction or disappearance 
as classified by the original authors), and the rate and type of adverse events. Finally, we 
reviewed the completed registry forms to evaluate possible discrepancies, which were 
resolved through discussion and reexamination of the original data.
EFFICACY AND SAFETY OF ASPIRATION SCLEROTHERAPY OF SIMPLE HEPATIC CYSTS
25
2
Data synthesis and analysis
According to distribution, values were presented as mean ± SD or as median and interquartile 
range. Proportional change in cyst volume or diameter was separately presented for each 
study and collectively presented as a range. If the original authors reported only absolute 
reduction rates, we calculated proportional volume or diameter reduction from the available 
data. Symptomatic change was summarized per study as the proportion of patients with 
relief and disappearance of symptoms after treatment. Symptomatic change was defined 
by the authors of the primary studies; a standardized instrument was not mandatory for 
inclusion. We compared symptomatic relief between patients with a solitary cyst or PLD in 
case these were reported separately. Adverse events were counted per study and collectively 
presented as range. Similar adverse events reported differently in separate studies were 
merged. These included signs of drunkenness and high serum ethanol levels (characterized 
as ethanol intoxication) and all types of pain and tenderness (characterized as pain). 
Except when specified otherwise, we assumed that a single treatment per cyst per patient 
was performed.
We compared ranges of hepatic cyst volume reduction between studies with a Newcastle-
Ottawa rating of good or fair versus a rating of poor to explore possible differences between 
studies with low or high risk of bias. We compared efficacy range between published and 
unpublished (conference abstracts) studies. Finally, we compared ethanol with nonethanol 
studies, studies with a follow-up period shorter than 12 months with those with follow-up 
periods 12 months or longer, and short (< 30 minutes) with prolonged sclerotherapy 
(≥ 30 minutes) studies.
RESULTS
Inclusion
We identified 9348 publications in the database search, and nine additional articles were 
found through cross-referencing (Figure 1). Finally, 16 studies were included for review. 
The publication dates ranged from 1994 to 2015 (Table 1).
Critical appraisal
The selected studies were randomized controlled trials (n = 2), prospective cohort studies 
(n = 7) and retrospective cohort studies (n = 6) (Table 1). The design of one study was not 
reported.30 In general, included studies had a high risk of bias: 12 studies scored poor; 
two studies, fair; and two studies, good (Table 2). Eleven of the 12 studies rated poor were 
uncontrolled. None of the controlled studies had a control arm that represented a group 
without treatment or simple aspiration without sclerotherapy.
Baseline characteristics
In total, 16 included studies included 526 patients with 588 treated cysts (Table 1). In one 
study the total number of treated cysts was not reported.35 A median of 21 patients (IQR 
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Figure 1. Flow diagram shows elements of systematic review
13-54) were treated per study. The most commonly applied sclerosing agent was ethanol 
(n = 12). In one study postprocedural drainage lasted 24 hours.10 For other studies the use 
of preprocedural or postprocedural drainage was not reported. Length of hospital stay was 
reported for seven studies, and the range was 1-2 days.
Cyst volume and diameter reduction
The treated cyts were most commonly measured by ultrasonography (Table 1). Seven 
studies applied the same imaging modalities before and after treatment, but only two of 
these reports specifically mentioned the use of standardized operating procedures.24, 38
Twelve studies (414 patients, 435 cysts treated) reported proportional volume reduction. 
Median proportional volume reduction ranged between 76% and 100% after a follow-up 
period of 1-54 months (Table 3). Correspondingly, seven studies (255 patients, 304 treated 
cysts) reported reduction in terms of proportional diameter reduction that ranged between 
40% and 100% (Supplementary File 2).
Studies with a Newcastle-Ottawa rating of good or fair that reported volume reduction 
(n = 3) described a range between 90% and 99%, which was comparable to the observed 
volume reduction of 76-100% in studies with poor ratings (n = 7). Two of three unpublished 
studies 26, 30 reported lower rates of volume reduction (76% and 84%) than did published 
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Table 2. Quality assessment of studies according to Newcastle-Ottawa Scale
First author Year Selection Comparability Outcome Total (level of evidence)
Benzimra 2014 2 0 3 5 (Poor)
Choi* 2009 2 0 2 4 (Poor)
Chrispijn* 2012 3 0 3 6 (Poor)
Jusufovic 2011 3 0 2 5 (Poor)
Larssen 1997 3 0 2 5 (Poor)
Montorsi 1994 2 0 2 4 (Poor)
Nakaoka 2009 3 0 2 5 (Poor)
Nido* 2012 2 0 3 5 (Poor)
Radojkovic* 2012 2 0 3 5 (Poor)
Souftas 2015 3 0 3 6 (Poor)
Sparchez 2014 3 0 2 5 (Poor)
Tikkakoski 1996 3 0 2 5 (Poor)
Yan-Hong 2012 3 2 2 7 (Good)
Yang 2006 2 2 3 7 (Fair)
Yu 2014 2 2 3 7 (Fair)
Zerem 2008 3 2 2 7 (Good)
* Conference abstract
studies (n = 9, [88-100%]). Using explorative analysis, we found comparable ranges in 
proportional volume reduction between ethanol studies (n = 6 [84-99%]) and nonethanol 
studies (n = 5 [88-100%]) studies. Furthermore, studies with a follow-up period shorter than 
12 months reported lower efficacy rates (n = 3 [76–88%]) than did studies with a follow-up 
period of 12 months or longer (n = 9 [ 90–100%]). Finally, the five studies with a short duration 
of sclerotherapy (< 30 minutes) had overlapping efficacy rates with the six studies with 
a prolonged duration (≥ 30 minutes), reporting ranges of 84–100% for short and 76–98% 
for longer duration.
Symptomatic relief
Symptomatic relief was defined in 10 studies (321 patients with symptoms) (Table 4). 
Symptomatic reduction was achieved in 72% to 100% of patients after a median follow-up 
period of 2-54 months. Complete symptom disappearance was reported in six studies (148 
patients) and ranged from 56% to 100%. In one study, investigators evaluated symptom 
relief using a standardized questionnaire and reported symptom reduction in 95% and 
disappearance in 78%.24
Two studies described differences in clinical outcomes between patients with solitary 
cysts and those with PLD.24, 34 In total, 32 of 34 (94%) patients with a solitary cyst had 
a reduction in symptoms, and 28 of 34 (82%) had symptom disappearance. In contrast, only 
21 of 29 (72%) PLD patients reported reduction, and 17 of 29 (59%) had complete resolution 
of symptoms.
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Safety
Thirteen studies reported on safety. The most common adverse event was pain. This was 
reported in 8 of 13 studies with a range between 5% (1/21) and 90% (9/10). In these studies 
either ethanol (n = 7) or ethanolamine oleate (n = 1) was used. In 9 of 13 studies ethanol was 
the sclerosing agent. Three of those studies reported ethanol intoxication, characterized by 
signs of drunkenness, headache, nausea, and flushing. The highest frequency of intoxication 
was 93% (25/27), reported in the study with the longest sclerotherapy duration (120–240 
Table 3. Studies showing cyst volume reduction
Author, year Patients, n Cysts, n Volume reduction, %1 (range) Follow-up, months1
Benzimra, 2014 24 57 58 94.0 (58.0-1004) 27.3
Chrispijn, 2012 26* 106 106 75.62 (NS) 2.42
Jusufovic, 2011 27 20 20 96.32 (74.9-1003) 24.02
Larssen, 1997 28 10 10 90.82 (77.0-1003) 17.32
Nakaoka, 2009 10 13 17 93.1 (47-1003) 54.02
Nido, 2012 30* 14 19 84.42 (24.8-1003) 8.5
Radjokovic, 2012 31* 57 57 92.52 (NS) 18.0
Souftas, 2015 32 10 14 100 (68.9-1003) 12.02
Sparchez, 2014 33 13 13 88.0 (3.0-99.23) 1.02
Yan-Hong, 2012 35 67 67 96.22 (NS) 30.0
Yang, 2006 36 27 31 98.12 (83.6-1003) 29.6
Zerem, 2008 38 20 23 90.22 (76.9-1003) 24.02
Range 10-106 10-106 76-100 1.0-54.0
Note – NS = not stated; * Conference abstract; 1 Median; 2 Mean; 3 Range; 4 Interquartile range
Table 4. Studies showing symptomatic relief
Author, year
Symptomatic 
patients, n
Symptom 
reduction, %
Symptom 
disappearance, % Follow-up, months1
Benzimra, 2014 24 57 94.7 78.9 27.32
Choi, 2009 25* 21 85.7 85.7 26.92
Chrispijn, 2012 26* 106 72.6 NS 2.42
Larssen, 1997 28 10 80.0 NS 14.5
Montorsi, 1994 29 21 100 100 18.02
Nakaoka, 2009 10 13 100 NS 54.0
Nido, 2012 30* 14 100 100 8.6
Souftas, 2015 32 10 100 100 12.0
Tikkakoski, 1996 34 25 72.0 56.0 48.02
Yan-Hong, 2012 35 44 86.4 NS 30.02
Range 10-106 72.0-100 56.0-100 2.4-54.0
Note – NS = not stated; * Conference abstract; 1 Median; 2 Mean
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minutes) and highest median volume of ethanol (138 mL) of all included studies.36 Ethanol 
studies (n = 6) that did not report ethanol intoxication had shorter sclerotherapy duration 
(19-65 minutes) and smaller median volumes of ethanol injected (60-113 mL).
Temperature elevation was observed in only four studies and ranged between 4% (1/25) 
and 15% (3/20). Three studies reported postprocedural hepatic cyst hemorrhage in 2% 
(1/57), 5% (5/106) and 23% (3/13) of patients. One study reported a postprocedural hepatic 
cyst infection (1/106 [1%]), which was treated adequately with antibiotics.26 Mortality was 
not reported.
DISCUSSION
In this systematic review, we observed high clinical and technical efficacy rates following 
aspiration sclerotherapy of hepatic cysts without severe morbidity. However, overall risk of 
bias was high.
Given that included evidence comes from small and mainly uncontrolled studies with 
inevitable high risk of biased evidence, the precise efficacy rate of this intervention remains 
unclear. Strikingly, none of these studies compared aspiration sclerotherapy with a control 
group that underwent aspiration alone or with an untreated group. In addition, the reported 
high efficacy rates imply possible publication bias. Two conference abstracts included in this 
review reported lower efficacy rates that the published studies did. These findings emphasize 
the need for larger, controlled studies to more accurately determine the efficacy and safety 
of aspiration sclerotherapy.
Nonetheless, this systematic search enabled us to evaluate current available evidence in 
order to estimate the range of efficacy and safety of aspiration sclerotherapy. The reports 
of large volume reductions observed in this study contrasts previous statements that 
framed aspiration sclerotherapy as an ineffective treatment option.14, 15, 19 This discrepancy 
may be partly explained by referral to studies in which aspiration was performed without 
sclerotherapy, which invariably results in complete recurrence of the cyst.6, 39 Second, 
earlier studies reported the number of cysts with complete regression or recurrence after 
treatment, rather than actual cyst volume or diameter reduction.1 Therefore, substantial cyst 
reduction could be interpreted as incomplete cyst regression and treatment failure, despite 
excellent clinical outcomes. Moreover, cyst fluid reaccumulation in the first weeks after 
aspiration sclerotherapy is a well-known transitory phenomenon that can lead to temporary 
recurrence of the cyst and result in possible misconception of recurrence.40 Nonetheless, as 
supported by our review, long-term results show sustained cyst volume regression rates.
The variety of reported symptomatic relief was high between studies. The large range may 
be partly explained by underlying disease; patients with a solitary cyst especially had a high 
clinical response rate. Another factor that may have contributed to this variety is the lack 
of standardized measurements in most studies. Only one study measured symptoms in 
a standardized manner. In none of the included studies was a validated questionnaire used 
to evaluate symptomatic relief. Implementation of a disease-specific questionnaire 41 would 
be valuable for proper evaluation of change in symptoms after aspiration sclerotherapy.
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Similar to previous reviews, our review showed a low incidence of adverse events.13, 16 
The use of alternative sclerosing agents was initiated to reduce complications observed 
after instillation of ethanol, especially ethanol intoxication and pain.8, 42 Pain was reported in 
seven of nine ethanolstudies. In contrast, pain was not found in studies in which alternative 
sclerosing agents (hypertonic saline or polidocanol) were used. Because efficacy of treatment 
had overlapping results in ethanol and nonethanol studies, one might argue that alternative 
sclerosing agents should be chosen with the aim of reducing adverse events. Nonetheless, 
comparative studies of these agents are needed to draw definite conclusions.
Cyst fenestration, which includes surgical deroofing of the hepatic cyst, is often 
recommended as alternative treatment option of large symptomatic hepatic cysts.14, 17 
One review compared aspiration sclerotherapy with fenestration and reported similar 
failure rates (4/91 versus 5/85), but showed a slightly lower incidence of adverse events 
after aspiration sclerotherapy.13 Because of differing endpoints in studies and the lack of 
randomization, it remains unclear which treatment is safest and most effective. At this point, 
we suggest performing the treatment that is most convenient in terms of local expertise and 
available equipment.
Regardless of the heterogeneity of aspiration sclerotherapy treatment protocols, we 
observed comparable cyst reduction between studies. This implies that the observed 
success rates are not restricted to a specific treatment protocol. We suggest that a single-
session treatment should be performed with an inexpensive sclerosing agent and a short 
duration of sclerotherapy, in order to achieve high efficacy with minimized patient burden.
The main strength of this study is the large sample size of patients treated with 
aspiration sclerotherapy. To our knowledge, this is the first review to systematically evaluate 
the efficacy and safety of aspiration sclerotherapy of hepatic cysts. This study had several 
limitation, however. Although we excluded case reports and case series, the risk of bias 
in individual studies was high, which hampered precise conclusions. Second, we did 
not use meta-analytical methods, such as assessment of publication bias, for this review 
because of the heterogeneity of treatment protocols and outcome reporting. In addition, 
the studies reviewed were published over an extended time period that exceeded 20 years. 
Finally, imaging modalities varied within and between studies, which may have biased 
the reported volume reduction. Future studies should unify imaging modalities and perform 
measurements by standardized procedures.
CONCLUSIONS
We observed favorable results of sustained volume reduction, symptomatic relief, and safety 
after aspiration sclerotherapy of hepatic cysts. Patients with solitary hepatic cysts especially 
seem to have an excellent clinical success rate. Nonetheless, the high risk of bias of included 
the studies precludes definite conclusions.
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SUPPLEMENTARY FILES
Supplementary File 1. Search strategy PubMed Medline – August 2015
No. Search queries Yield
#1 Hepatic[tw] OR liver[tw] OR livers[tw] 974225
#2 “Liver”[MeSH Terms] OR “Liver diseases”[Mesh] 760173
#3 1 OR 2 1080399
#4 Cyst[tw] OR cysts[tw] 125948
#5 “Cysts”[MeSH Terms] OR “Cyst Fluid”[Mesh] 90624
#6 4 OR 5 144143
#7 3 AND 6 11955
#8 “Polycystic liver”[tw] OR PCLD[tw] 656
#9 “Polycystic liver disease”[Supplementary Concept] 94
#10 8 OR 9 656
#11 7 OR 10 12075
#12 Aspiration[tw] OR aspirations[tw] 69884
#13 Sclerotherapy[tw] OR sclerotherapies[tw] 7265
#14 Sclerosing[tw] OR sclerosis[tw] OR sclerosation*[tw] 135341
#15 “Sclerotherapy”[Mesh] 4489
#16 Sclerosant*[tw] 827
#17 “Sclerosing Solutions”[Mesh] OR “Sclerosing Solutions” [Pharmacological Action] 9940
#18 Ablation*[tw] 70068
#19 “Ablation Techniques”[Mesh] 92597
#20 Instillation*[tw] OR instillment[tw] OR instilment*[tw] 18085
#21 “Instillation, Drug”[Mesh] 1290
#22 Drainage*[tw] 88980
#23 “Drainage”[Mesh] 46612
#24 Evacuation*[tw] 12831
#25 Percutaneous*[tw] 111693
#26 Transdermal*[tw] OR transdermic*[tw] 11526
#27 Transcutaneous*[tw] 14341
#28 Infusion*[tw] 259119
#29 “Infusions, Intralesional”[Mesh] 210
#30 Injection*[tw] 619503
#31 “Injections”[Mesh] OR “Punctures”[Mesh] OR “Biopsy, Needle”[Mesh] 343433
#32 “Ultrasonography, Interventional”[Mesh] OR “Radiology, Interventional”[Mesh] 19563
#33 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 
25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32
1468800
#34 11 AND 33 2292
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Supplementary File 2. Proportional cyst diameter reduction
Author, year Patients, n Cysts, n Diameter reduction, %1 (range) Follow-up, months1
Choi, 2009 25* 21 21 72.62 (NS) 26.92
Chrispijn, 2012 26* 106 106 39.52 (±29.23) 2.42
Montorsi, 1994 29 21 21 85.72 (NS) 18.02
Souftas, 2015 32 10 14 100.0 (33-1004) 12.02
Tikkakoski, 1994 34 25 59 71.42 (NS) 48.02
Yang, 2006 36 27 31 79.82 (NS) 29.62
Yu, 2014 37 45 52 82.02 (NS) 12.0
Range 10-106 14-106 39.5-100 2.4-48.0
* Conference abstract; 1 Median unless stated otherwise; 2 Mean; 3 Standard deviation; 4 Range; Abbreviations: 
NS = not stated
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ABSTRACT
Background
Over de past decades, multiple approaches of aspiration sclerotherapy of large symptomatic 
hepatic cysts have been investigated. However, comparative data are absent.
Our objective was to compare two treatment protocols using ethanol- and 
polidocanol-sclerotherapy.
Methods
In this retrospective study, we compared efficacy and safety data between sclerotherapy 
approaches of two European tertiary referral centers. Adult patients with a symptomatic 
hepatic cyst who underwent aspiration sclerotherapy were eligible for inclusion. 
Center 1 injected ethanol, center 2 applied polidocanol-sclerotherapy. Primary endpoint 
was proportional cyst diameter reduction (%) within 12 months after treatment. Secondly, 
we evaluated symptomatic relief and safety.
Results
We included 71 patients from center 1, and 66 patients in center 2 (median age 57 years; 
126/137 (92%) female). Cyst reduction was comparable between center 1 and 2: 37.5% 
[IQR 15.7-61.0%] versus 44.2% [IQR 24.6-60.5%], respectively (P=0.35). Correspondingly, 
symptomatic relief was comparable: 30/53 (56.6%) versus 43/66 (65.2%), respectively 
(P=0.88). Although numbers were small, center 1 reported significantly (P=0.047) more 
adverse events than center 2.
Conclusions
We found comparable cyst reduction and symptomatic relief rates between ethanol- and 
polidocanol-sclerotherapy, whilst adverse events occurred more often in the ethanol group. 
Prospective studies focused on clinical relief are needed to further explore differences 
in approaches.
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INTRODUCTION
Hepatic cysts are fluid-filled cavities located in the liver that arise from congenital 
malformations of the biliary tract. Prevalence is estimated around 2.5-18.0% of the general 
population.1-3 They can occur solitary or as an autosomal dominant inherited disease known 
as polycystic liver disease (PLD).4 Although typically asymptomatic, a proportion of patients 
with large hepatic cysts develop symptomatic disease. Treatment should be considered in 
these cases and consists of surgical or radiological interventions.5
Aspiration sclerotherapy consists of ultrasonography-guided drainage of the hepatic 
cyst with subsequent instillation of a sclerosing agent aiming to eradicate the lining cystic 
epithelium. Lysis of the fluid-producing cells results in regression of the cyst.
Multiple protocols for aspiration sclerotherapy are available and traditions rather than 
science stipulate the choice of a protocol. There are a number of variables such as sclerosing 
agents (e.g. ethanol, tetracycline, and polidocanol), varying concentrations, volumes, 
and instillation times.6-12 Literature mainly contains case series that highlight one specific 
protocol. However, comparative data are absent.
For this study, we compared two institutes who were subjected to a distinct aspiration 
sclerotherapy protocol including the use of different sclerosing agents: ethanol and 
polidocanol. Historically, ethanol is generally applied as sclerosing agent in most centers.13 
However, due to side effects of pain and intoxications, other sclerosing agents were explored 
in the last decades. One of these alternative agents is polidocanol. Inspired by the success 
in varices and renal cysts, polidocanol was instilled in hepatic cysts with both toxic and 
anesthetic effects on the epithelium.14, 15 Our aim was to compare efficacy in terms of cyst 
reduction, clinical response, and safety between these different standardized aspiration 
sclerotherapy approaches, in order to explore possible superiority between these protocols.
METHODS
Study design and population
In this study we assessed treatment outcome following aspiration sclerotherapy of 
hepatic cysts. This retrospective cohort consists of patients that have been treated in 
the following two tertiary referral centers: (1) Radboud university medical center, Nijmegen, 
the Netherlands and (2) Medical School of Hannover, Hannover, Germany (Table 1). Ethical 
approval was obtained by the local medical ethical committee in both centers. As this was an 
observational, retrospective cohort, informed consent was not deemed necessary by ethical 
boards. We included adult (≥18 years) patients who underwent aspiration sclerotherapy of 
a non-parasitic, non-neoplastic hepatic cyst between 2004-2012 (center 1) and 2007-2013 
(center 2). Both centers treated sporadic cysts and dominant cysts within the context of 
PLD. A dominant cyst was identified as the largest hepatic cyst surrounded by smaller cysts. 
The treated cyst had to be measured by ultrasonography (US) or computed tomography (CT) 
within six months before, and within 12 months after aspiration sclerotherapy. We excluded 
a patient if the treated cyst could not be identified from other (non-treated) cysts on post-
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interventional imaging.  Measurements that were recorded after a second intervention of 
the cyst (i.e. second aspiration sclerotherapy or surgical fenestration) were not included.
Aspiration sclerotherapy procedures and follow-up
Both centers worked by standardized, single session procedures (Table 1). Center 1 
performed complete ultrasound-guided drainage of the cyst using a 5-French pigtail 
catheter (Cook Medical, Bloomington, United States of America).16 Subsequently, 100% 
ethanol was injected in the cyst in a volume of 10% of the aspirated cyst fluid volume. For 
safety reasons a maximal amount of 50 mL was applied. The procedure was performed using 
conscious sedation and local anesthesia. In center 2, cysts were treated percutaneously 
by aspiration under ultrasound guidance (20G Chiba needle), followed by instillation of 
polidocanol 1% (Aetoxisclerol 1%, Kreussler Pharma, Wiesbaden, Germany) in a volume of 
10% of aspirated volume with a safety margin of 120 mL. After 5 minutes polidocanol was 
partially re- aspirated and a maximum of 60 mL polidocanol remained in the cyst.17 In center 
2, only local anesthesia was applied.
In both centers, patients visited the outpatient clinic before (<6 months) and after (<12 
months) aspiration sclerotherapy.  During these visits, ultrasonography was performed 
to assess the three orthogonal diameters of the cyst from which one mean diameter 
was calculated (Figure 1). In addition, during both visits, symptoms of the patients were 
monitored. Treatment protocols remained unchanged during the study period.
Study endpoints
The primary endpoint of this study was proportional (%) cyst diameter reduction, compared 
between treatment strategies of center 1 and 2. We calculated proportional diameter 
reduction using baseline and the last available measurement within 12 months after 
aspiration sclerotherapy. Secondary endpoints were symptomatic change and safety. 
Symptomatic change was extracted from the patients’ charts and dichotomized into two 
categories: reduction or no reduction of symptoms. To evaluate safety, we documented type, 
rate, and date of any complication following treatment within 12 months. 
Table 1. Treatment protocols
Center 1 Center 2
Sclerosing agent Ethanol Polidocanol
Ratio SA to aspirated volume (%)1 10 10
Maximal volume SA (mL) 50 120
Instillation time of SA (minutes) 10 minutes Remains intracystic1 
1 maximum of 60 mL is not re-aspirated from the cyst
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Data collection
We performed an Electronic Patients Database search and included all patients who 
underwent aspiration sclerotherapy between January 2004 to December 2012 (Center 1) and 
January 2007 to December 2013 (Center 2). Data was subtracted from medical reports from 
clinical charts. Patient history and US or CT images were used to assess patient eligibility. 
We assembled a dataset with all primary and secondary endpoints. In addition, we included 
the following variables: age, gender, underlying diagnosis (presence of > 20 hepatic cysts, 
indicated as PLD), relevant medical history, and dates of aspiration sclerotherapy and follow-
up. Data were entered in a pooled database by one of the two primary researchers and cross-
checked for errors.
Statistical analysis
Frequency tables were provided for all demographic information and compared between 
centers. Continuous and categorical data were compared between centers using Mann-
Whitney U test and Pearson’s Chi-Square test, respectively. By linear regression analysis, we 
compared proportional cyst diameter reduction between centers. We included proportional 
diameter reduction as dependent variable and center as independent variable. Moreover, 
we included the following variables to correct for confounding: age, gender, PLD, baseline 
cyst diameter, amount of sclerosing agent, and follow-up time. Similarly, we compared 
symptomatic change (dependent variable) between centers (independent variable) using 
logistic regression analysis including aforementioned confounding variables.
Figure 1. Orthogonal measurement of a treated hepatic cyst.
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Within each treatment regimen, we compared cyst reduction between patients with 
or without symptomatic relief using Mann-Whitney U test. In addition, we compared 
cyst reduction and symptomatic relief between patients with or without PLD, by Mann-
Whitney U and Chi-Square testing, respectively. Finally, adverse event rates were compared 
using Fisher’s exact test. We performed statistical analysis using IBM SPSS statistics (SPSS 
Inc, Chicago, IL, USA). All reported P-values were two tailed, values <.05 were considered 
statistically significant.
RESULTS
Baseline characteristics
We identified 111 patients in center 1 and 121 patients in center 2 (Figure 2). From these 
232 patients, 137 were eligible for inclusion: 71 from center 1, and 66 patients from center 
2. Age, gender, underlying diagnosis and location of the cyst were comparable between 
centers (Table 2). The occurrence of renal cysts  (21.1% versus 51.5%; P<.01) and baseline 
cyst diameter (11.2 cm [IQR 8.4-16.0 cm] versus 8.4 cm [IQR 7.0-10.7 cm]; P<0.01) differed 
between centers.
Figure 2. Flowchart: identification and selection of patients in center 1 and 2. FU = follow-up.
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Cyst reduction
In center 1, cysts reduced to a mean diameter of 6.7 cm [IQR 3.7-10.6 cm] after a follow-up 
of 2 months [IQR 1-5 months], corresponding with a reduction of 37.5% [IQR 15.7-61.0%]. 
Patients treated in center 2 had a median diameter of 4.9 cm [3.5-6.8 cm] after 7 months 
[IQR 3-9 months], which was a proportional reduction of 44.2% [IQR 24.6-60.5 months] 
(Figure 3). By multivariable linear regression analysis we found no statistical difference 
between centers (P=0.35). Although median follow-up time differed between centers this 
was not associated with a difference in cyst reduction between centers (P=0.87).
Table 2. Demographics
Center 1 (n = 71) Center 2 (n = 66) p-value1
Age at treatment, years 55 (47-65) 58 (52-67) 0.16
Gender, female (%) 68 (95.8) 58 (87.9) 0.09
Diagnosis, PLD (%) 56 (78.9) 50 (75.8) 0.67
Renal cysts (%) 15 (21.1) 34 (51.5) <0.01
Baseline cyst diameter, cm 11.2 (8.4-16.0) 8.4 (7.0-10.7) <0.01
Liver lobe, right2 39 (54.9) 38 (57.6) 0.76
1Continuous values by Mann-Whitney U test; categorical data by Pearson Chi-Square test; 2 in both centers, 
five patients had a cyst centrally located. PLD = polycystic liver disease (> 20 hepatic cysts)
Figure 3. Cyst diameter reduction compared between center 1 and 2. 1 Linear regression analysis.
Symptomatic relief
In center 1, 30 out of 53 (56.6%) patients reported symptomatic relief, compared to 43 out 
of 66 (65.2%) in center 2. In center 1, clinical response could not be retrieved from patient 
charts in 18 patients. Logistic regression showed no differences between centers (OR 0.90; 
95% CI 0.23-3.52; P=0.88). Again, median follow-up time was not associated with differences 
in symptom response (OR 1.02; 95% CI 0.85-1.20; P=0.90).
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Cyst reduction and symptomatic relief
In both centers, higher efficacy of cyst reduction was associated with improved clinical 
response. In center 1, we found significantly larger median cyst reduction in patients who 
reported decrease of symptoms compared to patients without symptom improvement: 
48.8% [32.0-65.3%] versus 23.4% [10.3-61.0%], P=0.02. In center 2, we found similar results: 
53.2% [32.5-68.7%] versus 28.7% [7.9-47.0%], P=0.03.
Cyst reduction and symptomatic relief compared between diagnosis
In general, we observed higher cyst and symptom reduction rates in patients without PLD.
In center 1, non-PLD and PLD patients had comparable cyst reduction rates: 42.7% [15.2-
86.7%] versus 34.8% [16.1-55.1%]; P=0.38. In contrast, in center 2, cysts of patients without 
PLD had stronger regression rates: 70.3% [55.0-84.6%] versus 36.3% [20.9-53.4%]; P<0.01.
Correspondingly, symptom reduction was higher in patients without PLD compared to 
PLD patients in both centers: 7/10 (70.0%) versus 23/43 (53.5%; P=0.34) in center 1, and 
16/16 (100%) versus 27/54 (54.0%; P<0.01) in center 2.
Safety
In total, center 1 reported 11 adverse events: 10 patients had pain following treatment 
of which five had a suspect cyst hemorrhage, and one hepatic cyst infection (Table 3). 
No ethanol-intoxications were reported. In center 2, three adverse events were reported: 
one hepatic cyst hemorrhage and two cyst infections, no patients reported pain. Center 
1 reported significantly more adverse events (P=0.047). All adverse events were treated 
conservatively (analgesics or antimicrobial treatment) and resolved without sequelae.
Table 3. Adverse events
Center 1 (n = 71) Center 2 (n = 66) P-value1
Post-procedural pain, n/N 5/71 (7.0%) 0/66 0.06
Cyst hemorrhage, n/N 5/71 (7.0%) 1/66 (1.5%) 0.21
Cyst infection, n/N 1/71 (1.4%) 2/66 (3.0%) 0.61
Total, n/N 11/71 (15.4%) 3/66 (4.5%) 0.047
1 Fisher’s exact test
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DISCUSSION
The primary finding of this study is that we found comparable efficacy rates of cyst reduction 
and clinical relief regardless of the aspiration sclerotherapy protocol used. In contrast, 
ethanol resulted in more adverse events compared to polidocanol. 
In the past decennia, multiple centers have described their experiences of sclerotherapy 
protocols.13 More recently, studies compared single variables within these protocols.18, 19 
onetheless, head-to-head comparisons between these strategies are lacking. In this study, 
we compared two distinct treatment protocols using different sclerosing agents, volumes 
and time intervals. Despite these different approaches, we found highly comparable cyst 
reduction and symptomatic relief rates.
Compared to previous studies, we found lower cyst diameter reduction and clinical 
response rates.20, 21 Our smaller reduction rates may be explained by our short follow-up 
interval. Previous studies reported continuous cyst reduction in the first year after aspiration 
sclerotherapy.22 As cyst reduction increase over time, our follow-up may have been too short 
to reach higher efficacy rates.23
In line with cyst reduction, our clinical response rates were relatively small. One cohort of 
57 patients24 reported symptom reduction in 95% of patients, another study of 25 patients20 
found reduction of symptoms in 72%. Both studies had high cyst reduction rates. Possibly, 
these high levels of symptom relief could be explained by the stronger cyst reduction rates. 
Indeed, in this study the amount of cyst reduction was associated to clinical response.
Ethanol is the most common sclerosing agent reported in literature as it is cheap, safe 
and widely available. On the downside, ethanol sclerotherapy had side effects, mainly pain 
and intoxications are described.13 Polidocanol was introduced as sclerosing agent for hepatic 
cysts aiming to reduce peri- and post-procedural pain. Indeed, in our ethanol sample, pain 
was reported more frequently. Interestingly, ethanol intoxications were not encountered, 
this may be explained by the low maximal volume (50 mL) of instilled ethanol and short 
sclerotherapy duration of 10 minutes.
How do our findings affect clinical practice? First, although treatment protocols included 
different variables, we found comparable cyst reduction and clinical response rates. This 
implicates that the currently available approaches probably have similar efficacy that 
results from cyst wall destruction with curtailed cyst fluid regression leading to reduction 
of symptoms. As efficacy rates between ethanol and polidocanol are highly comparable, we 
could argue that polidocanol should be preferred as sclerosing agent as adverse event rates 
were smaller. To draw definite conclusions, a prospective comparison between these agents 
is needed. In addition, we found that PLD patients had less chance to gain symptomatic 
relief. Several studies reported comparable findings.20, 24 This restricted clinical response may 
be explained by the remaining large liver volume. In contrast, patients with solitary cysts 
proved to be excellent candidates for this intervention.
The main strength of this study is the large sample of patients included from two tertiary 
centers. This large sample size allowed us to correct for known confounders. Our study was 
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limited by several factors. First, median follow-up time in both centers was short. Longer 
follow-up periods would have provided insight in possible long-term efficacy differences. 
Second, although we included confounding variables in regression analyses, some 
variables (e.g. needle size, amount of sclerosing agent, sclerosing time) were collinear 
with center and could therefore not be included as variable in our regression analyses. 
The individual effect of these variables on our outcome could therefore not be evaluated. 
Finally, our clinical response and safety measurements were not assessed by standardized 
instruments and therefore susceptible for bias. Recently, a disease-specific questionnaire has 
been validated to assess severity and frequency of symptoms in patients with hepatic cysts.25 
This instrument opened the door for a prospective observational study to observe long-term 
clinical efficacy rates. Hepatic cysts are benign lesions, therefore we strongly recommend to 
use such patient-reported outcome measures as primary endpoint to evaluate efficacy of 
aspiration sclerotherapy.
CONCLUSIONS
To conclude, despite two distinct sclerotherapy protocols we found comparable efficacy 
rates of cyst reduction and clinical relief. Polidocanol-sclerotherapy had less adverse events 
than ethanol-sclerotherapy. Future prospective studies are needed that primarily focus on 
clinical relief and safety using validated instruments.
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ABSTRACT
Mass-related symptoms caused by hepatic cysts are effectively treated by aspiration 
sclerotherapy (AS). This minimal-invasive intervention is regarded as a safe procedure. 
Hence, occurrence of complications is low.
Transient fever is commonly reported as a side effect. However, documentation on a post-
procedural hepatic cyst infection as a complication of AS is limited. We present ¬five cases 
in which a tentative diagnosis of postprocedural hepatic cyst infection was made. Patients 
typically presented with abdominal pain and fever, had to be admitted to our hospital, and 
were treated with long term antibiotics. Ultimately, the cyst infection successfully resolved 
with ciprofloxacin in all cases.
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INTRODUCTION
Hepatic cysts are benign, fluid-filled cavities located in the liver that are estimated to occur in 
2.5-11.3% of the general population.1, 2 Over lifetime, cysts tend to increase in volume, leading 
to mass-related symptoms requiring treatment.3 Aspiration sclerotherapy is a minimally 
invasive treatment option that curtails hepatic cyst volume and thereby alleviates mass-
related symptoms.4 Aspiration sclerotherapy is a procedure that comprises ultrasonography-
guided percutaneous drainage of the hepatic cyst with subsequent instillation of a sclerosing 
agent. Sclerotherapy induces lysis of secreting cholangiocytes that cover the inner cyst 
wall.5 The literature describes the use of many different sclerosing agents but ethanol is 
most commonly applied as it is effective, safe, inexpensive, and widely available.6-8 The most 
common side effect of aspiration sclerotherapy is pain during or after the procedure.3, 9, 10 
Other systemic complications include transient fever, ethanol intoxication, and pleural 
effusion.8, 11, 12 Local complications resulting from aspiration sclerotherapy, such as cyst 
infections, have only incidentally been documented. Spontaneous hepatic cyst infection 
is a severe complication that frequently necessitates invasive treatment and may even 
lead to sepsis or death.13, 14 Over the past ten years we have performed over 250 aspiration 
sclerotherapy procedures and encountered a number of hepatic cyst infections. This 
paper highlights five cases of postprocedural hepatic cyst infection to better understand 
the natural history of this complication, in order to provide therapeutical guidance.
Case 1
A 59-year-old female with a history of polycystic liver disease presented with increasing 
abdominal pain. Ultrasonography showed multiple large hepatic cysts and aspiration 
sclerotherapy was suggested in order to reduce mass-related symptoms. Without 
the administration of antibiotic prophylaxis, two large hepatic cysts were drained (5 Fr pigtail 
catheter). The first cyst located posteriorly in the right hepatic lobe contained 800 ml of 
serous fluid, the second cyst located anteriorly in the left lobe contained 1500 ml of brown, 
turbid fluid. One month following the procedure, the patient was seen in the emergency 
room with complaints of right-sided flank pain, fever and chills. Laboratory analysis showed 
an increased serum C-reactive protein (CRP) of 100 mg/L (Figure 1). Ultrasonography revealed
debris in the anterior hepatic cyst. Under the suspicion of a hepatic cyst infection, 
clindamycin (300 mg three times daily) and ciprofloxacin (500 mg twice daily) oral antibiotic 
therapy was initiated (Table I). During the next days, symptoms resolved and the patient 
was discharged. Clindamycin and ciprofloxacin were continued for a total of six weeks. Two 
weeks later the stopping of antibiotics, the serum CRP had returned to normal (8 mg/L).
Case 2
A 54-year-old woman with a history of multiple hepatic cysts was referred to our outpatient 
clinic with complaints of upper abdominal pain. The largest hepatic cyst (7 cm) was located 
cranially in the right hepatic lobe. Because of continuous pain, aspiration sclerotherapy was 
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Figure 1. Serum C-reactive protein (CRP) in response to antibiotic treatment (Case 1-5). Filled areas 
correspond with intravenous (dotted) or oral (solid) antibiotic therapy. 
performed. During the procedure the catheter dislocated after aspiration of 200 ml of clear 
cyst fluid. The  intervention was discontinued prior to administration of ethanol. Initially, 
the patient experienced a relief of pain. However, three weeks later, upper abdominal pain 
and fever (38.8°C) ensued. Laboratory analysis revealed increased serum CRP (107 mg/L) 
and white blood cell count (13.2x109/L). Ultrasonography showed recurrence of the treated 
cyst with internal debris. The patient was admitted and treated with intravenous amoxicillin 
and clavulanic acid antibiotic therapy. After four days, antibiotic therapy was switched 
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to oral moxifloxacin for six weeks (400 mg daily). This was later switched to ciprofloxacin 
(500 mg twice daily) for four additional weeks which led to a resolution of symptoms and 
normalization of serum CRP.
Case 3
A 55-year-old Caucasian female with a solitary hepatic cyst complained of increased 
abdominal pain and early satiety. A hydatid cyst was excluded during the initial workup.
Ultrasonography showed a solitary hepatic cyst in the left hepatic lobe with a diameter 
of 18 cm. Aspiration sclerotherapy was performed and 2500 ml of clear fluid were aspirated. 
After the procedure, the patient became febrile (38°C) without pain or other complaints. 
The next day, body temperature had normalized and the patient was discharged. Three 
days later, the patient presented with fever (38.5°C) and chills. Ciprofloxacin (500 mg twice 
daily) for 14 days was started under the suspicion of a cyst infection. Due to a persisting 
elevated serum CRP (68 mg/L), ciprofloxacin was continued for another 30 days. Although 
serum CRP remained elevated (47 mg/L), ciprofloxacin was ultimately stopped. During an 
outpatient clinic visit two months later, the patients’ symptoms had resolved and serum CRP 
had decreased to 10 mg/L.
Case 4
A 57-year-old woman with polycystic liver disease was seen in our outpatient clinic with 
continuous right flank pain since several months. Previous aspiration sclerotherapy treatment 
of three hepatic cysts had led to a successful reduction of cyst volume and complaints. Recent 
computed tomography showed a dominant hepatic cyst of 9 cm seated cranially in the right 
hepatic lobe. The patient was therefore again referred for aspiration sclerotherapy. Drainage 
yielded hemorrhagic cyst fluid and as active bleeding could not be ruled out, sclerosing with 
ethanol was not performed. Three weeks later, the patient presented with upper abdominal 
pain and fever (39.9°C). Laboratory analysis showed an elevated serum CRP of 203 mg/L. 
Table 1. Clinical presentation and treatment of post-procedural hepatic cyst infection cases
Case Age/sex
Time between AS 
and symptoms Symptoms Treatment
1 59/F 4 weeks Pain, fever and chills Oral antibiotics 
2 54/F 3 weeks Pain and fever Intravenous and  
oral antibiotics
3 55/F 3 days Fever and chills Oral antibiotics
4 57/F 3 weeks Pain and fever Intravenous and  
oral antibiotics
5 69/F 7 weeks Diarrhea, nausea, vomiting and 
subfebrile body temperature
Cyst drainage + intravenous 
and oral antibiotics
AS = aspiration sclerotherapy, F = female
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Blood cultures returned negative. 18F-FDG PET/CT revealed increased metabolic activity 
at the aspirated hepatic cyst, suggesting cyst infection (Figure 2). We initiated ceftriaxone 
and as the patient rapidly improved we switched to oral ciprofloxacin. After 12 weeks of 
treatment, the patient had completely recovered with normalized CRP (5 mg/L).
Case 5
A 69-year-old female was referred to our clinic because a cardiological work-up for chest 
pain had led to the discovery of multiple hepatic cysts. Ultrasonography revealed a large 
cyst (21 cm) located in the right hepatic lobe. During aspiration sclerotherapy, 3000 ml of 
clear, yellow fluid was drained. Seven weeks later, the patient complained of diarrhea (>10 
times daily), nausea, and vomiting (> 5 times daily). Physical examination revealed right 
and left upper quadrant abdominal tenderness and a subfebrile body temperature (38.1°C). 
Laboratory investigations showed a highly increased serum CRP of 374 mg/L. To support 
the diagnosis of a cyst infection in this patient, the recently aspirated cyst was punctured 
with aspiration of pus. A pigtail drain (10.5 Fr) was inserted to allow complete drainage of 
the cyst during the following days (Figure 3). Whereas blood cultures remained negative, 
cyst aspirate culture grew, Klebsiella pneumoniae confirming cyst infection diagnosis. 
Intravenous ceftriaxone and metronidazole was started. During the next week, serum CRP 
gradually decreased to 68 ml/L. The drain was removed and antibiotic therapy was switched 
Figure 2. 18F-FDG PET/CT shows increased metabolic activity surrounding the previously aspirated 
hepatic cyst located in the right hepatic lobe (asterisk). 
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to oral treatment with ciprofloxacin. After eight weeks of treatment symptoms resolved and 
serum CRP normalized.
DISCUSSION
We describe the spectrum of inflammatory complications of aspiration sclerotherapy that led 
to the tentative diagnosis of post-procedural hepatic cyst infection. All patients presented 
with acute onset abdominal pain and fever three days to seven weeks following aspiration 
sclerotherapy. All patients required hospitalization, received prolonged antibiotic therapy 
(4-10 weeks), and recovered without any sequela.
An extensive literature search identified two cases of postprocedural hepatic cyst 
infection.12, 15 These case reports lack diagnostic findings that support hepatic cyst infection 
diagnosis, such as raised inflammatory markers, positive imaging or microbiological findings. 
Alternatively, the rise in body temperature directly following aspiration sclerotherapy 
could be the result of an inflammatory response of the cystic wall, rather than a sign of 
postprocedural infection.16 Indeed, transient fever is a commonly reported side effect.10, 17 
However, both cases required intravenous antibiotic treatment,12, 15 suggesting a diagnosis 
of postprocedural hepatic cyst infection.
The proposed gold standard in diagnosing a cyst infection is presence of a cyst aspirate 
containing neutrophils and pathogens.13 In absence of a cyst aspirate, a mix of clinical 
and biochemical findings are used to establish a probable cyst infection diagnosis.13 In 
hindsight, four of our five patients were labeled with the diagnosis of probable hepatic cyst 
infection. Treatment of cyst infection is empiric and primarily consists of long term antibiotic 
treatment.18 In case of failure, invasive strategies such as prolonged cyst drainage or even 
Figure 3. Computed tomography demonstrating a large hepatic cyst in the right hepatic lobe (asterisk) 
with a pigtail drain inserted.
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partial hepatectomy have been described as a management option.18 In our experience, 
prolonged treatment with oral ciprofloxacin successfully resolved the episode.
To minimize the risk of infection, aspiration sclerotherapy is performed in an interventional 
suite to provide a sterile environment. One hour before the intervention we administer 
cefazolin (intravenous, 1000 mg). Dutch guidelines recommend cefazolin, a first-generation 
cephalosporin, for perioperative prophylaxis.19 Cefazolin is selectively active against micro-
organisms most frequently isolated from surgical site infections and has a favourable 
plasma-half-life which allows single-dosing.19 Cefazolin is not used as a therapeutic agent.19 
Nonetheless, in our series a postprocedural hepatic cyst infection developed despite 
antibiotic prophylaxis. This could be explained by an inadequate bactericidal intracystic 
concentration, as it is unknown if cefazolin is able to penetrate into the cyst. Future studies 
investigating the penetration capacity of cefazolin into hepatic cysts would be valuable. 
Alternatively, the antimicrobial spectrum of first-generation cephalosporins might not cover 
the micro-organisms that caused the infection.
CONCLUSIONS
We presented five cases with inflammatory complications following aspiration sclerotherapy, 
in which a postprocedural hepatic cyst infection was suspected. Antibiotic prophylaxis 
with cefazolin is unsuccessful in preventing cyst infection. In cases where a postprocedural 
hepatic cyst infection is suspected, we recommend pragmatic treatment with ciprofloxacin. 
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ABSTRACT
Objective
To identify predictive variables of treatment response following aspiration sclerotherapy of 
large symptomatic hepatic cysts. 
Methods
We collected individual patient data from two tertiary referral centers and included all 
patients treated with aspiration sclerotherapy of a large (>5 cm), symptomatic hepatic 
cyst. At six months, clinical response was defined as complete or incomplete. Secondary, 
suboptimal technical response was defined as lower quartile of cyst reduction. Predictive 
variables of clinical and technical response were analyzed by logistic regression analysis. 
Results 
We included 86 patients (58 ± 10 years; female 90 %). Complete clinical response rate was 
55 %. Median cyst diameter and volume reduction were 71%(IQR 50-87 %) and 98% (IRQ 
88-100 %), respectively. Patients with complete clinical response had a significantly higher 
cyst reduction compared to incomplete responders (OR 1.02, 95 % CI 1.00-1.04). Aspiration 
of haemorrhagic cyst fluid (OR 4.39, 95 % CI 1.34-14.39) or a lower cyst reduction at one 
month (OR 1.06, 95 % CI 1.02-1.10) was associated with a suboptimal technical response at 
six months. 
Conclusions
Complete clinical response is associated with effective cyst reduction. Aspiration of 
haemorrhagic cyst fluid or a restricted diameter reduction at one month predicts 
a suboptimal technical treatment response, however, these variables did not predict 
symptom disappearance.
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INTRODUCTION
Hepatic cysts are fluid-filled cavities that arise from congenital malformations of biliary 
ducts.1 The estimated prevalence of these benign, non-parasitic lesions is 2-18% in 
the general population.2-4 Hepatic cysts occur solitary or as multiple lesions in the context 
of polycystic liver disease (PLD).5 Aspiration sclerotherapy is a minimally invasive treatment 
option and serves as first-choice treatment for symptomatic hepatic cysts.6-8 Aspiration 
sclerotherapy combines percutaneous drainage of cyst fluid with subsequent instillation 
of a sclerosing agent that destroys the inner cyst lining. This treatment is effective and 
safe.9-14 There are two components that are important to the perceived success of aspiration 
sclerotherapy treatment. First, clinical response as experienced by the patient, and second, 
technical response in terms of reduction of the treated cyst. It is not well understood 
which factors determine clinical success or are important for technical response. Due 
to the infrequency of large symptomatic hepatic cysts, published studies are relatively 
small, which is an obstacle on the road to identification of predictive factors. In this 
study, we collected individual patient data from two observational cohort studies with 
comparable treatment protocols and follow-up measurements. The goal of this study was 
to identify variables that predict response of aspiration sclerotherapy of large symptomatic 
hepatic cysts.
METHODS
Patients and study design
We performed a pooled analysis of data collected from patients that consecutively 
underwent aspiration sclerotherapy in two tertiary referral centers: Radboud University 
Medical Center, Nijmegen, the Netherlands (center 1) and University Hospitals Paris Nord 
Val de Seine, Beaujon, Clichy, France (center 2) (Table 1). Center 1 prospectively included 
patients treated within a timeframe of June 2012 to March 2014, center 2 retrospectively 
included patients treated from December 2003 to September 2011. Within this timeframe 
the treatment protocol remained unchanged. For this analysis we included a cohort (center 
2) that was previously published to report efficacy of aspiration sclerotherapy.13 In the current 
study, we extended our data by pooling this sample with a second prospective cohort 
(center 1). By this, we created a large sample size that was needed to evaluate predictors of 
treatment response.
Included patients were aged over 18 years and underwent aspiration sclerotherapy 
of a simple, symptomatic, solitary or dominant hepatic cyst larger than 5 cm (Figure 1). 
A simple cyst was diagnosed by ultrasound (US), computed tomography (CT), or magnetic 
resonance imaging (MRI) based on the following criteria: a well-circumscribed anechoic 
lesion with increased posterior echo enhancement and no evidence of mural nodularity 
on US; a water-density (−10 to 10 HU) lesion with sharply defined margins and smooth 
thin walls with no contrast enhancement or septations on CT; or a homogeneous lesion, 
hypointense on T1-weighted images and hyperintense on T2-weighted images without 
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contrast enhancement or septations on MRI.15, 16 A history of a previous cyst haemorrhage 
was not considered an exclusion criterion. The diagnosis of a haemorrhagic cyst was based 
on pre-defined criteria.16 If deemed necessary, serology and/or more extensive imaging was 
applied to rule out hydatid or (pre-)malignant lesions. Parasitic or neoplastic cysts were not 
treated by aspiration sclerotherapy. In PLD patients (>20 cysts), the largest cyst was regarded 
as dominant cyst. A patient was excluded from analysis if the treated cyst could not be 
identified following treatment or was lost to follow-up. If a patient underwent two or more 
aspiration sclerotherapy procedures of the same cyst, only the first procedure was included 
in this analysis. The institutional review board of both participating centers approved this 
study and requirement for informed consent was waived.
Table 1. Design characteristics of included studies
Center 1 Center 2
Number of patients 
Design
29
Prospective cohort
57
Retrospective cohort
Type treatment Single session, ethanol Single session, ethanol
Population Solitary cysts and PLD Solitary cysts and PLD
Inclusion criteria > 18 y; simple, non-parasitic cyst > 18 y; simple, non-parasitic cyst
Endpoints Clinical and technical outcome, 
safety
Clinical and technical outcome, 
safety
Timepoints Baseline, one, and six months Baseline, one, six, and 12 months
Abbreviations: PLD, polycystic liver disease; y: years
Figure 1. Computed tomography demonstrating (asterisk) a solitary (a) and dominant hepatic cyst in 
polycystic liver disease (b).
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Baseline and follow-up study visits
At baseline and at one and six months following aspiration sclerotherapy, the patient visited 
the outpatient clinic to evaluate clinical and technical parameters. In both centers, overall 
clinical response was assessed at six months by standardized instruments and defined as 
Figure 2. Ultrasonography-guided placement of pigtail catheter to perform aspiration (a) followed by 
fluoroscopy demonstrating a collapsed hepatic cyst without leakage (b).
Aspiration sclerotherapy
Patients were informed about possible related risks and agreed to undergo aspiration 
sclerotherapy. In both centers, patients underwent aspiration sclerotherapy of a single 
hepatic cyst following a standardized single-session percutaneous ethanol sclerotherapy 
protocol.13 The intervention was performed with local anaesthesia and conscious sedation 
center 1, and under general anaesthesia in center 2. The cyst was localized by US and 
punctured with a 5-French pigtail catheter (center 1: Cook Medical, Bloomington, United 
States of America; center 2: Cordis Corporation, Bridgewater, United States of America) to 
perform complete fluid drainage of the hepatic cyst (Figure 2). Aspirated fluid was classified 
as clear or haemorrhagic (red or brown) fluid and evaluated by microscopy. Subsequently we 
performed fluoroscopy following instillation of contrast fluid (center 1: Iomeron 300, Bracco 
Imaging, Konstanz, Germany; center 2: Iobitridol, xenetix 350, Guerbet, France) to rule out 
leakage or communication with vasculature or the biliary tree (Figure 2). Sclerotherapy was 
performed by injecting 96-100% ethanol (center 1: up to 50 mL, 10 minutes; center 2: up to 
150 mL, 60 minutes) in the cyst. Following sclerotherapy, all ethanol was re-aspirated and 
the catheter was removed from the patient. Patients were discharged one day following 
the procedure.
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“disappearance”, “reduction”, “no change”, or “aggravation” of symptoms.13, 17 If a patient had 
not completed the questionnaire, we retrospectively reviewed the patients’ clinical chart (n 
= 10). Detailed information of symptom assessment can be found in the supplemental file 1.
The maximal cyst diameter of the treated cyst was measured during all visits (Figure 3). 
Subsequently, we estimated cyst volume by multiplying available orthogonal diameters by 
0.523 using the ellipsoid volume formula (d1*d2*d3*0.523). If an orthogonal diameter was 
missing, we substituted this value by the maximal diameter. In center 1, all measurements 
were performed by US (Acuson X150TM, Siemens Healthcare, Erlangen, Germany) by the same 
investigator. In center 2, US (Aixplorer ultrasound system, SuperSonic Imagine, Aix-en-
Provence, France; Aplio, Toshiba Medical system, Tokyo, Japan), CT (Advantage LightSpeed 
VCT, GE Healthcare, Milwaukee, United States of America), or MRI (1.5-T imager, interna, 
Philips Healthcare, Best, the Netherlands) were applied and measured by two investigators. 
Both centers monitored adverse events until six months following treatment.
Outcome variables
The primary outcome was the overall clinical response at six months following treatment. 
To predict optimal clinical success, we divided clinical outcome into two groups: complete 
clinical responders that reported “disappearance” or incomplete clinical responders that 
reported “reduction”, “no change” or “aggravation” of symptoms.
As a secondary outcome, technical response was evaluated by the proportional cyst 
reduction at six months. From a technical point of view, we were mainly interested in patients 
with a low (suboptimal) outcome to identify factors that are associated with lower efficacy 
of the procedure. To do so, we grouped technical response into patients with or without 
a suboptimal response, defined by a cyst diameter reduction in the lower quartile of the total 
sample. Secondly, we repeated this evaluation with cyst volume reduction measurements.
Predicting variables
The following variables were selected for analysis: age at treatment (years), gender, PLD 
(defined as > 20 cysts), previous drainage of the treated cyst, baseline cyst diameter (cm), 
location of the treated cyst (right or left liver lobe), haemorrhagic aspect of aspirated cyst 
fluid, volume of injected ethanol (mL), and proportional diameter reduction (%) at one and 
six month(s) following aspiration sclerotherapy.
Data collection
Both centers completed an electronic form containing all variables of interest. A pooled 
dataset was created by the initiating investigator. If possible, data inconsistencies were 
corrected in agreement with both centers.
Statistical analysis
Baseline characteristics are given in mean ± SD or median with interquartile range according 
to distribution. Patients characterized as complete clinical responder were compared with 
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patients with an incomplete clinical response on predefined predicting variables by univariate 
analysis. Similarly, we compared patients with or without a suboptimal technical response. 
Variables were selected as fixed effects in logistic regression analysis (generalized linear mixed 
models) if a P-value < 0.2 was found. To identify predictors of clinical and technical response, 
we used backward selection by excluding variables with a P-value > 0.05 in the multivariate 
analysis. The variable center retained in univariate and multivariate analysis as a random 
effect to correct for possible differences between centers. Within groups of symptomatic 
relief we compared proportional cyst diameter at six months by the non-parametric Kruskal-
Wallis test. In addition, we explored whether a suboptimal technical response was associated 
to clinical response using the Pearson’s chi-square test. Finally, to confirm our findings, we 
repeated all uni- and multivariate analyses using cyst volume measurements instead of 
diameter measurements. Statistical analyses were performed using IBM SPSS software, 
version 20.0. P-values were 2-tailed and a value < 0.05 was considered statistically significant.
RESULTS
Baseline characteristics
A total of 93 patients was retrieved from both centers. Seven patients were excluded from 
analysis (Figure 4). Reasons for exclusion were loss to follow-up (n = 4) or inability to identify 
the treated cyst from other surrounding cysts after aspiration sclerotherapy (n = 3). This 
Figure 3. Hepatic cyst diameter measurement by ultrasonography; transversal (left) and coronal (right) 
plane to estimate hepatic cyst volume.
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resulted in a pooled sample of 86 patients with a mean age at treatment of 57.8 (range 
28 - 80) years (Table 2). Female patients (n = 77, 89.5%) had a mean age of 57.0 (range 28 - 80) 
years, male patients (n = 9) had a mean age of 65.0 (57 – 79) years. 
Cysts were most frequently localized in the right hepatic lobe (69.8%). PLD was present 
in 38.4%. The median maximal diameter at baseline of the treated hepatic cyst was 11.0 cm 
(9.3-15.0 cm) corresponding with a median estimated baseline volume of 696 mL (381-1584 
mL). Aspect of cyst aspirate was assessed in 84 cases: 52 (61.9%) aspirates were classified as 
clear and 32 (38.1%) aspirates contained hemorrhagic constituents. This was confirmed by 
microscopic evaluation.
Figure 4. Overview of included patients
Table 2. Demographics (n = 86)
Age at treatment, mean (SD) 57.8 (10.2)
Female gender, n (%) 77 (89.5%)
PLD, n (%) 33 (38.4%)
Previous drainage treated cyst, n (%) 19 (22.1%)
Location cyst in right liver lobe, n (%) 60 (69.8%)
Cyst diameter baseline, median (IQR) 
Cyst volume baseline, median (IRQ)
11.0 (9.3-15.0)
696 (381-1584)
Volume aspirate, median (IQR) 500 (300-1200)
Hemorrhagic aspect of cyst fluid, n (%) 32 (38.1%)1
Volume of ethanol, median (IRQ) 70 (50-110)
1 Cyst fluid aspect was not characterized in two patients. Age is presented in years, diameters in centimeters, 
and volumes in milliliters. Abbreviations: PLD, polycystic liver disease; SD, standard deviation; IQR, 
interquartile range
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Overall clinical and technical response
At six months, 47 patients (54.7%) reported disappearance of symptoms and were defined 
as complete clinical responders. Thirty patients (34.9%) reported reduction, and nine 
patients (10.5%) had no change of symptoms following aspiration sclerotherapy and were 
collectively defined as incomplete clinical responders. In total, 89.6% of patients had either 
disappearance or reduction of symptoms. No patients reported aggravation of symptoms.
Median cyst diameter decreased from 11.0 cm (9.3-15.0 cm) to 8.6 cm (6.0-11.0 cm) 
one month following aspiration sclerotherapy, corresponding to a median proportional 
reduction of 29.7% (17.4-39.2%). Cyst diameter regression continued to a median cyst 
diameter of 3.5 cm (1.0-6.4 cm) six months following aspiration sclerotherapy, corresponding 
to a proportional reduction of 70.7% (50.0-87.2%). In line, median proportional cyst volume 
regressed by 68.0% (40.4-78.4%) to 264 mL (103-605 mL) in the first month. At six months, 
median volume regressed to 22 mL (1-101 mL) corresponding with a proportional reduction 
of 97.8% (87.5-99.8%). Overall, center 2 reported a higher cyst reduction at six months than 
center 1: 99% (94-100%) vs 92% (68-98%), respectively.
Predictors of complete clinical response
After univariate analysis, we selected location of the treated cyst, volume of injected ethanol, 
proportional diameter reduction at one month, and proportional diameter reduction at six 
months for subsequent regression analysis (Table 3). Multivariate analysis identified that an 
increased proportional diameter reduction at six months was associated with a complete 
clinical response (OR 1.02, 95% CI 1.00-1.04, P = 0.046). When we replaced proportional 
diameter reduction at six months for volume measurements, statistical significance was lost 
(OR 1.02, 95% CI 0.99-1.05, P = 0.665, Supplementary File 2). We observed no significant 
center effect (P = 0.13). Further explorative analysis revealed that proportional diameter 
reduction at six months was 78.6% (60.0-92.9%) in patients with symptom disappearance, 
62.9% (43.4-82.8%) in patients with symptom reduction, and 50% (24.5-66.4%) in patients 
who reported no change of symptoms (P = 0.01) (Figure 5). In accordance to our diametric 
analysis, patients with symptom disappearance showed a statistically significant higher 
median volume reduction at six months of 99.0% (94.1-100%), compared to 94.4% (79.1-
99.5%) and 87.5% (60.6-95.9%) in patients with reduction or no change of symptoms, 
respectively (P = 0.02).
Predictors of suboptimal technical response
The lower quartile in technical response (n = 22) was defined by a proportional diameter 
reduction smaller than 50.0% and a volume reduction smaller than 87.5%, characterized 
as suboptimal technical response.  Age, baseline cyst diameter, proportional cyst diameter 
reduction after one month, and aspect of cyst fluid were selected for subsequent regression 
analysis (Table 4). By multivariate analysis, we identified that patients with lower diameter 
reduction at one month had higher risk of having a suboptimal technical response at six 
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months (OR 1.06, 95% CI 1.02-1.10, P < 0.01). In addition, cysts containing haemorrhagic 
fluid were associated with a suboptimal technical response (OR 4.39, 95% CI 1.34-14.39, P 
= 0.02). We confirmed our findings when diameter outcome and predictors were replaced 
by volume measurements (Supplementary File 3). A suboptimal technical response was 
predicted by a lower volume reduction at one month (OR 1.04, 95% CI 1.02-1.06, p < 0.01) 
and haemorrhagic cyst fluid (OR 4.78, 95% CI 1.38-16.54, P = 0.01). Again, we found no 
significant center effect (P = 0.06). Finally, explorative analysis revealed that 8 of 22 (36.4%) 
patients with a suboptimal technical response had complete clinical response, compared 
to 39 of 64 (60.9%) patients without a suboptimal technical response, a difference that was 
statistically significant (P = 0.046).
Safety
Overall, nine adverse events (10.7%) occurred. Four patients developed an adverse event 
immediately after treatment, these included: hypotension (n = 2), transient fever (n = 1), 
and a cyst haemorrhage (n = 1). During follow-up, four patients reported pain between 2-24 
days after treatment, in three of these patients a cyst haemorrhage was suspected based on 
clinical and radiological presentation. Finally, one patient developed an hepatic cyst infection 
(n =1) which was treated adequately by antibiotic treatment. The remaining adverse events 
were managed by conservative treatment. All adverse events resolved without sequelae.
DISCUSSION
The primary finding of this study is that a strong hepatic cyst reduction following aspiration 
sclerotherapy predicts complete clinical response. We also identified that haemorrhagic cyst 
aspirate and a limited cyst size reduction at one month predicted a suboptimal long-term 
cyst reduction but did not affect clinical response.
Figure 5. Proportional cyst diameter reduction within groups of symptom relief at six months
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Clinical efficacy in this pooled cohort was high as 89.6% of treated patients reported 
reduction of symptoms while symptoms disappeared completely in 54.7%. The literature 
contains four large studies that assessed symptomatic response following aspiration 
sclerotherapy with various sclerosing agents. Similar to our results, these studies reported 
reduction of symptoms in 72.0-92.2%, while 46.1-85.0% had complete resolution of 
symptoms.7, 10, 18, 19 However, these studies failed to investigate which factors contribute to 
clinical treatment response. We used the model of an individual patient data analysis with 
data coming from two independent cohorts, to demonstrate that a significant reduction of 
the treated cyst was associated to a better overall clinical response. Indeed, patients with 
a cyst diameter reduction over 50% were more likely to have complete clinical response. 
This underlines that effective technical success is needed to increase the patients’ chance to 
benefit of treatment. 
We observed a median proportional diameter reduction of 71% at six months following 
aspiration sclerotherapy, corresponding with a volume reduction of 98%. This strong 
reduction rate is comparable to other studies that evaluated long-term technical success 
of aspiration sclerotherapy. These studies achieved a proportional diameter reduction 
ranging from 54.8-85.7% after 12-48 months.7, 20-22 Correspondingly, studies that reported 
efficacy in terms of proportional volume reduction ranged from 90.8-98.9% following 
12-30 months.18, 23-25
Sclerotherapy of hepatic cysts containing haemorrhagic fluid is not contraindicated 
and leads to reduction of the cyst.13 Nonetheless, we found that drainage of haemorrhagic 
cyst fluid predicted an increased risk of a suboptimal technical treatment response. This 
may be the result of several reasons. Due to increased viscosity, residues of haemorrhagic 
cyst fluid may remain in the cyst following drainage, leading to a diluted concentration of 
the sclerosing agent.7, 26 Alternatively, clots or debris in the cyst may prevent contact with 
the cyst wall.10 A spontaneous cyst bleeding is estimated to occur in around 8% of hepatic 
cysts.27 Remarkably, 32 (38%) patients in our sample had cyst fluid containing haemorrhagic 
constituents. This relatively large proportion of haemorrhagic cyst fluid in treated patients 
may result from the symptomatic course following a cyst bleed, ultimately leading to 
treatment of the cyst. In this study, haemorrhagic content was not associated to a reduced 
clinical response. The present results validate the use of aspiration sclerotherapy in this 
subgroup of patients.
Furthermore, we found that a lower cyst reduction at one month predicted a suboptimal 
technical response at six months. Intracystic fluid re-accumulation directly following 
aspiration sclerotherapy is a well-known phenomenon that leads to a restricted cyst 
reduction in first weeks.28 Although temporary, the cyst may relapse completely following 
aspiration sclerotherapy.24 Previous studies speculated that secretory function of cyst-lining 
epithelial cells may persist following sclerotherapy; others considered fluid re-accumulation 
as a component of inflammatory response.7, 29 Although transient in most cases, we found 
that a strong relapse predicted a suboptimal long-term cyst reduction.
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Apart from aspiration sclerotherapy, surgical fenestration is often advocated as a primary 
treatment option for hepatic cysts. In a review of 43 studies (311 patients) evaluating 
the efficacy and safety of cyst fenestration, reduction of symptoms was found in 92% of 
treated patients.8 This clinical response is consistent with our results. However, 22% of 
laparoscopic procedures were converted to open fenestration and overall morbidity 
following cyst fenestration was reported in 23% of cases, whereas in our study 11% of 
patients experienced an adverse event. Our results suggest that aspiration sclerotherapy has 
comparable clinical efficacy with lower morbidity rates compared to its surgical alternative.
In this study, we confirm that aspiration sclerotherapy is highly effective in reducing 
symptoms. Therefore, we advocate that aspiration sclerotherapy should be primary 
treatment for patients with a symptomatic, solitary, or dominant hepatic cyst. In patients 
with haemorrhagic cyst fluid aspirate or a strong fluid reaccumulation following aspiration 
sclerotherapy, we advise increased attention. If symptoms recur, initiation of a subsequent 
aspiration sclerotherapy or referral for surgical treatment may be favorable.
The main strength of this study is that we pooled results of two similar studies from 
different countries and thereby increased the generalizability of our results. Moreover, this 
relatively large sample size enabled us to evaluate predictors of treatment response. Some 
limitations come with this study. Firstly, symptomatic change was evaluated by two different 
questionnaires. A detailed evaluation of specific symptoms could not be performed due 
to differences between these instruments. However, as both instruments assessed overall 
symptomatic response in a comparable standardized manner, we were able to pool results 
of overall clinical response and believe that possible introduced bias is limited. Secondly, 
due to small numbers of patients without reduction of symptoms, we grouped patients with 
“reduction” of symptoms and “no change” as incomplete clinical responder. As a result, we 
were unable to evaluate predicting variables of clinical non-responders. Furthermore, our 
follow-up extends over a period of six months and should ideally be validated over a longer 
period. However, we regard six months as sufficient as the most prominent cyst regression 
occurs within these first months and sustains thereafter.24 Moreover, cyst diameter 
measurements were performed by different imaging modalities and investigators between 
centers; this could have led to differences in outcome measurements. Finally, duration of 
ethanol instillation differed between center 1 and center 2. As this was completely co-linear 
to center, we could not include this variable in our analysis. A prolonged exposure of 
the sclerosing agent to the cyst wall may improve efficacy of treatment. On the other hand, 
previous studies stated that ethanol eliminates epithelial cells within minutes.24, 30 The impact 
of duration of sclerotherapy on treatment efficacy remains to be tested.
CONCLUSIONS
To conclude, aspiration sclerotherapy of hepatic cysts effectively reduces symptoms in 
the vast majority of patients. Chance of complete clinical response is increased in patients 
with higher proportional cyst reduction. We identified that a limited cyst reduction in 
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the first month and the presence of haemorrhagic cyst fluid predict a suboptimal technical 
treatment response, however, these variables did not predict symptom disappearance.
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SUPPLEMENTARY FILES
Supplementary file 1. Clinical response evaluation
In center 1, the gastrointestinal symptoms (GIS) questionnaire was applied evaluating 11 
abdominal symptoms on an adjectival scale ranging from 0 (“none”) to 6 (“severe”).17 One 
question was added evaluating overall clinical response of symptoms (“decrease”, “no 
change” or “aggravation” of symptoms) following AS. Likewise, in center 2, symptomatic 
change (“disappearance”, “persistence but decrease”, “no change” or “aggravation” of 
symptoms) following AS was assessed.13
To pool results of overall symptomatic response, we re-evaluated the GIS scores from 
patients in center 1 who had characterized their symptoms as “decrease” and determined 
if a patient had “disappearance” or “persistence but decrease” of symptoms. If a patient had 
not completed the GIS questionnaire, we retrospectively assessed symptomatic relief by 
reviewing the patient’s chart.
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ABSTRACT
Background
Aspiration sclerotherapy is an effective therapeutic option for large symptomatic hepatic 
cysts. However, incomplete cyst reduction following aspiration sclerotherapy is frequently 
reported. Strong post-procedural cyst fluid secretion by cholangiocytes, which line 
the epithelium of the hepatic cyst, seems to be associated with lower reduction rates. 
Previous studies showed that somatostatin analogues curtail hepatic cyst fluid production. 
This trial will evaluate the effect of aspiration sclerotherapy combined with the somatostatin 
analogue pasireotide on cyst reduction. By combining treatment modalities we aim 
to improve cyst reduction leading to greater symptomatic relief and reduced rates of 
cyst recurrence.
Methods
This single center, randomized, double-blind, placebo-controlled clinical trial evaluates 
the additional effect of pasireotide when combined with aspiration sclerotherapy in patients 
with a large (> 5 cm) symptomatic hepatic cyst. A total of 34 participants will be randomized 
in a 1:1 ratio. In the active arm, patients will receive pasireotide (long-acting release, 60 mg 
injection) two weeks prior to and two weeks following aspiration sclerotherapy. Patients 
in the control arm will receive placebo injections at corresponding intervals. The primary 
outcome is proportional cyst diameter reduction four weeks after aspiration sclerotherapy 
compared to baseline measurements, obtained by ultrasonography. As secondary outcomes, 
proportional volume reduction, recurrence, symptomatic relief and improvement of health-
related quality of life will be assessed. Furthermore, safety and tolerability of the combination 
of pasireotide and aspiration sclerotherapy will be evaluated.
Discussion
This trial aims to improve efficacy of aspiration sclerotherapy by a combined approach 
of two treatment modalities. We hypothesize that pasireotide will decrease fluid 
reaccumulation after aspiration sclerotherapy leading to effective hepatic cyst reduction and 
symptomatic relief.
Trial registration
This trial is registered with ClinicalTrials.gov (identifier: NCT02048319; registered on January 
6, 2014) and EudraCT (identifier: 2013-003168-29; registered on August 16, 2013).
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INTRODUCTION
Hepatic cysts are fluid-filled cavities originating from congenital malformations of biliary 
duct cells. Isolated cysts occur at a prevalence of 2.5-18%, while polycystic liver disease 
(PLD) is infrequent.1-4 Large or multiple hepatic cysts may cause symptomatic disease. Mass-
related symptoms include abdominal distension, pain, postprandial fullness, nausea, and 
dyspnea, collectively leading to a compromised health-related quality of life.5, 6 Treatment 
should be considered in all symptomatic patients.4, 7 Aspiration sclerotherapy is a minimally 
invasive procedure indicated for both solitary and dominant hepatic cysts in PLD. Aspiration 
sclerotherapy includes percutaneous drainage of cyst fluid with subsequent intracystic 
instillation of a sclerosing agent (such as ethanol or tetracycline) aiming to destroy the inner 
cystic lining of cholangiocytes.8, 9 However, the efficacy of aspiration sclerotherapy is limited 
due to direct fluid reaccumulation following treatment.10 Although reaccumulation is 
transient, strong fluid secretion is associated with lower efficacy rates leading to failure of 
symptom relief and the necessity to re-intervene.7, 10, 11
Somatostatin analogues inhibit cyst fluid production.12 Several randomized clinical trials 
demonstrated that somatostatin analogues (octreotide and lanreotide) decrease polycystic 
liver volume.13-15 Pasireotide (SOM230) is a more potent somatostatin analogue compared 
to conventional somatostatin analogues as it has a broader binding profile and stronger 
affinity to its receptors.16, 17 We hypothesize that pasireotide administration reduces fluid 
re-accumulation following aspiration sclerotherapy and therefore increases diameter 
reduction. We expect that inhibited re-accumulation results in effective symptomatic relief 
and reduced recurrence rates. To this end, we have designed a randomized, double-blind, 
placebo-controlled clinical trial to evaluate clinical efficacy of aspiration sclerotherapy 
combined with pasireotide.
METHODS
Study aim
The primary objective of the SCLEROCYST trial is to evaluate the combined effect of 
aspiration sclerotherapy and pasireotide on cyst diameter reduction. Secondary objectives 
are to determine symptomatic relief and cyst recurrence.
Hypothesis
We hypothesize that administrating pasireotide curtails fluid reaccumulation following 
aspiration sclerotherapy and thereby increases cyst diameter reduction.
Study design and setting
The SCLEROCYST trial is a randomized, double-blind, placebo-controlled clinical trial. This 
single-center study is performed at the Radboud university medical center, Nijmegen, 
the Netherlands. Trial duration will be 30 weeks consisting of a screening period of four 
weeks and a treatment period of 26 weeks (Figure 1).
ASPIRATION SCLEROTHERAPY COMBINED WITH PASIREOTIDE: STUDY PROTOCOL
88
6a
Randomization and treatment allocation
A total of 34 patients will be randomized in a 1:1 ratio to receive either pasireotide or 
placebo. All patients will be subjected to aspiration sclerotherapy. Randomization will be 
performed using block randomization with a block size of four. Included patients will be 
assigned a randomization number, corresponding to a treatment arm, concealed in a closed 
envelope. Access to treatment allocation will be restricted to research nurses who prepare 
and administer the injections. Both patients and treatment allocators will be unaware of 
the allocated treatment.
Study population
All patients who are diagnosed with a symptomatic, hepatic cyst that meet the following 
eligibility criteria will be suitable for participation in this study.
Inclusion criteria
The inclusion criteria for this study are as follows:
1. Aged between 18 and 70 years;
2. Indication for treatment with aspiration sclerotherapy, made upon diagnosis of 
a symptomatic, simple hepatic cyst exceeding 5 cm in diameter;
3. The treated hepatic cyst must be solitary or dominant by nature; a dominant hepatic cyst 
is the largest cyst surrounded by multiple smaller cysts in patients with PLD and
4. Provision of informed consent to participate.
Figure 1. Study design of the SCLEROCYST trial. AS = aspiration and sclerotherapy; INJ = injection of 
pasireotide or placebo; Q = assessment of GIS, PLD-Q and SF-36 questionnaires; US = ultrasonography
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Exclusion criteria
The aspiration sclerotherapy-related exclusion criteria are as follows:
1. Suspicion of a complicated hepatic cyst (active cyst hemorrhage, rupture, or infection);
2. Coagulopathy (international normalized ratio (INR) >2 or platelet count <80 x 109/l) or
3. Severe co-morbidity contraindicating anesthesia (ASA 4 classification).
The pasireotide treatment-related exclusion criteria are as follows:
1. Known long QT syndrome and/or corrected QT interval (QTc) at screening >470 ms;
2. Family history of long QT syndrome or idiopathic sudden death;
3. Uncontrolled or significant cardiac disease including a recent myocardial infarction, 
congestive heart failure, unstable angina or sustained and/or clinically significant cardiac 
arrhythmias;
4. Risk factors for torsades de pointes: hypokalemia, hypomagnesemia, hypocalcaemia, 
clinically significant bradycardia, or high grade atrioventricular block;
5. Concomitant disease that could prolong QT interval such as autonomic neuropathy, HIV, 
cirrhosis, uncontrolled hypothyroidism or cardiac failure;
6. Use of anti-arrhythmic medicinal products or other substances known to lead to QT 
interval prolongation;
7. Symptomatic cholecystolithiasis;
8. Uncontrolled diabetes, defined as glycated hemoglobin (HbA1C) level >64 mmol/ml 
despite adequate therapy;
9. Moderate to severe hepatic impairment defined by a Child-Pugh classification of more 
than six points;
10. History of acute pancreatitis;
11. Hypersensitivity to somatostatin analogues or any component of pasireotide or
12. Non-malignant medical illnesses that are uncontrolled or whose control may be 
jeopardized by the treatment with the study therapy.
Further exclusion criteria are as follows:
1. Pregnant or nursing women;
2. Use of oral contraception or estrogen supplementation;
3. Intervention (aspiration with or without sclerotherapy or surgical intervention) within six 
months prior to baseline;
4. Treatment with somatostatin analogues within six months prior to baseline or
5. Any current or prior medical condition that may interfere with the conduct of the study 
or the evaluation of its results in the opinion of the investigator.
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Trial treatments
Aspiration sclerotherapy
All included patients will undergo aspiration sclerotherapy of a single hepatic cyst following 
standard of care. This single session procedure will be performed by one of our five 
interventional radiologists, experienced in performing aspiration sclerotherapy. Patients 
will be admitted the day of aspiration sclerotherapy and will receive intravenous antibiotic 
prophylaxis (cefazolin 1000 mg (Eurocept, Ankeveen, the Netherlands) or clindamycin 600 
mg (Sandoz, Holzkirchen, Germany) as an alternative in case of allergies). The procedure will 
be carried out with conscious sedation. Briefly, the cyst will be localized by ultrasonography. 
Following disinfection and local anaesthesia of the skin, a 5 French pigtail catheter (Cook 
Medical, Bloomington, United States of America) attached to a three-way tap will be 
inserted in the hepatic cyst to perform complete fluid evacuation (aspiration). Cyst leakage 
or communication with vessels or bile ducts will be examined by instillation of contrast 
medium (Iomeron 300, Bracco Imaging, Konstanz, Germany), up to 20 ml, into the cyst cavity. 
Contrast medium will then be aspirated from the cyst followed by an injection of 100% 
ethanol (sclerotherapy). The amount of instilled ethanol consists of 10% of the aspirated cyst 
volume (up to a maximum of 50 ml). After 10 minutes, ethanol is aspirated and the drain will 
be removed.
Pasireotide
Subjects in the active treatment arm will receive two intragluteal injections of 60 mg 
pasireotide (SOM230, Novartis, Basel, Switzerland) long-acting release (LAR). The first 
injection will be administered two weeks prior to aspiration sclerotherapy, the second 
injection will be administered two weeks following aspiration sclerotherapy. Pasireotide 
LAR, powder for suspension for injection, is a one-month depot microparticle formulation 
for intramuscular administration. No dose adjustment is required for race, age, gender, body 
weight, mild hepatic impairment, or renal impairment. The most common adverse events 
are gastrointestinal by nature and include mild diarrhea, nausea and abdominal pain.18 These 
events are more frequent in the first days after treatment initiation and mitigate within time. 
Moreover, transient hyperglycemia, local injection site skin reactions and headaches are 
common side effects of pasireotide.18, 19 Previous studies have indicated that pasireotide may 
prolong the QT interval.20 Therefore, patients with a prolonged QTc at screening (> 470 ms) are 
not eligible to participate in this study. Known long term side effects, such as development 
of gallstones, are not expected in this study given the limited number of injections.
Placebo
Patients in the placebo arm will receive two intragluteal injections of 2 ml sodium chloride 
solution 0.9%. (Fresenius Kabi, Hesse, Germany) The first injection will be administered two 
weeks prior to aspiration sclerotherapy and the second injection will be administered two 
weeks following aspiration sclerotherapy.
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Study endpoints
Primary outcome
The primary outcome of the SCLEROCYST trial is the mean proportional change (%) in cyst 
diameter of the treated hepatic cyst four weeks after aspiration sclerotherapy, as measured 
by ultrasound.
Secondary outcome
Secondary outcomes are mean proportional change (%) in cyst diameter two, 12, and 
24 weeks after aspiration sclerotherapy. Moreover, proportional change (%) in volume, 
absolute diameter reduction (cm) and rate of cyst recurrence (>80% of original diameter) 
at follow-up visits will be assessed. In addition, symptoms and health-related quality of life 
will be measured at baseline, four, 12, and 24 weeks after aspiration sclerotherapy. Finally, 
any complications or adverse events reported during procedure or follow-up visits will 
be recorded.
Ultrasound measurements
The blinded primary investigator will perform cyst diameter measurements by 
ultrasonography. The treated hepatic cyst will be visualized in two planes to measure each 
maximal orthogonal diameter (craniocaudal, anteroposterior and mediolateral) three times. 
As a secondary endpoint, cyst volume will be estimated by multiplying the maximum of 
each orthogonal diameter by 0.523.10 The measurement will be performed using a 3.5 MHz 
convex transducer (Acuson X150TM, Siemens Healthcare, Erlangen, Germany). A blinded 
independent investigator will repeat all measurements. Both investigators are trained and 
experienced in measuring hepatic cyst diameter.
Patient-reported outcome measures
Abdominal symptoms and health-related quality of life will be assessed at screening and 
during follow-up visits. The standardized gastrointestinal symptom questionnaire (GIS) 
assesses 11 abdominal symptoms using a seven-point Likert scale ranging from 0 (‘none’) 
to six (‘severe’).21 The Medical Outcomes Study 36-item short-form health survey (SF36) 
will be completed to evaluate health-related quality of life.22 This generic questionnaire 
assesses health-related quality of life in eight different domain scores and two summarizing 
(physical and mental) component scores. Additionally, a disease-specific questionnaire for 
PLD in development (PLD-Q, Radboud university medical center, Nijmegen) that assesses 
frequency and discomfort of 13 PLD-related symptoms over a timeframe of one month, will 
be completed by all subjects in order to validate this instrument in patients treated for large 
symptomatic hepatic cysts.
Study procedures
This study consists of seven visits including one screening visit, three treatment visits and 
three follow-up visits.
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Screening visit (within four weeks prior to starting the trial)
Potential subjects with an indication for aspiration sclerotherapy will be asked to participate. 
Informed consent will be obtained from all participants. Upon providing informed consent, 
each subject will be screened for eligibility during a separate screening visit performed within 
28 days prior to the start of the trial. During this screening visit the following assessments 
will be made:
1. obtain written informed consent;
2. extensive medical history and physical examination;
3. laboratory markers: potassium, calcium, magnesium, estimated glomerular filtration rate 
calculated by the Modification of Diet in Renal Diseases (MDRD) formula, platelets, INR, 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase 
(ALP), gamma-glutamyl transpeptidase (GGT), total bilirubin (TB), albumin, and fasting 
blood sugar (FBS);
4. urine pregnancy test in female patients with childbearing potential;
5. electrocardiogram: frequency, QTc, and atrioventricular conduction;
6. ultrasonography: cyst diameter and volume measurement and
7. questionnaires: GIS-, PLD- and SF-36 questionnaire.
First injection (week 0)
The first injection will be administered 14 days prior to aspiration sclerotherapy and indicates 
the start of this trial. Patients in the treatment arm will receive the first injection of pasireotide 
LAR 60 mg, while patients in the placebo arm will receive an injection of the sodium 
chloride solution. The injections will be administered by an independent unblinded health 
professional who is not involved in the design, execution or analysis of the trial.
Aspiration sclerotherapy (week two)
Patients will be admitted the day of aspiration sclerotherapy. Prior to the intervention, 
adverse events in the previous two weeks will be assessed. Moreover, blood will be drawn to 
evaluate safety laboratory markers (potassium, magnesium, FBS, ALT, AST, TB, and amylase). 
Aspiration sclerotherapy will be performed following standard procedure in both arms. 
Aspirated cyst fluid will be stored in our laboratory for future analyses.
Second injection (week four)
Two weeks following aspiration sclerotherapy (4 weeks following the first injection) 
the patient will visit the outpatient clinic to receive the second injection. Cyst diameter 
will be assessed. All adverse events will be documented and blood will be obtained. In 
case the following laboratory parameter levels are found, the second injection will not 
be administered:
1. FBS >9.9 mmol/l;
2. AST or ALT >5 x upper limit of normal (ULN);
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3. AST or ALT >3 x ULN with TB >2 x ULN or
4. amylase >10 x ULN.
If the parameters fall within the margin of safety, the second injection will be administered.
Follow-up visits (week six, 14, and 26)
Three follow-up visits will be planned at six, 14, and 26 weeks following the first injection 
(i.e. 4, 12, and 24 weeks following aspiration sclerotherapy). The researcher will document 
adverse events and blood will be drawn to assess safety laboratory markers (FBS, ALT, 
AST, ALP, and GGT). The diameter of the treated cyst will be captured and cyst volume will 
be calculated. The primary endpoint of this study, mean proportional change (%) in cyst 
diameter at four weeks after aspiration sclerotherapy, will be obtained during the first 
follow-up visit. Furthermore, abdominal symptoms and health-related quality of life will be 
measured using the GIS, PLD-Q, and SF-36 questionnaires.
Study withdrawal
Subjects can withdraw informed consent and leave the study at any time. The investigator 
will withdraw a subject from the study for any of the following reasons: pregnancy, 
consistent failure to adhere to protocol requirements, unacceptable toxicity of study 
medication, surgical interventions during the study or any other reason if in the best interest 
of the patient. All data generated up to the time of discontinuation from the study will be 
analyzed and the reason(s) for discontinuation will be recorded.
Sample size considerations
Recent data showed that patients treated by aspiration sclerotherapy have a mean diameter 
reduction of 29.7 ± 19.76% after four weeks.23 By adding pasireotide, we want to establish 
a decrease in cyst diameter of 50% after four weeks. A sample size of 15 patients per arm, 
leading to a total of 30 patients is required to be able to obtain a significant difference 
between the two groups (power: 80%; α: 0.05). Taking into account the possibility of 10% 
protocol violators and/or dropouts, we aim to include 17 subjects per arm, giving a total of 
34 patients.
Statistical analysis
Intention-to-treat (ITT) analyses will be used for all clinical outcome variables. The ITT sample 
includes all patients who received at least one dose of study medication. In addition, we will 
carry out a parallel analysis on the per-protocol treated population. This sample is defined as 
all patients who have received both injections, aspiration sclerotherapy and all ultrasound 
measurements. The primary outcome of this study is the proportional (%) change in cyst 
diameter of the treated hepatic cyst four weeks after aspiration sclerotherapy, as measured 
by ultrasound. The mean diameter of each orthogonal diameter measured by the blinded 
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primary investigator will be used for analysis. Subsequently, we will calculate a mean 
diameter from the three mean orthogonal diameters. Proportional change will be calculated 
by dividing the reduction of mean cyst diameter at four weeks by mean cyst diameter at 
baseline, multiplied by 100. Depending on distribution, values will be presented as mean ± 
SD or as median and interquartile range. Consequently, differences between the treatment 
and placebo arm will be calculated using the independent student’s t-test or the Mann 
Whitney U test, respectively. Absolute reduction and volume reduction will be presented 
and analyzed similar to date for the primary endpoint. Cyst recurrence will be compared 
between both groups using Fisher’s exact test. The cyst diameter measurements from 
the second, blinded, investigator will be used as a control to evaluate intra- and interobserver 
variability by performing a Bland-Altman analysis. Symptoms of the GIS-questionnaire will 
be dichotomized (0 to one versus two to six) and compared between the treatment and 
placebo arm using the chi-square test. Health-related quality of life domain scores and 
component scores (SF-36) will be compared between both arms using the Mann Whitney 
U test. Frequency tables will be compiled for (Serious) Adverse Events classified according 
to the standard World Health Organization-Adverse Reaction Terminology (WHO-ART) 
Body System Dictionary and preferred terms. All statistical analyses will be two-sided, with 
a critical significance level of 5%.
Ethical considerations
Ethical approval of the study protocol was given by the Central Committee on Research 
Involving Human Subjects and by the local accredited Medical Research Ethics Committee 
of the region Arnhem-Nijmegen, the Netherlands (reference number 2013/354). This study 
is to be conducted in accordance with the International Conferences of Harmonization Good 
Clinical Practice Guidelines, the principles of the Declaration of Helsinki 1964 as modified by 
the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 including two notes 
of clarification on paragraph 29 and 30, and the local national laws governing the conduct 
of clinical research studies. An independent data and safety monitoring board has been 
formed to monitor patient safety and treatment efficacy during the trial.
DISCUSSION
The SCLEROCYST trial is designed to evaluate the additional effect of pasireotide on hepatic 
cyst diameter reduction in patients treated by aspiration sclerotherapy. We hypothesize that 
complementary pasireotide treatment results in an augmented treatment efficacy. Multiple 
studies have shown that aspiration sclerotherapy is an effective and safe method to reduce 
hepatic cyst volume.7, 23, 24 However, cyst reduction is curtailed by fluid reaccumulation 
following treatment.10 Fluid secretion by cyst-lining cholangiocytes is mediated by 
intracellular 3’-5’-cyclic adenosine monophosphate (cAMP). Increased levels of cAMP lead to 
activation of cystic fibrosis transmembrane conductance regulator (CFTR). Opening of these 
chloride channels results in chloride efflux, with a subsequent osmotic gradient facilitating 
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water transport into the cyst cavity.17, 25 Somatostatin analogues inhibit cAMP by activating 
the somatostatin receptor (SSTR), and thereby reduce cholangiocyte fluid production.12, 17, 26 
Indeed, previous randomized clinical trials showed that both octreotide and lanreotide are 
capable of reducing cystic liver volume.27
In the context of this study we want to evaluate whether these inhibitory mechanisms 
of somatostatin analogues can halt cyst fluid re-accumulation following aspiration 
sclerotherapy. We have chosen to apply the multireceptor-targeted, long-acting 
somatostatin analogue pasireotide (SOM230).16 This cyclohexapeptide has a high binding 
affinity to SSTR 1, 2, 3, and 5 which are all expressed on cholangiocytes.12 Compared to 
conventional somatostatin analogues, pasireotide has a broader binding profile and 
a higher affinity to SSTR 1, 3, and 5. In a polycystic kidney disease rodent model pasireotide 
decreased intracellular cAMP, cholangiocyte proliferation and expansion of hepatic cysts 
more effectively than octreotide.17 Pasireotide is approved in the European Union and 
Unites States for the treatment of Cushing’s disease, and is currently being investigated 
for treatment of other diseases such as acromegaly and neuroendocrine tumors. Two 
formulations of pasireotide are available: an immediate release and a one-month depot 
formulation. To ensure adequate pasireotide levels and optimize patient adherence, we have 
chosen to administer the LAR formulation of pasireotide. A previous pharmacokinetic study 
of pasireotide LAR in healthy volunteers showed that pasireotide levels reached a peak (tmax) 
around 20 days following administration.18 Therefore, to secure adequate levels subsequent 
to aspiration sclerotherapy, a first injection will be administered two weeks prior to AS, 
followed by a second injection two weeks following aspiration sclerotherapy.
The strength of this study is its design: a randomized, double-blind, placebo-controlled 
trial. This will minimize confounding of results. Further, this study is powered on a clinical 
relevant difference of 50% in the pasireotide arm compared to the expected 30% cyst 
diameter reduction in the controls arms. We believe that a statistical significant finding will 
have direct implications for future aspiration sclerotherapy treatment. Smaller differences 
between arms will not be detected in view of power issues. Nevertheless, given the additional 
costs and potential side effects of pasireotide, we believe that a strong improvement over 
conventional aspiration sclerotherapy is needed to justify the implementation of this 
combination treatment. Finally, with this study we hope to achieve a better understanding 
in the pathological mechanisms behind hepatic cyst development and fluid reaccumulation 
following aspiration sclerotherapy.
This study has several limitations. First, the effect of treatment will be measured by 
ultrasonography. Since we will perform cyst measurements within short intervals we have 
selected ultrasonography as most the appropriate imaging modality to avoid exposure to 
radiation (from computed tomography scans) and high costs (from magnetic resonance 
imaging). However, ultrasound measurements are operator-dependent and are therefore 
susceptible to bias. To minimize biased results, we have added several safety measures. 
All measurements will be performed according to standard operating procedures 
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and will be executed in triplicate. Moreover, all measurements will be performed by 
the same investigator who is blinded for treatment allocation. In addition, a second, blinded, 
independent investigator will repeat all measurements. Second, in this study sclerotherapy 
will be performed with 100% ethanol. Multiple sclerosing agents are in use for aspiration 
sclerotherapy ranging from ethanol to tetracycline antibiotics, polidocanol, ethanolamine 
oleate or hypertonic saline.8, 28-32 This might limit the generalization of our findings. On 
the other hand, ethanol is cheap, widely available and the clinical experience with this agent 
is large. Finally, aspiration sclerotherapy will be performed by a number of interventional 
radiologists, theoretically introducing performance bias. Nevertheless, this intervention is 
a protocol procedure and large differences in treatment outcome between interventional 
radiologists are not to be expected.
CONCLUSIONS
To summarize, the SCLEROCYST trial is designed to evaluate the additional effect of 
a somatostatin analogue combined with aspiration sclerotherapy. We aim to reduce fluid 
reaccumulation following treatment leading to increased cyst diameter reduction and 
symptomatic relief.
ACKNOWLEDGEMENTS
The authors would like to thank Marten Lantinga for his comments on the manuscript. 
Funding and study medication is supported by Novartis. Novartis had no role in the design 
and conduct of the study or in the writing and submission of the manuscript.
ASPIRATION SCLEROTHERAPY COMBINED WITH PASIREOTIDE: STUDY PROTOCOL
97
6a
REFERENCES
1. Gaines PA, Sampson MA. The prevalence 
and characterization of simple hepatic 
cysts by ultrasound examination. Br 
J Radiol 1989;62:335-7.
2. Larssen TB, Rorvik J, Hoff SR, et al. 
The occurrence of asymptomatic and 
symptomatic simple hepatic cysts. 
A prospective, hospital-based study. Clin 
Radiol 2005;60:1026-9.
3. Carrim ZI, Murchison JT. The prevalence of 
simple renal and hepatic cysts detected 
by spiral computed tomography. Clin 
Radiol 2003;58:626-9.
4. Everson GT, Taylor MR, Doctor RB. Polycystic 
disease of the liver. Hepatology 2004;40:774-82.
5. Gevers TJ, Drenth JP. Diagnosis and 
management of polycystic liver disease. Nat 
Rev Gastroenterol Hepatol 2013;10:101-8.
6. Wijnands TF, Neijenhuis MK, Kievit W, et al. 
Evaluating health-related quality of life in 
patients with polycystic liver disease and 
determining the impact of symptoms and 
liver volume. Liver Int 2013.
7. Drenth JP, Chrispijn M, Nagorney DM, et al. Medical 
and surgical treatment options for polycystic liver 
disease. Hepatology 2010;52:2223-30.
8. Bean WJ, Rodan BA. Hepatic cysts: treatment with 
alcohol. AJR Am J Roentgenol 1985;144:237-41.
9. Goldstein HM, Carlyle DR, Nelson RS. 
Treatment of symptomatic hepatic cyst by 
percutaneous instillation of Pantopaque. 
AJR Am J Roentgenol 1976;127:850-3.
10. Larssen TB, Rosendahl K, Horn A, et al. Single-
session alcohol sclerotherapy in symptomatic 
benign hepatic cysts performed with a time 
of exposure to alcohol of 10 min: initial 
results. Eur Radiol 2003;13:2627-32.
11. Erdogan D, van Delden OM, Rauws EA, et 
al. Results of percutaneous sclerotherapy 
and surgical treatment in patients 
with symptomatic simple liver cysts 
and polycystic liver disease. World J 
Gastroenterol 2007;13:3095-100.
12. Masyuk TV, Masyuk AI, Torres VE, et al. 
Octreotide inhibits hepatic cystogenesis 
in a rodent model of polycystic liver 
disease by reducing cholangiocyte 
adenosine 3’,5’-cyclic monophosphate. 
Gastroenterology 2007;132:1104-16.
13. van Keimpema L, Nevens F, Vanslembrouck 
R, et al. Lanreotide reduces the volume 
of polycystic liver: a randomized, double-
blind, placebo-controlled trial. 
Gastroenterology 2009;137:1661-8 e1-2.
14. Hogan MC, Masyuk TV, Page LJ, et al. 
Randomized clinical trial of long-acting 
somatostatin for autosomal dominant 
polycystic kidney and liver disease. J Am 
Soc Nephrol 2010;21:1052-61.
15. Caroli A, Antiga L, Cafaro M, et al. Reducing 
polycystic liver volume in ADPKD: effects 
of somatostatin analogue octreotide. Clin J 
Am Soc Nephrol 2010;5:783-9.
16. Schmid HA. Pasireotide (SOM230): development, 
mechanism of action and potential applications. 
Mol Cell Endocrinol 2008;286:69-74.
17. Masyuk TV, Radtke BN, Stroope AJ, et al. 
Pasireotide is more effective than octreotide 
in reducing hepatorenal cystogenesis in 
rodents with polycystic kidney and liver 
diseases. Hepatology 2013;58:409-21.
18. Dietrich H, Hu K, Ruffin M, et al. Safety, 
tolerability, and pharmacokinetics of a single 
dose of pasireotide long-acting release in 
healthy volunteers: a single-center Phase I 
study. Eur J Endocrinol 2012;166:821-8.
19. Breitschaft A, Hu K, Hermosillo Resendiz 
K, et al. Management of hyperglycemia 
associated with pasireotide (SOM230): 
healthy volunteer study. Diabetes Res Clin 
Pract 2014;103:458-65.
20. Breitschaft A, Hu K, Darstein C, et al. Effects 
of Subcutaneous Pasireotide on Cardiac 
Repolarization in Healthy Volunteers: a Single-
Center, Phase I, Randomized, Four-Way Crossover 
Study. J Clin Pharmacol 2014;54:75-86.
21. Bovenschen HJ, Janssen MJ, van Oijen MG, et 
al. Evaluation of a gastrointestinal symptoms 
questionnaire. Dig Dis Sci 2006;51:1509-15.
22. Ware JE, Kosinski M, Keller SD. SF-36 physical 
and mental health summary scales : a user’s 
ASPIRATION SCLEROTHERAPY COMBINED WITH PASIREOTIDE: STUDY PROTOCOL
98
6a
manual. Boston, Mass.: Health Institute, 
New England Medical Center, 1994.
23. Chrispijn M, Weimer FH, El-Massoudi Y, et 
al. Treatment Success of Aspiration and 
Sclerotherapy for Hepatic Cysts depends 
on Cyst Diameter and Volume of Sclerosing 
Agent. Hepatology 2012;56:837a-838a.
24. Benzimra J, Ronot M, Fuks D, et al. 
Hepatic cysts treated with percutaneous 
ethanol sclerotherapy: time to extend 
the indications to haemorrhagic cysts and 
polycystic liver disease. Eur Radiol 2014.
25. Torres VE, Harris PC. Strategies targeting cAMP 
signaling in the treatment of polycystic kidney 
disease. J Am Soc Nephrol 2014;25:18-32.
26. Alvaro D, Gigliozzi A, Attili AF. Regulation 
and deregulation of cholangiocyte 
proliferation. J Hepatol 2000;33:333-40.
27. Gevers TJ, Inthout J, Caroli A, et al. Young 
women with polycystic liver disease 
respond best to somatostatin analogues: 
a pooled analysis of individual patient data. 
Gastroenterology 2013;145:357-65 e1-2.
28. Hagiwara H, Kasahara A, Hayashi N, et al. 
Successful treatment of a hepatic cyst 
by one-shot instillation of minocycline 
chloride. Gastroenterology 1992;103:675-7.
29. vanSonnenberg E, Wroblicka JT, D’Agostino 
HB, et al. Symptomatic hepatic cysts: 
percutaneous drainage and sclerosis. 
Radiology 1994;190:387-92.
30. Potthoff A, Sandkuhler F, Boozari B, et al. 
Long-Term Follow up of 100 Patients with 
Polycystic Liver Disease - Efficacy of Percutaneous 
Us-Guided Polidocanol Sclerotherapy. Journal 
of Hepatology 2011;54:S359-S359.
31. Nakaoka R, Das K, Kudo M, et al. 
Percutaneous aspiration and ethanolamine 
oleate sclerotherapy for sustained 
resolution of symptomatic polycystic liver 
disease: an initial experience. AJR Am J 
Roentgenol 2009;193:1540-5.
32. Jusufovic R, Zerem E. Percutaneous 
treatment of symptomatic non-parasitic 
benign liver cysts with 20% NaCl solution. 
Med Arh 2011;65:35-7.

6b
PASIREOTIDE DOES NOT IMPROVE EFFICACY 
OF ASPIRATION SCLEROTHERAPY IN 
PATIENTS WITH LARGE HEPATIC CYSTS, 
A RANDOMIZED CONTROLLED TRIAL
Titus F.M. Wijnands
Tom J.G. Gevers
Marten A. Lantinga
René H. te Morsche
Leo J. Schultze Kool
Joost P.H. Drenth
Submitted
PASIREOTIDE DOES NOT IMPROVE EFFICACY OF ASPIRATION SCLEROTHERAPY
102
6b
ABSTRACT
Background
Hepatic cyst reduction after aspiration sclerotherapy is restricted by cyst fluid re-accumulation. 
Pasireotide, a long-acting somatostatin analogue, curtails cyst fluid production. Our aim was 
to test whether a combined approach of pasireotide and aspiration sclerotherapy would 
enhance cyst reduction and clinical response in patients with large hepatic cysts.
Methods
We conducted a double-blind, placebo-controlled trial in patients that underwent aspiration 
sclerotherapy of a large (>5 cm) symptomatic hepatic cyst at the tertiary Radboud university 
medical center from April 2014 through April 2016. Patients were randomized between 
intramuscular injections of pasireotide 60 mg long-acting release (n = 17) or placebo 
(n = 17). Injections were administrated two weeks before and two weeks after aspiration 
sclerotherapy. Primary endpoint was proportional cyst diameter reduction after six weeks. 
Secondary outcomes included long-term cyst reduction at 26 weeks, patient-reported 
outcomes including the polycystic liver disease-questionnaire (PLD-Q), and safety.
Results
Thirty-four patients (32 females (94%); mean age 53.6 ± 7.8 years) were randomized between 
pasireotide or placebo. Pasireotide did not improve efficacy of aspiration sclerotherapy at 
six weeks compared to controls (23.6% [IQR 12.6 - 30.0%] versus 21.8% [IQR 9.6 - 31.8%], 
respectively; P = 0.96). Long-term cyst diameter reduction was similar among groups (49.1% 
[IQR 27.0 - 73.6%] and 45.6% [IQR 29.6-59.6%]; P = 0.90). Mean PLD-Q scores improved 
significantly in both groups (P < 0.01) without differences between arms (P = 0.92). Except 
for transient hyperglycemia (pasireotide: n = 17; placebo: n = 5), adverse events were similar 
between groups.
Conclusions
In a randomized controlled trial of patients with large symptomatic hepatic cysts, 
administration of pasireotide to aspiration sclerotherapy did not improve cyst reduction or 
clinical response. 
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BACKGROUND
Hepatic cysts are fluid-filled cavities in the liver that congenitally arise from aberrant 
cholangiocytes.1 Cysts occur in a spectrum from sporadic lesions to numerous cysts as part 
of polycystic liver disease (PLD). Due to continuous cholangiocyte proliferation and fluid 
production, cysts grow over time.2, 3 Large hepatic cysts lead to invalidating symptoms as 
pain, nausea, and dyspnoea due to mechanical compression of surrounding organs that 
ultimately compromise the patients’ quality of life.4-6
Aspiration sclerotherapy is a minimally invasive procedure aimed at reducing the volume 
of these fluid-filled lesions. Injecting ethanol (or other sclerosing agents) directly in the cyst 
cavity destroys the inner cyst-lining cholangiocytes.7-9 Lysis of the cyst epithelium halts cell 
proliferation and cyst fluid production.10 Aspiration sclerotherapy generally reaches favorable 
results in solitary cysts or dominant cysts in PLD.7, 11, 12 However, reported long-term efficacy 
results are mixed and ranging from complete regression to recurrence of the cyst.13, 14 An 
important predictor of cyst reduction is the extent of intracystic fluid re-accumulation after 
treatment.15 Typically, cyst fluid re-accumulates in the first weeks after treatment.16 Although 
transient, an initial fluid relapse threatens long-term efficacy and may lead to recurrence of 
the cyst necessitating re-intervention.15, 16
Somatostatin analogues inhibit cyst fluid production and cholangiocyte proliferation by 
activating somatostatin receptors on the basolateral surface of the cyst.3, 17 Previous studies 
showed that lanreotide and octreotide reduce cystic volume in patients with polycystic liver 
disease.18, 19 Pasireotide (SOM230) is a more potent somatostatin analogue due to a broader 
binding profile and higher affinity to somatostatin receptor subtypes.20
Adjuvant treatment of pasireotide to aspiration sclerotherapy has the promise to curtail 
fluid re-accumulation and reduce cholangiocyte proliferation. This strategy has precedence 
as surgeons described the use of octreotide after surgical cyst fenestration in an observational 
study (n = 5) and observed a minimized fluid production by exposed remnants of fenestrated 
cysts leading to apparent control of ascites.21 
We hypothesized that the combined approach of aspiration sclerotherapy and pasireotide 
would decrease initial fluid accumulation and improve long-term cyst reduction and clinical 
response. Therefore, the purpose of this study was to test whether pasireotide could improve 
efficacy of aspiration sclerotherapy of large symptomatic hepatic cysts.
METHODS
This study was performed following approval by the Institutional Review Board (Medical 
Research Ethics Committee of the Region Arnhem-Nijmegen) conformed to the ethical 
guidelines of the 1975 Declaration of Helsinki. The trial was registered at ClinicalTrials.gov 
(NCT02048319). We previously reported a detailed protocol elsewhere22; a brief caption 
follows below.
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Study design and participants
This randomized, single-center, double-blind, placebo-controlled trial was carried out in 
the Radboud university center Nijmegen, the Netherlands between April 2014 and April 
2016. Trial duration was 26 weeks. Following informed consent in writing, we randomized 
patients in a 1:1 ratio to pasireotide or placebo. Randomization was concealed to patients 
and investigators.
Patients with a large (>5 cm) symptomatic simple (non-neoplastic, non-hydatid) hepatic 
cyst were eligible for participation. Inclusion criteria were: age between 18 and 70 years, and 
a solitary or dominant cyst. A dominant cyst was regarded as the largest cyst within PLD. 
Major exclusion criteria were a prolonged corrected QT-interval (>470 ms), symptomatic 
cholecystolithiasis, uncontrolled diabetes (HbA1C >64 mmol/mol), and surgical or 
radiological cyst interventions within six months prior to the study.
Study procedures
All patients received aspiration sclerotherapy. In brief, we performed a single-session 
sclerotherapy procedure. The procedure was performed using conscious sedation. Guided by 
ultrasound, the interventional radiologist inserted a 5 French pigtail catheter (Cook Medical, 
Bloomington, IL) in the cyst and performed complete fluid drainage. Cyst leakage was ruled 
out by instillation of contrast medium (Iomeron 300, Bracco Imaging, Germany) followed by 
a 10-minute sclerotherapy. We injected 100% ethanol in a 10% ratio of the aspirated cyst 
volume (up to 50 mL)11. All patients were hospitalized for 24 hours observation.
 The intervention arm received 60 mg pasireotide (SOM230, Novartis, Basel, Switzerland) 
long-acting release (LAR) two weeks prior and two weeks following aspiration sclerotherapy. 
Controls received placebo injections of sodium chloride 0.9% (Fresenius Kabi, Hesse, 
Germany) at equal time points. Injections were omitted if safety laboratory margins (fasting 
blood sugar, alanine aminotransferase, aspartate aminotransferase, bilirubin, and amylase) 
were exceeded.22 Injections were administered intramuscularly by unblinded healthcare 
professionals not involved in the design or analysis of this trial.
Study endpoints
The primary outcome was the mean proportional change (%) in cyst diameter of the treated 
hepatic cyst at week 6, compared between treatment arms, as measured by ultrasonography. 
Secondary outcomes were change in cyst diameter at 14 and 26 weeks; cyst volume 
reduction at 6, 14 and 26 weeks; recurrence rate (<20% reduction) at 6 and 26 weeks; change 
in symptoms and health-related quality of life (HRQL) at 6 and 26 weeks; and rate and severity 
of adverse events during trial participation. 
Ultrasonography measurement
All ultrasound measurements were performed by the primary blinded operator (TW) using 
a 3.5 MHz convex transducer (Acuson X150TM, Siemens Healthcare, Erlangen, Germany). At 
baseline, the indicated cyst was visualized in two planes to measure the maximal orthogonal 
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diameters, from which we calculated one mean diameter (Supplementary File 1). In addition, 
cyst volume was estimated by the ellipsoid volume formula (D1*D2*D3*0.523).16 In case of 
a dominant cyst, the segmental location and surrounding structures (cysts and vessels) were 
closely documented to secure identification of the treated cyst at follow-up. Measurements 
were repeated at week 6, 14, and 26 to obtain proportional (%) change. A second blinded, 
independent operator (ML) repeated all measurements of all patients to assess interobserver 
variability. In addition, the primary operator repeated measurements in a subset of nine 
patients to evaluate intraobserver variability.
Patient-reported outcomes
To evaluate symptoms, patients completed the Polycystic Liver Disease-Questionnaire 
(PLD-Q) that assesses frequency and discomfort of 13 PLD-related symptoms over 
a timeframe of one month.23 Scores can be compiled to a total score from 1 (asymptomatic) to 
100 (severe symptomatic) points. To evaluate HRQL we used the generic Medical Outcomes 
Study 36-item short-form health survey (SF-36).24 Scores were summarized to a norm-based 
physical (PCS) and mental component score (MCS), with a general population reference of 
50 ± 10.25 Lower PCS or MCS scores indicate a compromised HRQL.26
Statistical analysis
Based on data from a previous cohort27, we expected 30% cyst diameter reduction 4 weeks 
after aspiration sclerotherapy. We hypothesized that this reduction at 4 weeks would be 
improved to 50% by adjuvant treatment with pasireotide. In order to detect a statistical 
difference between groups, we needed a sample size of 34 participants (power: 80%; α: 0.05; 
drop-out rate: 10%). Intention-to-treat analysis was performed including all patients who 
received at least one dose of pasireotide. In addition, a parallel per-protocol analysis was 
conducted in patients who received both injections and aspiration sclerotherapy. Values 
were reported as median with interquartile range. For continuous endpoints, we calculated 
differences between arms using Mann-Whitney U test. To correct for baseline diameter 
differences and underlying diagnosis (solitary cyst or PLD) between arms, we performed 
a sensitivity analysis using ANCOVA. Wilcoxon signed-rank test was used to compare within-
group differences. Cyst recurrence was compared between groups by the Fisher’s exact test. 
In case of a missing variable, we carried the last available value forward. To assess safety, 
we compiled frequency tables for adverse events classified according to WHO adverse 
reaction terminology. Statistical analyses were performed prior to unblinding using SPSS 
(version 22.0; SPSS, Chicago, IL). Analyses were two-sided with a P-value < 0.05 considered 
as statistically significant.
RESULTS
Baseline characteristics
We screened 71 consecutive patients with symptomatic hepatic cysts for eligibility. Of these, 
28 patients did not meet the inclusion criteria and nine patients declined to participate 
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(Figure 1). In total, 34 participants (female n = 32, male n = 2) were randomly assigned to 
either pasireotide or placebo. Baseline characteristics are shown in Table 1. 
All subjects were included in the intention-to-treat analysis. One aspiration sclerotherapy 
procedure failed as the targeted cyst could not be punctured due to a deep cranial position. 
This patient did not receive a second injection. In both groups one patient did not receive 
a second injection due to adverse events (hyperglycemia and dizziness). Finally, one patient 
(pasireotide-arm) had a second aspiration sclerotherapy procedure at week 24 due to 
ongoing severe complaints. From another patient (placebo-arm), the treated cyst could not 
be identified from other cysts at week 26. Findings at week 14 of these two patients were 
carried forward to week 26 for analysis. 
Figure 1. Flow Diagram. ITT = intention-to-treat; PP = per-protocol.
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Figure 2. Primary outcome. Diameter reduction compared to baseline at week 6.
Primary outcome
Intention-to-treat analysis
Median cyst diameter in the pasireotide-arm decreased with 23.6% [IQR 12.6-30.0%] 
compared to 21.8% [IQR 9.6-31.8%] in patients assigned to placebo (Figure 2). Proportional 
diameter reduction was similar (P = 0.96) between groups. When corrected for baseline 
diameter and diagnosis by ANCOVA, proportional reduction remained equal (P = .64).
Per-protocol analysis
The three patients who did not receive a second injection were excluded from per-protocol 
analysis, resulting in a sample of 31 patients (Figure 1). In the pasireotide-sample (n = 15), 
cyst diameter reduced by 23.6% [IQR 15.8-32.0%] compared to 22.6% [IQR 12.4-32.4%] 
in patients receiving placebo (n = 16). Similar to intention-to-treat analysis, we found no 
statistical significant difference between groups (P = 0.83).
Table 1. Demographics and baseline characteristics
Pasireotide (n = 17) Placebo (n = 17)
Age at treatment, years 54 [51-61] 50 [45-61]
Female sex, n (%) 16 (94%) 16 (94%)
PLD (>20 cysts), n (%) 10 (59%) 13 (76%)
Baseline cyst diameter, cm 10.4 [8.2-13.4] 9.0 [7.1-10.8]
Baseline cyst volume, ml 529.8 [288.4-1027.1] 378.2 [188.5-635.7]
BMI, kg/m2 27.3 [25.1-30.2] 23.2 [22.2-27.4]
Continuous data are reported as median [interquartile range], absolute numbers as n (%).
PLD = polycystic liver disease; BMI = body mass index.
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Intra- and interobserver variability
We found a mean difference of 0.45% ± 2.72% between measurements of the primary operator 
with an excellent intraclass coefficient (r = 0.99; P < 0.01). Compared to measurements of 
the second operator there was a mean difference of 1.75% ± 5.30%, with a strong intraclass 
coefficient of r = 0.97 (P < 0.01). These findings indicated strong agreement between 
measurements within and between operators. 
Figure 3. Cyst diameter (A) and volume (B) reduction from baseline to week 6, 14, and 26 compared 
between pasireotide and placebo.
Secondary outcomes
Long-term cyst diameter reduction
Both groups showed similar progressive long-term diameter reduction (Figure 3). At week 
14, median proportional cyst diameter reduction was 37.5% [IQR 24.0-52.6%] in patients 
assigned to pasireotide and 30.3% [IQR 19.5-48.4%] in controls (P = 0.84). At week 26, treated 
cyst diameters had further reduced to 49.1% [IQR 27.0-73.6%] (pasireotide) and 45.6% [IQR 
29.6-59.6%] (placebo) compared to baseline (P = 0.90; Supplementary File 2).
Volume reduction and cyst recurrence
Changes of volume from baseline to 26 weeks are shown in Figure 3. Similar to diameter 
results, groups achieved comparable volume reduction rates (Supplementary File 3). In both 
groups, 8/17 (47%) patients showed cyst recurrence at week 6. This decreased to one patient 
in the pasireotide sample and two patients in placebo at the end of the trial (P = 0.6).
Patient-reported outcomes
Total PLD-Q score showed statistically significant (P < 0.01) decrease over time in both groups 
indicating symptomatic improvement (Figure 4). Final PLD-Q improvement was comparable 
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between groups (P = .95; Supplementary File 4). At baseline, the physical domain of HRQL 
was restricted at baseline in both arms. After treatment, PCS improved in both groups with 
a statistical significant effect in the pasireotide sample (P < 0.01). Nonetheless, PCS at week 
26 was similar among arms (P = 0.43). Baseline MCS was slightly restricted in the pasireotide 
group and normal in controls. Both groups increased; final MCS was alike (P = 0.56).
Adverse events
There were four serious adverse events requiring hospital admission. One female patient 
developed a cyst bleeding ten days after aspiration sclerotherapy which was treated with 
analgesics. A male patient developed urolithiasis treated surgically. Furthermore, a female 
patient developed a pneumonia which was treated with antibiotics and analgesics. 
Finally, a female patient underwent a second aspiration sclerotherapy of the treated 
cyst due to ongoing severe abdominal distension and inadequate cyst reduction from 
the first procedure. 
The most common adverse event was abdominal pain (pasireotide n = 13; placebo 
n = 11) which was mild and self-limiting in 20 cases (Table 2). In the remaining four cases, 
pain was more severe (grade III) and analgesics were needed to relieve symptoms. Glucose 
levels in the pasireotide group rose from 5.3 mmol/L [IQR 5.1-6.1 mmol/L] to 6.8 mmol/L [IQR 
6.6-7.7 mmol/L] at week 4 (P < 0.01) and normalized at end of follow-up. By contrast, levels 
in patients on placebo did not differ over time (Supplementary File 5).
DISCUSSION
The key finding of this study is that a pre- and postprocedural intramuscular injection of 
pasireotide LAR in addition to aspiration sclerotherapy does not improve cyst reduction 
Figure 4. Symptomatic improvement from baseline to week 26 (T26), assessed by the disease-specific 
Polycystic Liver Disease Questionnaire (PLD-Q) leading to a summarizing score. The dotted line 
(reference) indicates to the general population score.
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or clinical outcomes compared to controls. In both arms, we found symptomatic 
relief and normalized HRQL, underlining the clinical benefit that can be achieved by 
aspiration sclerotherapy.
We expected that a combined approach to target cysts, i.e. pasireotide and aspiration 
sclerotherapy, would enhance efficacy over mere aspiration sclerotherapy. This hypothesis 
was based upon the working mechanism of somatostatin analogues. Somatostatin 
analogues lower intracellular levels of 3’-5’-cyclic adenosine monophosphate (cAMP) by 
binding somatostatin receptors (SSTR).3, 17 This second messenger cAMP stimulates cyst fluid 
production by activating chloride (cystic fibrosis transmembrane conductance regulator; 
CFTR) and water (aquaporin 1) channels on the apical side of the cholangiocyte.28 In addition, 
cAMP stimulates cholangiocyte hyperproliferation leading to cyst growth.29, 30 Therefore, by 
lowering intracellular levels of cAMP, cyst fluid production is curtailed and cholangiocyte 
proliferation suppressed, collectively leading to cyst regression.17, 30 Previous clinical studies 
showed how somatostatin analogues reduce polycystic liver volume.18 We expected that 
these features would reduce post-intervention fluid re-accumulation and improve long-term 
cyst reduction.
Table 2. Adverse events
Pasireotide (n = 17) Placebo (n = 17)
Total Grade 3 Total Grade 3
number (percent)
Hyperglycemia 17 (100) 0 5 (29) 0
Abdominal pain 13 (76) 1 (6) 11 (65) 3 (18)
Loose stools 13 (76) 0 10 (58) 0
Fatigue 10 (58) 0 7 (41) 0
Nausea 8 (47) 0 6 (35) 0
Injection Response 6 (35) 0 1 (6) 0
Palpitations 4 (24) 0 1 (6) 0
Vomiting 3 (18) 0 1 (6) 0
Decreased Satiety 3 (18) 0 1 (6) 0
Overall malaise 3 (18) 0 1 (6) 0
Menstruation disorders1 2 (13) 0 0 0
Dizziness 2 (12) 0 2 (12) 0
Thrombotic events2 2 (12) 1 0 0
Pneumoniae/pneumonitis 1 (6) 0 1 (6) 1 (6)
Urolithiasis 1 (6) 1 (6) 0 0
Serious adverse events3 2 (12) 2 (12)
1 prolonged period (n = 1); irregular menstruation (n = 1); 2 trombosis vena subclavia after peripheral catheter 
left arm (n = 1); superficial thrombosis lower right leg (n = 1); 3 serious adverse events: cyst bleeding (n = 1); 
urolithiasis (n = 1); re-intervention hepatic cyst (n = 1); pneumonia (n = 1).
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Why was our hypothesis not recapitulated by the results of our study? First, while other 
somatostatin analogues such as lanreotide and octreotide decrease hepatic cyst volumes, it 
is possible that pasireotide does not inhibit hepatic cystogenesis in humans. Compared to 
conventional somatostatin analogues, pasireotide has a broader binding profile (octreotide 
SSTR 2, 3, and SSTR5; pasireotide SSTR 1,2,3, and SSTR5) and a higher affinity to SSTR 1, 3 and 
SSTR5.
20 Based on this pharmacologic profile, it is reasonable to assume that pasireotide also 
reduces cyst progression in humans. However, no human studies have reported the effects 
of pasireotide on hepatic cysts. Currently, a randomized clinical trial is running to investigate 
efficacy of pasireotide in polycystic liver disease which will provide better insight in the cyst-
reducing properties of pasireotide (Clinicaltrials.gov; NCT01670110).
In addition, we may have administrated pasireotide in an inadequate dosage or scheme 
to be effective. In order to optimize the efficacy/safety balance we targeted our patients with 
pasireotide in a limited period before and after the procedure. To reach optimal drug levels, 
we administered the highest available dosage of 60 mg in a long-acting release formulation. 
The mild hyperglycemia that followed pasireotide injections suggest adequate exposure to 
the drug.
Finally, the process of postprocedural cyst fluid re-accumulation leading to recurrence 
may not be affected by pasireotide. Alternatively, it is hypothesized that fluid re-
accumulation results from an inflammatory response induced by cell lysis following 
sclerotherapy, rather than fluid production of remaining functional cholangiocytes.14 An 
exploratory study repunctured treated cysts 2-8 days following aspiration sclerotherapy 
and observed an increase in leukocytes compared to the primary aspirate, suggesting 
ongoing inflammation.31
Traditionally, efficacy studies of aspiration sclerotherapy focused on technical response 
of aspiration sclerotherapy.5 As hepatic cysts are benign lesions, indication of treatment 
is driven upon the patients’ symptomatology. This was the first study to assess patient-
reported outcomes at standardized time points using validated instruments. At baseline, 
we found low physical SF-36 scores and increased PLD-Q scores indicating a restricted 
HRQL a symptomatic burden compared to general population references.25 In this study we 
demonstrated that aspiration sclerotherapy significantly reduces disease-specific symptoms 
and normalizes HRQL. These findings support that aspiration sclerotherapy is an excellent 
first-line choice to treat patients with large symptomatic hepatic cysts.
The strength of this study is that we combined an invasive and medical strategy to optimize 
cyst reduction in a clinical trial-design. This study has several limitations. Firstly, our primary 
endpoint was measured by ultrasonography which introduces variability as it is operator-
dependent. Computed tomography or magnetic resonance imaging may reduce variability, 
but would have led to unnecessary exposure to radiation and/or costs as this study required 
multiple measurements within short intervals. To minimize bias, all measurements were 
performed by the same investigator following standardized operating procedures. Indeed, 
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we found excellent intraclass coefficients of intra- and interobserver variability. Secondly, 
we powered our study assuming a large beneficial effect from pasireotide. Possible smaller 
differences between our groups cannot be ruled out. However, we believe that such small 
differences would not be relevant for clinical practice, given the costs of pasireotide. Finally, 
we included both sporadic hepatic cysts and dominant hepatic cysts within PLD. The genetic 
background of both congenital cyst types corresponds as somatic loss of PLD-type alleles 
from cyst epithelium is required to drive cyst formation.32 Indeed, both cyst types have 
a thin wall lined by a single layer of cholangiocytes which are targetable by somatostatin 
analogues.4, 33 However, it is unclear if germline mutations in PLD patients alter susceptibility 
to these agents. In our study, we found no differences in efficacy between patients with or 
without underlying PLD, as reflected in previous literature.7
CONCLUSIONS
In summary, adjuvant pasireotide treatment to aspiration sclerotherapy in patients with 
large hepatic cysts is no more effective than aspiration sclerotherapy alone. Mere aspiration 
sclerotherapy normalizes HRQL-rates and decreases symptomatic disease, this proves 
aspiration sclerotherapy as excellent choice of therapy for large hepatic cysts. 
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SUPPLEMENTARY FILES
Supplementary File 2. Median proportional (%) diameter reduction compared to baseline
Pasireotide (n = 17) Placebo (n = 17) P value
Week 6, % 23.6 [12.6-30.0] 21.8 [9.6-31.8] 0.865
Week 14, % 37.5 [24.0-52.6] 30.3 [19.5-48.4] 0.838
Week 26, % 49.1 [27.0-73.6]1 45.6 [29.6-59.6]1 0.901
Data are reported in median [interquartile range] and analyzed by Mann Whitney U test; 1 last value carried 
forward  in pasireotide-arm (n = 1) and placebo-arm (n = 1).
Supplementary File 1. Cyst measurement of orthogonal diameters (anteroposterior, mediolateral, 
and craniocaudal) in two planes. In this case, a mean diameter of 84.1 mm and volume of 291.7 mL 
were obtained 
Supplementary File 3. Volume proportional (%) reduction compared to baseline
Pasireotide (n = 17) Placebo (n = 17) P value
Week 6, % 56.3 [31.0-63.3] 51.8 [25.0-68.0] 0.919
Week 14, % 76.4 [55.5-89.3] 67.0 [46.8-86.7] 0.838
Week 26, % 86.9 [60.0-98.0]1 83.1 [66.3-93.4]1 0.901
Data are reported in median [interquartile range] and analyzed by Mann Whitney U test; 1 last value carried 
forward  in pasireotide-arm (n = 1) and placebo-arm (n = 1).
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ABSTRACT
Background
Hepatic cyst infection is a potentially severe complication in cystic disease. Treatment 
demands effective antibiotic concentrations within the infected cyst. The aim of this study 
was to use elective hepatic cyst drainage as a unique pharmacokinetic model to investigate 
whether cefazolin, a first-generation cephalosporin, is able to penetrate hepatic cysts.
Methods
Patients scheduled to undergo percutaneous aspiration sclerotherapy of a symptomatic non-
infected, non-neoplastic hepatic cyst were eligible for this study. All participants received 
a single perioperative prophylactic dose of cefazolin (1000 mg, intravenously). We collected 
blood and cyst fluid samples to determine total and unbound cefazolin concentrations 
using high-performance liquid chromatography. The primary outcome was hepatic cyst 
penetration, expressed as the ratio (%) of unbound concentration of cefazolin in cyst fluid to 
plasma (both in mg/L).
Results
We included eight patients (male 25%, age 60 yrs [IQR 54-75], estimated glomerular 
filtration rate 97 mL/min/1.73m2 [IQR 67-102], serum albumin 40 g/L [IQR 37-40]). We 
detected low concentrations of unbound cefazolin in cyst fluid (≤ 1.0 mg/L). Median plasma 
unbound cefazolin peak level was 36.6 mg/L [IQR 23.7-54.1] and 16.1 mg/L [IQR 13.0-20.1] 
during the procedure. In total, the hepatic cyst penetration of free cefazolin was only 
2.2% [IQR 0.7-5.2].
Conclusions
We developed a study model to investigate the penetration of antibiotics into hepatic 
cysts. Cefazolin did not reach adequate intracystic concentrations. Future studies should 
explore alternatives.
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INTRODUCTION
Hepatic cysts are fluid-filled cavities located in the liver that primarily cause mass-related 
abdominal complaints.1 Cysts are seen in the context of two genetic disorders. Autosomal 
dominant polycystic liver disease (ADPLD) is characterized by the isolated presence of 
a polycystic liver, whereas the phenotype of autosomal dominant polycystic kidney disease 
(ADPKD) includes hepatic cysts as an extrarenal manifestation in >90%.2, 3 
Bacterial infection of hepatic cysts is a potentially life-threatening complication of cystic 
disease that requires effective antibiotic treatment.4 Antibiotics are the cornerstone of cyst 
infection treatment,5 but it is unclear which drug to administer and when to stop treatment. 
Escherichia coli (E. coli) is the most frequent microorganism that is isolated from blood 
cultures in patients with hepatic cyst infection.6 Fluoroquinolones, such as ciprofloxacin, 
are favoured because of their Gram-negative activity and presumed ability to penetrate 
the cyst.7 Alternative drugs are needed because of the increasing rate of E. coli resistance 
against fluoroquinolones.8 
Aspiration sclerotherapy is a minimally invasive procedure indicated to reduce the volume 
of symptomatic cysts. It includes percutaneous drainage of cyst fluid with subsequent 
instillation of a sclerosing agent to destroy the inner cyst epithelium. In our center, we 
administer cefazolin, a first-generation cephalosporin, as perioperative prophylaxis in patients 
receiving aspiration sclerotherapy to prevent postprocedural infections.9 Cephalosporins are 
used as an alternative to fluoroquinolones because of their activity against E. coli.10 However, 
data indicating their ability to reach an adequate intracystic concentration are absent. 
Aspiration sclerotherapy offers a unique model to study the pharmacokinetic characteristics 
of drugs and their ability to penetrate into cyst fluid.
The aim of this study was to use this procedure as a pharmacokinetic model to allow 
a detailed investigation of the ability of cefazolin to penetrate hepatic cysts.
METHODS
Study design and settings
The PENTAC trial is an explorative clinical trial (ClinicalTrials.gov identifier NCT02368015). 
This single center study was performed at the Radboud university medical center Nijmegen, 
the Netherlands, from December 2014 until December 2015. Following standard of care, 
all participants received a single dose of cefazolin (Kefzol®; Eurocept Pharmaceuticals, 
Ankeveen, the Netherlands) at 1000 mg intravenously one hour prior to the scheduled 
procedure through a peripheral intravenous cannula (IVC). The trial consisted of a screening 
period of four weeks, a 24-hour per-procedural hospital admission and a follow-up period of 
four weeks following standard of care.
Population
All patients scheduled to undergo percutaneous drainage of a non-infected, non-neoplastic 
hepatic cyst were eligible for study participation. A detailed description of the aspiration 
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sclerotherapy procedure performed in our center is available elsewhere.11 In brief, a pigtail 
catheter (5 French, Cook Medical, Bloomington, United States of America) was placed in 
the cyst, guided by ultrasonography to completely empty the cyst. Subsequently, up to 50 
mL of 100% ethanol was instilled into the cyst cavity. After ten minutes, ethanol was re-
aspirated and the pigtail catheter removed. Exclusion criteria were cefazolin and/or penicillin 
allergy, signs of phlebitis at both extremities or presence of an arteriovenous fistula, history 
of mastectomy or lymph node dissection at both extremities.
Sampling
In addition to the IVC for cefazolin administration, patients received an additional IVC at 
the contralateral side dedicated to blood withdrawals. If establishing the second intravenous 
access failed, blood was obtained by venipuncture. We collected blood at three time points 
during hospital admission and collected cyst fluid subsequent to cyst drainage. 
We obtained the first blood sample directly after completing cefazolin administration 
to estimate peak cefazolin levels (mg/L). During cyst fluid drainage, the second blood 
sample was withdrawn to calculate the ratio (%) of cefazolin penetration. The third and 
final blood sample was obtained after four times the expected t1/2 of cefazolin (6-8 hours as 
t1/2 cefazolin is 1.5-2 h). The exact time and duration of cefazolin infusion, timing of blood 
sample withdrawals and cyst fluid collection were recorded. All samples were collected on 
ice and immediately transported after collection. After centrifuging blood samples at 4°C for 
10 minutes at 2000 g, plasma and cyst fluid samples were stored at -80°C. 
Outcome measures
Our primary outcome was hepatic cyst penetration of unbound cefazolin, expressed as 
the ratio (%) of unbound concentration of cefazolin in cyst fluid to plasma (both in mg/L). 
Secondary study parameters included clinical characteristics including age, gender, body 
weight, body length, cyst location in the liver and estimated cyst volume determined 
with ultrasonography during screening. Furthermore, we analyzed the following blood 
parameters: total protein (g/L), albumin (g/L), C-reactive protein (CRP; mg/L), white blood 
cell count (109/L) and differentiation, total and direct bilirubin (µmol/L), urea (mmol/L), 
creatinine (µmol/L) and carbohydrate antigen (CA) 19-9 (U/mL).12 Cyst fluid was analyzed 
for total protein (g/L), albumin (g/L), CRP (mg/L), white blood cell count (109/L), total and 
direct bilirubin (µmol/L), urea (mmol/L), CA 19-9 (U/mL), sodium (mmol/L) and pH. Finally, 
we monitored all adverse events during hospital admission and follow-up period.
Blood and cyst fluid analysis
Blood and cyst fluid parameters were analyzed by standard kits using an autoanalyzer 
(Hitachi 912; Roche Diagnostics) at the Radboud university medical center clinical 
chemistry laboratory. We measured cefazolin concentrations with high-performance liquid 
chromatography (HPLC) based on a previously validated method.13 Briefly, we added 90 µl of 
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normal human plasma (Sanquin Plasma Products, Amsterdam, the Netherlands) to 10 µl of 
cefazolin (Kefzol®; Eurocept Pharmaceuticals, Ankeveen, the Netherlands) solutions in water 
(2000, 200, 20, and 2 mg/L). We added 10 µl internal standard (1000 mg/L Cefoxitin; Sigma-
Aldrich, Saint Louis, MO, USA) to 100 µl of cefazolin standards, plasma and cyst fluid samples 
to determine the total cefazolin concentration.
For the detection of unbound cefazolin in plasma and cyst fluid samples, 20 µl internal 
standard was added to 200 µl of plasma or cyst fluid. We performed ultrafiltration by 
transferring the sample to an Amicon® Ultra 0.5 mL 30K centrifugal filter unit (Merck Millipore 
Ltd., Cork, Ireland). After centrifugation at 2000*g during 10 minutes, 110 µl was transferred 
to a fresh tube. This was followed by addition of 12.5 µl 50% trichloroacetic acid (Merck 
Millipore Ltd.) to 110 µl of plasma, cyst fluid samples and cefazolin standards. After vortexing 
for 30 seconds, the samples and standards were centrifuged for 5 minutes at 2000*g. We 
then transferred 20 µl of supernatant to a glass insert which was placed in an HPLC vial.
We ran prepared samples and standards at room temperature on an HPLC (JASCO, 
Tokyo, Japan) through a Kinetex 5u EVO C18 100A (150x4.6 mm) column over a period of 12 
minutes with a flowrate of 1 mL/min and UV detection wavelength set at 270 nm. The mobile 
phase consisted of 10% acetonitrile in 0.01 M phosphate buffer pH 6.5. The HPLC system 
consisted of a JASCO AS-2055 Plus auto sampler, JASCO UV-2075 Plus UV/VIS detector and 
JASCO PU-2089 Plus quaternary gradient pump in combination with a JASCO LC-NET II/ADC 
interface and JASCO ChromPass chromatography data system software version 1.4. 
Quantification was based on the cefazolin standard calibration curve. The four-point 
standard curves (range of concentrations: 0.2-200 mg/L for plasma and cyst fluid) were 
linear with high regression coefficients (r2 > 0.998). The lower limit of cefazolin quantification 
(LLOQ) was 0.2 mg/L in plasma and cyst fluid, which was the lowest concentration of 
the standard curve.
Intra- and inter-day coefficients of variation (CV %) of assay precision were < 1% and 
< 2% respectively for both unbound and total cefazolin. Samples were analyzed in duplicate.
Statistical and pharmacokinetic analysis
Statistical analysis was performed using SPSS 22 (SPSS Statistics, Inc., Chicago, IL, USA). We 
used Phoenix® 64 WinNonlin® version 6.4 (Scientific Consultants, Lexington, KY, USA) to 
estimate pharmacokinetic parameters (AUC 0-inf, Vd, CL) for cefazolin.
Continuous variables were expressed as median with interquartile range. The primary 
endpoint was the hepatic cyst penetration of cefazolin. Penetration was expressed as 
the ratio (%) of unbound cefazolin in cyst fluid (mg/L) to the unbound plasma concentration 
of cefazolin (mg/L) at the time of cyst drainage. In addition, we performed a Spearman’s 
correlation test to evaluate a possible association between cefazolin concentration and 
interval between cefazolin concentration and cyst fluid drainage. We did not perform 
a power calculation, due to the exploratory nature of this study. 
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Ethical considerations
The PENTAC trial was conducted in accordance with the study protocol, International 
Conference of Harmonization Good Practice Guidelines (GCP) and adhered to 
the ethical principles of the Declaration of Helsinki. The data were collected and stored 
using a validated and GCP-approved data management system Castor EDC (Ciwit B.V., 
Amsterdam, the Netherlands). The protocol (reference number 2014-1178) was approved 
by the Institutional Review Board (IRB): the committee human research region Arnhem-
Nijmegen (CMO Arnhem-Nijmegen). All patients provided written informed consent.
RESULTS
Participants
Nine patients with symptomatic non-infected, non-neoplastic hepatic cysts who underwent 
aspiration sclerotherapy were assessed for eligibility to participate in the trial. One patient 
was excluded because of a previous allergic reaction to penicillin. We included a total of 
eight patients (Table 1). Cyst fluid aspiration and blood sampling were performed in all 
patients. In one patient, the third (final) blood collection failed.
Clinical characteristics and timings
The median age of the study cohort was 60 years [IQR 54-75] and most patients were 
female (75%). Renal function (median estimated glomerular filtration rate [eGFR] = 97 mL/
min/1.73m2 [IQR 67-102]) and serum albumin (40 g/L [IQR 37-40]) were within normal limits.
Median duration of cefazolin infusion was 24 minutes [IQR 6-34]. Time between start of 
cefazolin infusion and first blood withdrawal was 35 minutes [IQR 10-39]. We obtained cyst 
fluid and the second blood sample after a median interval of 1 hour and 43 minutes [IQR 
1:27-2:05]. Final blood sample was drawn after a median time of 6 hours and 53 minutes 
[IQR 6:32-7:08].
Cefazolin concentration
The median peak total plasma cefazolin concentration was 118.9 mg/L [IQR 97.7-169.2] with 
a median unbound concentration of 36.6 mg/L [IQR 23.7-54.1] (Table 2). At the time of cyst 
drainage, median total and unbound plasma cefazolin concentrations were 61.0 and 16.1 
mg/L, respectively. In the last blood sample, plasma total cefazolin was 10.6 mg/L, whereas 
unbound cefazolin was 2.4 mg/L. 
More than half of plasma cefazolin was bound to protein (median 74.2%, IQR 71.8-81.2). 
We calculated a median volume of distribution of 8.4 L [IQR 7.7-9.9], with an estimated 
cefazolin clearance of 3.1 L/h [IQR 2.4-4.5].
Low cyst fluid concentrations of unbound cefazolin were measured in 6/8 (75%) of 
patients (≤ 1.0 mg/L) of which three patients had a cefazolin concentration below the LLOQ. 
In the two remaining patients (25%) we could not recover cefazolin from cyst fluid. Plasma 
concentrations of total and unbound cefazolin followed a one-phase decay (Figure 1A 
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Table 1. Clinical characteristics and timings
Characteristic Patients (n=8)
Patient characteristics
 Male, n (%) 2 (25.0)
 Age, yrs 60 [54-75]
 BMI, kg/m2 28 [26-30]
 Estimated volume aspirated cyst, mL 1254 [637-1650]
 Location aspirated cyst, n (%)
 - Left hepatic lobe 3 (37.5)
 - Right hepatic lobe 5 (62.5)
Serum parameters 
 Albumin, g/L 40 [37-40]
 Total protein, g/L 72 [68-78]
 CRP, mg/L 4 [3-8]
 WBC, 109/L 6.5 [5.5-7.7]
 Creatinine, µmol/L 59 [57-97]
 Urea, mmol/L 5.6 [4.7-6.2]
 eGFR (MDRD), mL/min/1.73m2 97 [67-102]
 CA 19-9, U/mL 16 [12-25]
 Total bilirubin, µmol/L 11 [6-15]
 Direct bilirubin, µmol/L** 4 [3-4]
Cyst fluid parameters
 Albumin, g/L 4 [3-21]
 Total protein, g/L 8 [3-44]
 Sodium, mmol/L 147 [143-147]
 WBC, 109/L 0.1 [0.0-0.7]
 pH* 7.6 [7.4-7.7]
 Urea, mmol/L 6.0 [5.4-6.9]
 CA 19-9, 104 U/mL* 5.0 [2.2-19.0]
 Total bilirubin, µmol/L* 4 [1-4]
 Direct bilirubin, µmol/L* 4 [1-4]
Cefazolin and sample timings
 Cefazolin infusion duration, hh:mm 0:24 [0:06-0:34]
 - Interval [start infusion] – [blood withdrawal I], hh:mm 0:35 [0:10-0:39]
 - Interval [start infusion] – [blood withdrawal II/cyst fluid  aspiration], hh:mm 1:43 [1:27-2:05]
 - Interval [start infusion] – [blood withdrawal III], hh:mm 6:53 [6:32-7:08]
All continuous values are expressed as median with interquartile range. Serum values: all median 
and IQR values fall within limits of normal. I: blood withdrawal directly following cefazolin infusion; 
II: blood withdrawal at the time of cyst fluid aspiration; III: blood withdrawal at 6-8 hours following 
start cefazolin infusion (~3-4x cefazolin t1/2). * measurement failed n=1; ** measurement failed n=2 
BMI = body mass index, CRP = C-reactive protein, WBC = white blood cell count, eGFR MDRD = estimated 
glomerular filtration rate using the Modification of Diet in Renal Disease Study equation, CA 19-9 = 
carbohydrate antigen 19-9.
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Figure 1. Cefazolin concentrations in blood and cyst fluid. Total cefazolin concentrations (mg/L) in 
blood and cyst fluid (A). Unbound cefazolin plasma concentrations (mg/L) in blood and cyst fluid (B)
and 1B). Regression coefficients were high for both total (r2 = 0.82) and unbound plasma 
cefazolin (r2 = 0.81).
The hepatic cyst penetration ratio of unbound cefazolin was low (median 2.2%, IQR 
0.7-5.2). We observed no association between cefazolin penetration ratio and the interval 
between cefazolin administration and cyst fluid drainage (P = 0.56).
Safety
One patient enrolled in the study was hospitalized 12 days after percutaneous cyst drainage. 
She had progressively developed abdominal pain in the days following the procedure 
and was admitted under suspicion of a postprocedural hepatic cyst bleed. At the time of 
admission, ultrasonography was inconclusive. Following adequate treatment with analgesics, 
the patient was discharged the following day. After two weeks, ultrasonography showed 
a hyperechogenic intracystic pattern combined with internal echoes raising the suspicion of 
a recent cyst bleed. The patient recovered without sequelae.
DISCUSSION
The main finding of our study is the minor penetration of cefazolin into hepatic cysts. 
We measured low cyst fluid concentrations of both total and unbound cefazolin after 
administration of a single intravenous dose of 1000 mg. This low cyst penetration leads 
to subtherapeutic intracystic levels of antibiotic prophylaxis and may put patients at an 
increased risk of developing postprocedural infections.
The hepatic cyst penetration of antibiotics has not been investigated extensively. One 
study investigated the hepatic cyst penetration of ciprofloxacin and showed that intracystic 
levels were severalfold higher than levels in serum, irrespective of the presence of an 
infection.7 Ciprofloxacin has a very large volume of distribution and a high tissue/serum 
ratio due to high lipid solubility and low protein binding. Ciprofloxacin is actively secreted 
by intestinal epithelium and reaches bile/serum ratios >1 in bile.14 It is not known whether 
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the cyst wall presents a specific permeability barrier for antibiotics of whether a cyst acts 
as an extravascular site in which passive diffusion principles apply. It is possible that active 
transport mechanisms may influence cefazolin concentrations in cyst fluid. This is likely 
because similar to ciprofloxacin, cefazolin is excreted in bile.15 
Our findings suggest that cefazolin is an inadequate choice as prophylactic drug to 
prevent postprocedural cyst infection and may not be effective in clearing a hepatic cyst 
infection. The efficacy of antibiotic treatment depends on its activity against the most 
common pathogens, its MIC for these pathogens and its pharmacokinetic properties. 
The observed high rate of cefazolin bound to protein (median 74.2%) is consistent with 
previous results.16 Only unbound plasma cefazolin is able to diffuse outside the intravascular 
compartment.17 Corresponding to earlier findings18, we showed that cefazolin has a low 
volume of distribution (median V = 8.4 L). Its efficacy against pathogens is determined by 
the amount of time the unbound cefazolin concentration exceeds the pathogen-specific 
MIC value.19 
EUCAST states that epidemiological cut-off studies have not been done for E. coli and 
cefazolin.20 EUCAST has no recommendation for cefazolin and Gram-negative bacteria. 
It simply states that there are no breakpoints and that susceptibility testing is not 
recommended. The American Clinical & Laboratory Standards Institute (CLSI) published 
revised breakpoints for E. coli and cefazolin: susceptible, ≤1 mg/L; intermediate, 2 mg/L; and 
resistant, ≥4 mg/L.21 These breakpoints are linked to a dosing schedule of 2 grams every 8 
hours in adults, a frequently recommended dose for serious infections in standard treatment 
guidelines.22 A study in patients with E. coli bacteraemia showed that these revised CLSI 
breakpoints for cefazolin performed well in patients without septic shock.23 It might be that 
concentrations of 1 mg/L inside hepatic cysts can result in killing of E. coli in the cyst. That 
said, cefazolin will have no antimicrobial activity in those cases where Enterobacteriaceae 
have extended-spectrum beta lactam (ESBL) properties, of which the prevalence in 
the Netherlands exceeds 10%.24 Therefore, using cefazolin as antimicrobial prophylaxis to 
prevent systemic inflammation from hepatic cyst drainage is questionable. 
This study demonstrates that aspiration sclerotherapy offers the unique opportunity to 
provide safe and easy access to obtain hepatic cyst fluid. This model, benefiting from an 
elective minimally invasive procedure, is able to facilitate novel antibiotic drug research. 
Future studies involving this model should focus on identifying an antibiotic that is superior 
to cefazolin in reaching protective intracystic concentrations. The ideal antibiotic drug 
should allow a high extravascular availability without being subjected to metabolization and 
a low MIC threshold against E. coli. Likewise, with increasing resistance against ciprofloxacin 
and subsequent treatment failures,25 alternatives to fluoroquinolones for treatment of cyst 
infection are desperately needed and demand investigation. 
The main strength of this trial is that we used aspiration sclerotherapy as a unique 
and effective model to study the cyst-specific pharmacokinetic properties of cefazolin. 
A limitation is that this study was confined to patients with non-infected cysts who received 
one dose of cefazolin. This could have resulted in an underestimation of the penetration 
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capacity of cefazolin during an infection as (1) the permeability of the cyst wall could 
alter during active infection and (2) the presence of a steady-state plasma concentration 
of cefazolin could induce increased cefazolin accumulation in the hepatic cyst as a deep 
compartment. A previous study on hepatic cyst infection penetration indeed showed 
that after repeated ciprofloxacin administration serum trough levels were lower than 
the intracystic concentration.7 However, the inflammatory effect is most likely negligible, as 
this study did not show differences in penetration between infected and non-infected cysts.7 
Another limitation is that we only included eight patients in our study. This sample size did 
not allow detailed investigation of secondary parameters influencing cefazolin penetration. 
A large-scale pharmacokinetic/pharmacodynamic modeling study is required to confirm 
our findings.
CONCLUSIONS
To conclude, we developed a novel study model to investigate the penetration of antibiotics 
into hepatic cyst fluid. This study showed that a prophylactic dose of cefazolin was unable 
to reach an adequate intracystic concentration. Future studies should focus on exploring 
alternative antibiotics for prophylactic and therapeutic strategies. 
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GENERAL DISCUSSION
Over the last decennia, many centers have shared their experience with aspiration 
sclerotherapy of large hepatic cysts.1, 2 Most data come from observational studies (case 
reports, case series and cohorts) and describe efficacy of various approaches. Because of 
the heterogeneity and high risk of bias, robust evidence on efficacy, safety and relative 
superiority of these approaches remain unknown. Despite the lack of an evidence-based 
consensus, there are authors who claim that aspiration sclerotherapy is ineffective.3, 4 Hence, 
alternative surgical methods are suggested as treatment of choice for large hepatic cysts.5 
In addition, there are a number of new avenues to be explored. For example, 
the combination of somatostatin analogues with aspiration sclerotherapy may further 
improve outcomes of treatment. Therefore, the aim of this thesis was to clarify efficacy and 
safety of aspiration sclerotherapy and to optimize current treatment strategies.
RESULTS OF THIS THESIS
Research question 1. What is efficacy and safety of aspiration sclerotherapy? 
We found a proportional cyst volume reduction between 76% and 100% after a follow-up 
period of 1-56 months (Chapter 2) in 414 patients with a total of 435 treated hepatic cysts. 
In addition, symptomatic relief was achieved in 72% and 100% of patients with complete 
resolution of symptoms between 56% and 100%. Only one study assessed clinical response 
by a standardized instrument.6 No severe morbidity, nor mortality was reported. The most 
common adverse event was peri- or postprocedural pain, which was reported between 5% 
and 90% over studies. Importantly, risk of bias was high as most studies had a retrospective 
design and were uncontrolled. Nevertheless, the results of this systematic review contradict 
previous statements that frame aspiration sclerotherapy as an ineffective treatment modality 
for hepatic cysts.5
Secondly, we compared patient data of two large cohorts that applied a different 
sclerotherapy approach: ethanol or polidocanol-sclerotherapy (Chapter 3). Technical and 
clinical efficacy rates from a total of 137 patients showed no statistical differences despite 
the distinct sclerotherapy protocols. The key finding of this study is that in spite of these 
different approaches highly comparable efficacy rates were found.
Alternative sclerosing agents were introduced to reduce side effects from ethanol-
sclerotherapy.7 Indeed, we found that ethanol approaches resulted in more adverse events 
(Chapter 2 and 3) compared to non-ethanol sclerotherapy. However, our results were 
biased as reporting of adverse events was not standardized and depended on the clinician’s 
judgment. A prospective comparison between different sclerosing agents using standardized 
criteria for adverse events would be valuable to establish the safety profile per agent.
Lastly, we reviewed our cohort for the occurrence of cyst infection after aspiration 
sclerotherapy (Chapter 4). In the literature, these postprocedural cyst infections are sparsely 
documented.8, 9 The course of this complication is unknown. From 250 cases treated between 
2004 to 2014 in our center, five patients (2%) developed inflammatory symptoms that were 
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thought to be compatible with a cyst infection. All patients had to be admitted for oral or 
intravenous antibiotic treatment for a total of 4-10 weeks. In one patient re-catheterization 
of the infected cyst was mandated. All patients recovered without sequelae. In contrast to 
reports of spontaneous hepatic cysts infections10, postprocedural cyst infection could be 
managed in a shorter period without the necessity to perform surgery.
Research question 2. How can we optimize efficacy and safety of aspiration 
sclerotherapy?
We performed a pooled analysis of individual patient data of patients that underwent ethanol 
sclerotherapy (Chapter 5). We identified that the extent of cyst reduction predicted clinical 
response after treatment. Indeed, patients with complete disappearance of symptoms had 
higher cyst regression rates compared to patients with partial or no symptom reduction. As 
such, we demonstrated that higher rates of technical efficacy will lead to increased chance 
of clinical benefit. In contrast to what we expected, the amount of injected ethanol was not 
associated to technical treatment response. 
We did observe that a strong cyst fluid relapse in the first month and aspiration 
of hemorrhagic cyst fluid predict a limited long-term cyst reduction. Debate remains 
whether this fluid relapse results from remnants of intact cyst epithelium or is caused 
by cyst wall inflammation.11-13 Our findings indicate that both concepts may be true. 
All cysts show a pattern of transient re-accumulation after sclerotherapy that reduces 
over time which indicates inflammatory response. However, the extent of regression 
that follows can be persistently weak which implicates functional epithelium remnants 
that survived sclerotherapy. In line, hemorrhagic fluid with clots and debris may prevent 
contact with the cyst wall and/or dilute the concentration of the sclerosing agent causing 
inadequate sclerotherapy. 
We demonstrated that adjuvant pasireotide injections two weeks before and two weeks 
after aspiration sclerotherapy does not restrict cyst fluid re-accumulation after aspiration 
sclerotherapy (Chapter 6a and 6b). In line with the primary endpoint of this randomized 
clinical trial, long-term efficacy and clinical response did not improve in the pasireotide arm 
compared to controls. Several explanations could be given for these negative results. First, 
pasireotide could be unable to inhibit fluid re-accumulation. In previous clinical studies, 
lanreotide and octreotide were effective in reducing hepatic cyst volume.14 Laboratory 
studies have shown that pasireotide has a stronger affinity and broader binding profile 
to somatostatin receptors compared to conventional somatostatin analogues.15 However, 
human studies to confirm these findings in cystic disease are still running (Clinicaltrials.
gov; NCT01670110). Alternatively, cAMP inhibition may be insufficient to prevent fluid re-
accumulation in the cyst. Previous studies hypothesized that this transient relapse is driven 
by inflammation rather than cholangiocyte fluid production, which will not be sensitive to 
cAMP inhibition.12, 13
A strength of this study is that we assessed clinical response by validated instruments: 
the disease-specific PLD-Q16 and the generic SF-36.17 Hence, we were able to identify 
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the strong clinical response that follows after aspiration sclerotherapy. Baseline symptom 
and health-related quality of life scores were strongly deviated from general population 
norms. At follow-up, these differences with the general population disappeared which 
demonstrates the strong clinical benefit that is reached by aspiration sclerotherapy.
Finally, we found that prophylactic administration of cefazolin leads to low intracystic 
levels despite adequate serum levels (Chapter 7). To prevent patients from developing 
postprocedural hepatic cyst infections, we initiated the administration of a cefazolin bolus of 
1000 mg, one hour prior to aspiration sclerotherapy. In this explorative study, we investigated 
serum and cyst fluid levels of cefazolin in eight patients. We observed a median level of 
0.4 mg/L of unbound cefazolin in cyst fluid and 16.1 mg/L in serum, which corresponds to 
2.2% penetration. Importantly, in five out of eight patients, cefazolin levels in cyst fluid were 
below detection level.
IMPLICATIONS
Aspiration sclerotherapy is a safe measure that reduces cyst volume and leads to equalization 
of symptoms and health-related quality of life compared to general population norms. This 
thesis contradicts previous guidelines that pose aspiration sclerotherapy as ineffective.5 
These guidelines also indicated surgical treatment as first-choice strategy for large 
symptomatic hepatic cysts. However, as comparative studies between these approaches are 
absent, superiority to one of these procedures cannot be established. One review reported 
clinical efficacy rates after laparoscopic fenestration between 43-100%, data that are in line 
with the results from our systematic review.2 None of these surgical studies evaluated clinical 
relief by validated measures. In a second review, failure rates of aspiration sclerotherapy and 
laparoscopic fenestration were compared and found to be highly similar (4/91 and 5/85, 
respectively) with a slightly lower incidence of adverse events after aspiration sclerotherapy.18 
At this point, we believe that no conclusions can be drawn and endorse to perform the most 
convenient approach based on local expertise and available equipment.
Despite the large heterogeneity of protocols, we observed comparable results of clinical 
and technical efficacy rates between aspiration sclerotherapy studies. These findings 
suggest that success rates are not restricted to one specific sclerotherapy approach. 
Nonetheless, centers that use ethanol as sclerosing agent seem to have higher rates of pain 
and intoxication. As efficacy rates between ethanol and non-ethanol approaches overlap, 
one might argue that these alternative sclerosing agents could be preferred to reduce 
adverse events. Prospective comparative studies between these agents are needed to draw 
definite conclusions.
Furthermore, we identified hemorrhagic cyst fluid and cyst fluid re-accumulation as 
predictors of technical treatment failure. We advise increased attention in patients with 
a hemorrhagic aspirate or a strong relapse in the first weeks after treatment as long-term 
efficacy may be limited. If symptoms persist, subsequent sclerotherapy or surgical measures 
may be sought.
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Pasireotide as adjunct to aspiration sclerotherapy does not improve efficacy outcomes 
compared to mere aspiration sclerotherapy. At present, combining somatostatin analogue 
treatment with aspiration sclerotherapy is not indicated.
Finally, the use of prophylactic antibiotic treatment to prevent postprocedural cyst 
infections remains unclear. The minor penetration levels of cefazolin suggest that 
this agent does not reach adequate levels to prevent cyst infections after aspiration 
sclerotherapy. However, the explorative design and small sample size of this study precludes 
definite conclusions.
STRENGTHS AND LIMITATIONS
The main strength of this thesis was that we have performed multicenter studies in order 
to gain sufficient power to tackle unanswered questions. As symptomatic hepatic cysts are 
rare, collaboration is crucial. To do so, we engaged new international collaborations with 
other expert centers.
In addition, we applied the powerful design of a randomized controlled trial to evaluate 
the effect of adjuvant pasireotide to aspiration sclerotherapy. Furthermore, we have initiated 
the first aspiration sclerotherapy study in which we evaluated patient-reported outcomes 
by the disease-specific PLD-Q. As aspiration sclerotherapy is only indicated in symptomatic 
cases, measurement of clinical response should be done by standardized and validated 
instruments. Finally, we have introduced a new pharmacokinetic model to directly study 
the effects of pharmaceutical agents in cysts fluid. Using this unique strategy, we were able 
to demonstrate the low penetration of cefazolin as antibiotic prophylaxis.
Our thesis is limited by several factors. First, the retrospective and uncontrolled design 
of included studies in our systematic review restricted our conclusions. High risk of bias of 
these studies emphasized the low grade evidence that is collected on this subject to date. 
In addition, we have generalized our conclusions on both solitary cysts as cysts that arise 
in the context of PLD. Both congenital cyst types are pathologically highly similar and 
seem to respond equally to aspiration sclerotherapy. In this thesis, we have corrected for 
this difference in our analyses. Nonetheless, the impact of the genetic background on our 
results remains unclear. Finally, our technical efficacy was measured by ultrasound which 
inevitably introduces bias. Ultrasound is operator-dependent and less suitable in obese 
patients or cranially-seated cysts. Three-dimensional scanning would reduce this variability 
but leads to either radiation exposure or higher costs. In order to minimize this bias in our 
studies, we strived to perform all measurements by the same investigator by standardized 
operating procedures.
FUTURE PERSPECTIVES
Traditionally, efficacy of aspiration sclerotherapy equated technical success. Currently, 
research in this field still focuses on cyst diameter or volume reduction rather than clinical 
endpoints. Future studies should shift its focus to clinical parameters as hepatic cysts are 
benign and treatment is only indicated in symptomatic disease.
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Recently, a disease-specific instrument is validated to assess symptomatic burden 
in patients with hepatic cysts.16 We advocate to use this questionnaire to assess clinical 
response of aspiration sclerotherapy studies rather than previous technical outcomes. In 
addition, further exploration of symptomatic relief from aspiration sclerotherapy using 
this questionnaire would be valuable. Identification of symptoms that are responsive to 
aspiration sclerotherapy could aid decision-making whether or not to treat a patient. 
Moreover, a minimally-important difference of cyst volume reduction could be identified. 
In other words, which reduction of cyst volume is needed to reach sufficient clinical response 
in patients? In case of a patient with refractory symptoms, one could measure cyst volume 
reduction and estimate whether a second intervention would be valuable.
Furthermore, we have designed a cyst fluid model that can be applied to investigate 
the effects of pharmaceutical agents on the cyst. Although still in development, we 
hypothesize that this may support further examination of the effects of specific agents that 
aim to restrict cholangiocyte fluid production or proliferation.
Our work has paved the way for a prospective comparative study. To this end, we 
have initiated a registry that includes all patients treated in three tertiary referral centers 
(Hannover Medical School, Hannover, Germany; University hospitals Beaujon, Clichy, France; 
and Radboud university medical center, Nijmegen, the Netherlands) using the PLD-Q as 
primary endpoint at fixed time intervals. Secondary endpoints include proportional cyst 
reduction and safety. By these established collaborations, we are able to compare treatment 
approaches aiming to distillate factors that contribute to better clinical response or safety.
Finally, further expansion of research should be sought in the direction of surgery. As 
stated previously in this thesis, surgical fenestration is often seen as first option to treat large 
hepatic cysts. However, statements from these guidelines are not supported by robust data. 
To this end, in collaboration with the surgical and radiological department of the Radboud 
university center, we have already undertaken the first steps to perform a randomized 
controlled trial between these procedures with clinical response and morbidity as 
main endpoints.
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Hepatic cysts are fluid-filled lesions in the liver that generally arise as congenital anomalies. 
Prevalence is estimated between 3 and 18%. Overall, cysts are benign and asymptomatic. 
However, hepatic cysts can increase to a volume of several liters as a result of continuous 
fluid production by the cyst wall. This may lead to symptomatic disease due to mechanic 
pressure on surrounding organs and tissue. Common symptoms in patients with large 
hepatic cysts are abdominal pain and distension, nausea, dyspnoea, and early satiety. These 
symptoms reduce health-related quality of life and treatment is indicated in these cases.
Aspiration sclerotherapy is a minimally invasive procedure that includes percutaneous 
cyst drainage (aspiration) followed by injection of a sclerosing agent which destroys 
the epithelium of the cyst (sclerotherapy). This procedure results in cyst volume reduction 
aiming to relief the patient clinically. Since the early seventies, studies have been published 
with results of different approaches of aspiration sclerotherapy. Generally, these reports 
show high rates of efficacy and safety. Despite these favorable results, efficacy and safety 
remain source of debate. Hence, more invasive surgical alternatives are proposed as primary 
treatment strategy for large symptomatic cysts.
In the first part of this thesis, we focus on efficacy and safety of aspiration sclerotherapy.  
Chapter 2 evaluates these endpoints of aspiration sclerotherapy as reported in literature. 
By systematically reviewing the literature we collected all studies that assessed efficacy and 
safety of aspiration sclerotherapy. In total, we included 16 studies. Case reports and case 
series were excluded to minimize bias. Overall, median efficacy of cyst volume reduction 
is high and varies between 76 and 100% over a follow-up period of one to 56 months. 
Symptomatic relief is reached in 72 to 100% of patients. No severe morbidity or mortality 
is reported. An important remark of this study is that most included studies have high risk 
of bias due to retrospective designs and/or the absence of a control group. Nonetheless, 
previous claims that aspiration sclerotherapy is ineffective with an unfavorable safety 
profile, are not substantiated in literature. Finally, despite large differences in sclerotherapy 
approaches, ultimate efficacy rates are comparable. This suggests that a simple single-
session procedure is justified as treatment strategy to obtain adequate efficacy in treating 
dominant hepatic cysts with minimized safety risks.
Secondly, in Chapter 3 we have compared outcome data of two tertiary referral centers 
(Radboudumc, Nijmegen, the Netherlands and Hannover Medical School, Hannover, 
Germany) that perform aspiration sclerotherapy with different sclerosing agents: ethanol 
and polidocanol. In this retrospective study, cyst en symptom reduction rates are comparable 
despite protocol differences between centers. Although small in numbers, we have found 
that ethanol results in more adverse events compared to polidocanol. As efficacy rates 
were similar, polidocanol may be superior to ethanol since adverse event rates are smaller. 
A prospective comparison is needed to form definite conclusions.
In Chapter 4, we describe the course of postprocedural cyst infection following aspiration 
sclerotherapy. Over a period of ten years, over 250 aspiration sclerotherapy procedures 
were performed in our center. Five patients (2% of procedures) experienced postprocedural 
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inflammatory symptoms and were admitted to the hospital under suspicion of cyst infection. 
All patients received antibiotic treatment between four to ten weeks, one patient additionally 
underwent percutaneous abscess drainage. This led to successful resolution of infection in 
all cases. In contrast to reports of spontaneous cyst infections in literature, postprocedural 
cyst infections could be managed in a relatively short period without the necessity for 
surgical interventions. 
In the second part of this thesis, we evaluate possible new modalities to optimize efficacy 
and safety of aspiration sclerotherapy. Chapter 5 evaluates possible predictors of clinical- 
(symptom response) and technical (cyst reduction) treatment response following aspiration 
sclerotherapy. We performed a pooled analysis of individual patient data from two tertiary 
referral centers (Radboudumc, Nijmegen, the Netherlands and Beaujon Hospital, Clichy, 
France). All patients underwent ethanol-sclerotherapy by standardized methods. By 
regression analysis, we have identified that symptomatic response is associated with cyst 
reduction: patients with complete clinical response had higher cyst regression rates. Secondly, 
we identified that aspiration of hemorrhagic cyst fluid and a strong postprocedural cyst 
relapse predict technical failure. As efficacy is limited in these patients a second intervention 
should be considered if symptoms persist after treatment.
A temporal postprocedural cyst fluid re-accumulation is a well-known response after 
treatment. However, a strong fluid relapse is associated with lower efficacy rates. Pasireotide, 
a long-acting somatostatin analogue, inhibits cyst fluid production. We hypothesized that 
a combination treatment with pasireotide would enhance efficacy rates of aspiration 
sclerotherapy by curtailing postprocedural fluid re-accumulation.
In Chapter 6a, the protocol of this randomized, double blind, placebo-controlled trial 
is summarized. All patients underwent aspiration sclerotherapy and were randomized 
between additional pasireotide or placebo injection two weeks before and two weeks 
after treatment. Primary outcome was cyst diameter reduction 4 weeks after treatment. 
Secondary, we evaluated long-term reduction, clinical response, health-related quality 
of life and safety. Chapter 6b presents the results of this trial. No differences were found 
between groups. These results indicate that pasireotide had no beneficial effects as adjuvant 
treatment to aspiration sclerotherapy. By performing this study we have gained more insight 
of the clinical response following aspiration sclerotherapy. This is the first prospective study 
that assessed clinical relief and health-related quality of life with validated instruments. 
Overall, aspiration sclerotherapy results in a strong clinical response with normalization 
of health-related quality of life. This finding supports that aspiration sclerotherapy is an 
adequate treatment strategy of large symptomatic hepatic cysts.
Finally, to reduce the chance of postprocedural infections, our center initiated 
prophylactic antibiotic therapy prior to aspiration sclerotherapy. In Chapter 7 we explored 
penetration levels of the antibiotic drug cefazolin into hepatic cyst fluid. We observed low 
concentrations of cefazolin in cyst fluid while serum levels were adequate. Even more, five 
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out of eight patients had cefazolin levels below detection rates. Although this study is small 
and explorative, we believe that cefazolin is inadequate as prophylaxis for postprocedural 
cyst infections. A prospective study including alternative prophylactic agents is needed to 
further seek out the role of preventive antibiotic therapy prior to aspiration sclerotherapy.
The results of this thesis show that aspiration sclerotherapy is an effective and safe 
measure to reduce hepatic cysts and thereby the patients’ symptoms. A combination 
treatment with pasireotide does not improve these outcomes. An important next step of 
aspiration sclerotherapy research is to compare efficacy and safety with surgical fenestration 
in a randomized fashion.
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Levercysten zijn met vocht gevulde holtes in de lever. Over het algemeen zijn dit aangeboren 
afwijkingen. De prevalentie van levercysten wordt geschat tussen de 3 en 18%. In de meeste 
gevallen zijn levercysten goedaardig en veroorzaken ze geen klachten. Echter, door een 
continue vochtproductie in de cyste kan deze fors in volume toenemen, waarbij de cyste 
een inhoud van meerdere liters kan bereiken. Door een mechanische druk op omliggende 
organen en weefsels kan dit leiden tot klachten bij de patiënt. Veelvoorkomende 
klachten bij deze patiënten zijn pijn en druk in de buik, misselijkheid, kortademigheid en 
vroege verzadiging. De klachten kunnen leiden tot een verminderde kwaliteit van leven. 
Behandeling is bij deze patiëntengroep geïndiceerd.
Aspiratie sclerotherapie is een minimaal invasieve behandeling waarbij de cyste percutaan 
wordt gedraineerd (aspiratie) gevolgd door het inbrengen van een sclerosant die de cellen 
aan de binnenzijde van de levercyste vernietigt (sclerotherapie). Door middel van deze 
behandeling neemt het volume van de cyste af met als doel de klachten van de patiënt te 
verhelpen. Reeds sinds de jaren zeventig worden studies gepubliceerd waarin de resultaten 
van verschillende varianten van aspiratie sclerotherapie zijn gepresenteerd. Deze studies 
rapporteren over het algemeen hoge uitkomsten van effectiviteit en veiligheid. Desondanks 
blijven de effectiviteit en veiligheid van deze behandeling onderwerp van debat.
In het eerste deel van deze thesis, richten we ons op de effectiviteit en veiligheid van 
aspiratie sclerotherapie. 
Hoofdstuk 2 evalueert deze klinische eindpunten in de literatuur. Middels een 
systematisch review hebben we studies verzameld waarin effectiviteit en veiligheid van 
aspiratie sclerotherapie wordt beschreven. In totaal hebben we 16 studies geïncludeerd 
voor de studie. Hierin wordt een mediane cyste volume afname tussen de 76 en 100% 
gerapporteerd met een follow-up periode van 1 tot 56 maanden na behandeling. Daarnaast 
beschrijven de studies een mediane symptoomvermindering bij 72 tot 100% van de patiënten. 
Geen van deze studies rapporteert ernstige morbiditeit of mortaliteit. Een belangrijke 
kanttekening bij deze studie is het hoge risico op bias. Dit wordt met name veroorzaakt 
doordat de meeste geïncludeerde studies retrospectief van opzet zijn, daarnaast mist het 
grootste deel een controlegroep. Ondanks deze beperking hebben we geen ondersteuning 
gevonden voor de eerdere uitspraken dat aspiratie sclerotherapie niet effectief of veilig is. 
Tenslotte zien we dat de uitkomsten van de studies dicht bij elkaar liggen, ondanks grote 
verschillen tussen behandelprotocollen. Deze bevinding suggereert dat een eenvoudige 
sclerotherapie behandeling adequaat effect zal bereiken met minimale veiligheidsrisico’s.
In Hoofdstuk 3 vergelijken we de uitkomsten tussen twee tertiaire centra (Radboudumc 
Nijmegen, Nederland en de Hannover Medische School, Hannover, Duitsland) met een 
verschillend aspiratie sclerotherapie protocol. Een belangrijk verschil tussen de centra is 
de toepassing van verschillende sclerosantia: ethanol en polidocanol. In deze retrospectieve 
studie hebben we vergelijkbare uitkomsten van cyste- en klachtreductie gevonden, ondanks 
de verschillen van behandeling tussen de centra. Hoewel de getallen klein zijn, vonden we 
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daarnaast dat de patiënten die met ethanol behandeld zijn vaker bijwerkingen doormaken 
dan patiënten in de polidocanol groep. Gezien de vergelijkbare effectiviteit tussen 
de centra, is polidocanol, met een beter veiligheidsprofiel, mogelijk superieur aan ethanol. 
Om hier een definitieve uitspraak over te kunnen doen, dient prospectief onderzoek te 
volgen waarbij mogelijke verstorende factoren kunnen worden uitgesloten.
Hoofdstuk 4 beschrijft het beloop van een aantal cyste infecties die zijn opgetreden 
na aspiratie sclerotherapie. Over een periode van tien jaar zijn meer dan 250 aspiratie 
sclerotherapie procedures uitgevoerd in het Radboudumc. Na deze behandeling 
ontwikkelden vijf patiënten (2% van alle procedures) ontstekingsverschijnselen als 
koorts, malaise en pijn. Onder de verdenking van een geïnfecteerde levercyste werden 
ze opgenomen voor antibiotica behandeling. De totale duur van antibiotica behandeling 
lag hierbij tussen de vier en tien weken. Bij één patiënt was tevens een percutane 
drainage nodig. Alle patiënten zijn succesvol genezen van de infectie. In vergelijking 
met spontane levercyste infecties zien we dat deze post-procedurele cyste infecties in 
een relatief korte periode succesvol behandeld kunnen worden zonder de noodzaak tot 
chirurgische interventies.
In deel twee van deze thesis evalueren we mogelijke nieuwe modaliteiten om 
de effectiviteit en veiligheid van aspiratie sclerotherapie verder te optimaliseren.
In Hoofdstuk 5 richten we ons op mogelijke voorspellers van klinische (afname van 
klachten) en technische (cyste reductie) respons na behandeling. Hiervoor hebben we 
individuele patiëntgegevens van twee tertiaire behandelcentra (Radboudumc Nijmegen, 
Nederland en het Beaujon ziekenhuis te Clichy, Frankrijk) samengevoegd. Alle patiënten 
ondergingen aspiratie sclerotherapie op gestandaardiseerde wijze. Met behulp van regressie 
analyse ontdekten we dat patiënten met een volledige klinische respons een hogere cyste 
reductie hebben dan patiënten zonder volledige klinische respons. Met andere woorden, 
een sterke cyste reductie is een voorspeller voor het verdwijnen van de symptomen na 
behandeling. Ten tweede voorspellen een bloederig aspiraat en een sterk recidief direct na 
behandeling, een lagere technische uitkomst op lange termijn. Bij deze patiënten kan een 
vroege tweede sclerotherapie behandeling overwogen indien klachten persisteren.
Een tijdelijk recidief van de cyste daags na de behandeling is een bekend fenomeen 
na aspiratie sclerotherapie. Echter de mate van deze terugvloed van cystevocht na 
behandeling is geassocieerd met een kleinere cyste reductie op langere termijn. Pasireotide 
is een somatostatine analoog die in staat is om cystevocht productie af te remmen. Wij 
formuleerden de hypothese dat een injectie pasireotide, voor en na aspiratie sclerotherapie, 
de effectiviteit van de behandeling zou vergroten door de vochtproductie direct na therapie 
af te remmen.
In Hoofdstuk 6a beschrijven we het protocol van dit gerandomiseerde, dubbelblinde, 
placebo-gecontroleerde onderzoek. In deze studie ondergaan alle patiënten aspiratie 
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sclerotherapie. De deelnemers werden daarbij gerandomiseerd tussen een pasireotide of 
placebo groep. Deze middelen werden middels een injectie twee weken voor, en twee weken 
na behandeling, toegediend. De primaire uitkomst van dit onderzoek is de cysteafname vier 
weken na aspiratie sclerotherapie. Secundaire uitkomsten zijn onder andere cysteafname na 
zes maanden, klachtenreductie, kwaliteit van leven en veiligheid. Hoofdstuk 6b beschrijft 
de uitkomsten van het onderzoek. We observeerden geen verschillen tussen de groepen. 
Toevoeging van pasireotide aan de behandeling is derhalve niet zinvol. De resultaten van 
deze studie hebben ons betere inzichten verschaft in zowel de klinische als technische 
respons na aspiratie sclerotherapie. Dit is de eerste prospectieve studie waarin de klinische 
respons van patiënten zijn gemeten middels gevalideerde instrumenten. We zien daarbij een 
sterke klinische respons met het normaliseren van kwaliteit van leven na behandeling. Deze 
bevinding ondersteunt dat aspiratie sclerotherapie een geschikte keuze is voor behandeling 
van grote symptomatische levercysten.
Om de kans op een levercyste infectie na de procedure te verkleinen is het Radboudumc 
gestart met een gift antibiotica voor behandeling. In Hoofdstuk 7 hebben we het penetratie 
niveau van het antibioticum cefazoline in het vocht van de levercyste onderzocht. We 
vonden lage concentraties van cefazoline in het cystevocht ondanks een adequate spiegel 
in het bloed. Bij vijf van de acht patiënten hebben we zelfs helemaal geen cefazoline in 
het cystevocht aangetroffen terwijl er wel een adequate spiegel in het bloed aanwezig 
was. Ondanks dat dit een kleine en exploratieve studie is, geloven we dat cefazoline 
als profylaxe niet geschikt is om infecties na behandeling te voorkomen. Om de rol van 
preventieve antibiotica verder te onderzoeken is een prospectief onderzoek nodig met 
alternatieve antibiotica.
De resultaten van deze thesis tonen dat aspiratie sclerotherapie een effectieve en 
veilige behandeling is om levercysten te verkleinen en daarmee klachten te verlichten. 
De toevoeging van pasireotide aan deze behandeling laat geen verbetering van uitkomsten 
zien. Een belangrijke vervolgstap binnen onderzoek naar aspiratie sclerotherapie is 
de vergelijking van effectiviteit en veiligheid tussen aspiratie sclerotherapie en 
chirurgische fenestratie, middels een gerandomiseerd onderzoek.
&
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Mijn boekwerk is klaar, wat een fantastisch gevoel. Het staat buiten kijf dat ik allen dank die 
ervoor hebben gezorgd dat ik dit onderzoek tot een mooi succes heb kunnen afronden!
Allereerst wil ik eenieder bedanken die heeft deelgenomen aan de onderzoeken van 
dit proefschrift. Zonder jullie waren deze resultaten er niet geweest. Bezoek uit alle 
windrichtingen, langdurige echometingen en een papierwerk aan vragenlijsten: ik waardeer 
jullie inzet ten zeerste!
Prof. dr. Drenth, beste Joost, veel dank voor je geweldige ondersteuning. De deur heeft altijd 
open gestaan. De snelheid van je begeleiding, ongeacht het uur van de dag, heeft mijn 
onderzoek draaiende gehouden. Je hebt me ruimte en vertrouwen gegeven om na een 
jaar onderzoek een andere richting te kiezen waarbij ik de nadruk heb kunnen leggen op 
aspiratie sclerotherapie. Ook je steun op persoonlijke ontwikkeling buiten het onderzoek 
heeft me energie gegeven. Ik kijk ernaar uit om als AIOS verder bij je in de leer te gaan.
Dr. Gevers, beste Tom, zonder jouw hulp, kennis en ondersteuning was mijn promotie 
onmogelijk geweest. Wat ben je een fantastische co-promotor! Altijd wist je tijd te maken en 
na ieder overleg zag ik weer nieuwe mogelijkheden om verder te gaan. Jouw vindingrijkheid 
en kritische blik zijn uitzonderlijk. Naast co-promotor ben je een fijne en gewaardeerd 
collega. Dank voor de mooie tijden, in verleden en die in de toekomst nog komen gaan!
Leden van de manuscriptcommissie: Prof. dr. Prokop, Prof. dr. Rosman en Prof. dr. van 
Delden, dank voor uw deelname in mijn manuscriptcommissie en de beoordeling van dit 
proefschrift.
Prof. dr. Vilgrain et dr. Ronot, merci infiniment pour notre collaboration indispensable.
Dear Valérie, thank you for your trust in working together with us. Dear Maxime, I am very 
grateful for our collaboration. Right from the start at the EASL in London, without hesitation, 
you agreed to a joint project. Our meeting in Paris sealed the deal. I want to thank you for 
your consultation and your fast and helpful advices. I look forward to new projects together 
and I am proud that you agreed to be a member of my corona. Merci pour tout!
Dr. Potthoff, bester Andrej, vielen Dank für die starke Zusammenarbeit. I remember our 
fruitful meeting in Hannover and multiple EASL congresses very well. I am proud that we have 
initiated a prospective cohort together, especially after our struggles with our retrospective 
research. As a future gastroenterologist I hope to learn more of your expertise and skills in 
the future. Dear Bastian Schönemeier, I also thank you for all the hard data work.
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Dr. Kievit, beste Wietske, met name in het eerste jaar hebben we veel samengewerkt. Wat 
was ik, net student-af, trots op onze eerste publicatie! Hartelijk dank voor je adviezen en 
verbeteringen die je aanbracht aan ons onderzoek. Ook dr. Groeneveld wil ik bedanken voor 
zijn uitleg en statistische ondersteuning gedurende de afronding van mijn promotietijd.
Prof. dr. Schultze Kool, beste Leo, zonder aspiratie sclerotherapie geen onderzoek over 
aspiratie sclerotherapie. Je gaf me altijd de mogelijkheid om patiënten te bespreken en 
dacht graag mee over ons onderzoek. Ik kijk met plezier terug op onze samenwerking. 
Germien, hartelijk dank voor je ondersteuning!
Aan het gehele team van interventieradiologen, laboranten en ondersteuning: hartelijk 
dank voor jullie enthousiaste samenwerking. Ik heb me als arts-onderzoeker van de MDL 
altijd zeer welkom gevoeld in de angio-kamers. Sjoerd Jenniskens in het bijzonder, het was 
mooi om tijdens de behandelingen met je te brainstormen over nieuwe ideeën.
Prof. dr. Burger en Prof. dr. Allegaert, beste David en Karel, hartelijk dank voor jullie input 
ten aanzien van de antibiotica studie. Zonder jullie waardevolle input hadden Marten en 
ik dit mooie project niet kunnen invullen. Mede dankzij jullie hulp hebben we een route 
uitgestippeld voor toekomstige farmacologische projecten.
Prof. dr. van Gool, beste Alain, dank voor de tijd en energie die je had voor de opzet van 
de nieuwe proteomics en glycomics studie. Ook al sta ik zelf niet meer aan het roer van deze 
projecten, ik kijk uit naar de resultaten die voort zullen komen uit onze mooie samenwerking.
Ayla Görtjes, wat hebben we een werk verzet voor het systematische review. Bedankt voor 
je inzet!
Beste Paul Rikken, dank voor je geweldige hulp bij het maken van de omslag. Dear Victor 
Sidy, thank you so much for correcting my language errors. 
Mijn dank gaat ook zonder meer uit naar de afdeling Maag-, Darm- en Leverziekten van 
het Radboudumc: specialisten, AIOS, PA’s, verpleegkundig personeel, secretariaat en alle 
andere medewerkers. Wat een mooie en leerzame tijd heb ik bij jullie de afgelopen jaren 
gehad. Beste Jessica, dank voor je scherpe blik en humor! Sietske en Irma, dank voor jullie 
geweldige ondersteuning.
Natuurlijk een woord van dank voor de groep arts-onderzoekers van het Radboudumc. Het 
begon goed in de buitenhoek, met Polat (Bebegim, ik blijf zoeken), Robin, Mieke, Melissa, 
Edgar, Evelyn, Wybrich en Tom: dank voor jullie warme ontvangst!
Marten, eeuwige kamergenoot, uiterst gedreven en gepassioneerd onderzoeker. Je 
werkkracht heeft me geïnspireerd! Ik wil je bedanken voor onze samenwerking die tot een 
tweetal prachtige publicaties heeft geleid. Lauranne en Yasmijn, dank voor jullie humor en 
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theekransjes. Jullie knip- en plakkunsten, groene AH-moestuin vingers en bakkwaliteiten 
hebben me altijd verwonderd. Floor, dank voor je kritische blik. Hedwig, dank dat je mijn 
RCT-rolmodel wilde zijn en natuurlijk voor de mogelijkheid om je studie te monitoren. 
Jos, treinbuddy van het eerste uur: ik kom graag weer eens GoT voor je zingen als je denkt 
incognito in een stiltecoupé te zitten. Mark Broekmeister, dank voor de hardlooptrainingen 
en wijnlezing. Simon, dank voor die eeuwig kritische en relevante vraag: waar is je buff? 
Karina, tante Knak, positieveling pur sang, ik hoop dat de VU je terug naar ons stuurt. 
Lamberts, dank dat ik in de weekenden nooit alleen was in het Radboud. Myrt(e), dank voor 
de samenwerking en natuurlijk de PLD-Q, eindelijk een mooi eindpunt! Isabelle, geweldige 
lief- en leedcommissaris, dank voor je evenwichtige glas en sublieme trend-adviezen. René, 
Rimmels, dank voor je prachtige uitspraak van het RIMLS en onnodige verwijzingen naar 
819. Goof, dank voor je tourkennis. Angelique, dank voor je af en toe iets te spannende 
verhalen over het Rijnstate. Yannick, dank voor de mooie potjes pool. Xavier, iedereen wil jou 
zijn, bedankt daarvoor. Dorian, dank voor de proeverijen en voor Jan-Joost! 
Daarnaast wens ik graag de nieuwe onderzoekers succes met hun onderzoek en bij voorbaat 
dank ik jullie voor de komende proefpromotie. Liyanne, ik ben heel benieuwd naar het 
vervolg van de eiwitanalyse. En natuurlijk Lucas, kersverse onderzoeker, veel succes met het 
vervolg van de komende aspiratie sclerotherapie studies!
Geacht Researchbureau, Sonja en Chantal in het bijzonder: zonder jullie ondersteuning had 
ik de SCLEROCYST trial nooit kunnen doen. Jullie nauwkeurige werk heeft ervoor gezorgd 
dat de studie goed is verlopen.
Ook dank ik het laboratorium van de MDL, in het bijzonder Rene, Hennie en Jody, voor jullie 
hulp, geduld, en ondersteuning van de verschillende projecten die ik bij jullie heb mogen 
uitvoeren.
Internisten en collega assistenten uit het Rijnstate ziekenhuis te Arnhem: wat heb ik het 
afgelopen jaar een goede tijd met jullie gedeeld. Jullie gaven me de juiste energie om nog ’s 
avonds of in het weekend mijn proefschrift af te maken. Een geweldig team om mee samen 
te kunnen werken. 
Prof. dr. Peerdeman, beste Saskia, mentor vanaf jaar 1, je hebt me ontzettend geïnspireerd. 
Dank voor je vanzelfsprekende raad en advies omtrent de studiekeuzes die ik gemaakt heb.
Geachte Prof. dr. Mulder, beste Chris, dank voor je raad en steun voor de PhD in 
het Radboudumc. Beste Yvo Kortmann, dank voor je hulp en advies naar de zoektocht voor het 
juiste promotietraject.
Lieve familie en vrienden. Wat heerlijk om het resultaat eindelijk met jullie te kunnen delen. 
Wat is het fijn dat jullie er zijn. Lieve familie Haenen, wat een cadeau om jullie als familie erbij 
te hebben. De Pops, Peet Patrick, Dijkers en Stilles: tijd om dit met jullie te kunnen vieren!
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God Mark en Pelli-Robson: LG made it.
Lieve vrienden uit het Zuiden: Floortje, Jasper, Ilona, dr. Rob, Alein en Philip. Wat is het 
bijzonder dat onze vriendschap de laatste jaren alleen maar hechter is geworden. Floortje en 
Jasper, fijne vrienden, dank voor jullie enthousiasme, laten we nog vele avondjes doorzakken.
Judemans, fijne vent, ondanks de afstand een geweldige trouw. Stralen met Von, ga zo door! 
Lieve Nups, wat hebben we een mooie tijd achter de rug. Heerlijke escapades chez-KT op 
de Veluwe, that Sauer feeling met Zwolle door de speakers of gewoon een avondje Lost 
Cities. Dit geeft altijd de juiste energie, laten we dit vooral gewoon blijven doen. Over het 
hek bij Deeler, dank voor je eeuwige humor en steun! Lieve Bul, Vod, Aart en Rein, wat zijn 
jullie een fijn stel. Gijs, het begon als een paradoxale vriendschap. Altijd benieuwd naar 
de (al dan niet) vorderingen van mijn boekje en een geweldige steun wanneer dat nodig 
was. Je trots heb je nooit onder stoelen of banken gestoken. Geweldig dat je straks als 
paranimf naast me staat.
Lieve Stoffels, lieve Peter, Carine, Marcelle en Vincent. Wat zijn jullie een geweldige 
schoonfamilie. Niet Heeze, maar jullie zijn de echte Parel!
Lieve zussen, wat een heerlijk stel bij elkaar. Allen een voorbeeld voor mij op jullie eigen 
manier. Barbara, wat is het fijn om (tijdens mijn nachtdiensten) mijn overdenkingen met je 
te delen. Esther, dank voor je directheid en scherpe inzichten. Judith, altijd attent, dank voor 
je kritisch blik. En samen met jullie gezinnen, de Lamothes, de Bende en de Firma, genieten 
we van de fijne dingen van het leven, laten we dat blijven doen! Wat een mooi vooruitzicht 
om ons kleine grut samen groter te zien worden.
Lieve pap en mam, de basis ligt bij jullie. Kwale. Dank voor jullie vanzelfsprekende steun en 
liefde: Force, Courage et Confiance!
Joline, mijn liefste, deze prestatie is echt van ons beide. Ik ben je eeuwig dankbaar voor je 
steun en  vertrouwen. Wat geweldig dat het proefschrift nu klaar is, wat heb je me in dit 
alles geholpen! Een volgende tijd breekt aan met nog zoveel samen te ontdekken en te 
beleven. Samen met onze kleine grote held Bruno, genieten van de kleine dingen die zo 
prachtig zijn. Zo fijn met jou, Osasuna. Wat een geluk!
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